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Abstract 
Chloroquine was one of the main malarial treatments until the late 1960s when resistance 
began to emerge. This antimalarial targets haemozoin formation which causes a cytotoxic 
accumulation of free haem in the malaria parasite leading to parasite death. This is still one 
of the most promising pathways for treatment of the most prevalent species of malaria 
parasite, Plasmodium falciparum to date but, owing to growing resistance to chloroquine and 
other current antimalarial drugs, there is a dire need for new drugs. One strategy is to 
investigate non-chloroquine haemozoin inhibitors. High-throughput screening (HTS) was 
previously used to investigate novel β-haematin (synthetic haemozoin) inhibitors with 
promising P. falciparum growth inhibition activities. Of the 144 330 compounds screened, two 
hit compounds were selected for investigation in this project with two different scaffolds, 
namely benzimidazole and carbazole indole. 
In order to preselect benzimidazole derivatives for synthesis, Discovery Studio and Pipeline 
Pilot where used in tandem to enumerate 325 728 in silico compounds. These were filtered 
according to predicted β-haematin inhibition activities, followed by predicted malaria 
parasite growth activities using previously developed models based on Bayesian statistics. 
The predicted active compounds were further subjected to an in silico aqueous solubility 
model and separated according to predicted solubility values however, only 68 out of the 
35 124 active compounds showed moderate solubility whilst the rest were poorly soluble. 
From this data, eighteen compounds were chosen for synthesis with varying functional 
groups. Using the same Bayesian models, biological activities for seven fragment compounds 
derived from the benzimidazole hit compound were predicted. Six out of seven were 
predicted to be β-haematin inhibitors while five out of seven were predicted active against 
the malaria parasite growth inhibition model. Similar Bayesian predictions were carried out 
on the seven proposed carbazole indole compounds with three compounds predicted to be 
β-haematin inhibitors while six compounds were predicted to be active against the malaria 
parasite growth inhibition model. 
The eighteen benzimidazole compounds were synthesized using a two-step synthesis, via a 
condensation reaction using polyphosphoric acid (PPA), 4-aminobenzoic acid and 
o-phenylenediamine to form the primary amine benzimidazole intermediate after which an
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acylation reaction with the appropriate acid chloride furnished the desired compounds.  
β-haematin inhibition analysis revealed a 78% hit rate compared to the Bayesian predictions 
which resulted in a 24-fold enrichment compared to random screening. SAR analysis revealed 
an activity trend related to the position of substituents on the ring system as follows: para  
< ortho < meta. The type of ring system was also investigated, with a trend of phenyl < furan 
< pyrrole < thiophene < pyridyl found. The fragment compounds were either purchased or 
synthesized via standard acylation conditions using acid chlorides or acetic anhydride with 
primary amines as before. β-haematin inhibition analysis showed all these compounds to be 
inactive at the 100 µM cut-off but these compounds were still carried through to the next 
stage of testing in spite of these results. 
Molecular docking was carried out on all eighteen benzimidazole compounds in Materials 
Studio using the (001) and (011) β-haematin crystal faces for adsorption, together with a 
modified CVFF force-field. This showed a correlation between adsorption energies of the 
(011) β-haematin crystal face with the experimental β-haematin inhibition values. This 
indicated that the (011) β-haematin crystal face was the most important for β-haematin 
inhibition. Analysis of the benzimidazole compounds and their π-π and hydrogen bonding 
interactions was performed. The number of π-π interactions were found to be important for 
β-haematin inhibition activity. Both sets of benzimidazole compounds were tested against 
the NF54 chloroquine sensitive malaria parasite using growth inhibition assays with a 50% hit 
rate shown for the benzimidazole compounds and a 71% hit rate for the fragment study 
leading to a 26-fold and 36-fold enrichments compared to random screening. SAR analysis of 
the benzimidazole compounds revealed a trend for activity in relation to substituent position 
of para ≈ ortho < meta and a ring system trend of phenyl < pyridyl < thiophene < furan  
< pyrrole. The benzimidazole compounds were further tested against the chloroquine 
resistant Dd2 P. falciparum strain which showed that disubstituted compounds were more 
active against this strain. Cellular haem fractionation studies revealed an increase in free 
haem and decrease in haemozoin confirming that haemozoin inhibition is the mode of action 
for the benzimidazole compounds. QSAR analysis of these compounds revealed a correlation 
between the -Log(P. falciparum IC50) which is also known as pLog(P. falciparum IC50) and 1/β-
haematin IC50, number of hydrogen bond donors and molecular depth with 1/β-haematin IC50 
the most dominant term. 
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The first four carbazole indole compounds were synthesized using a two-step synthesis via 
deprotonation of carbazole and reaction with epichlorohydrin or 1,3-dibromopropane to 
furnish the epoxide or alkylbromine intermediates. These intermediates underwent a further 
SN2 reaction using deprotonated indole to furnish four final compounds. Synthesis of another 
three derivatives required benzyl protection of 7-hydroxyindole alcohol first, followed by 
reaction with the epoxide intermediates via an SN2 mechanism to furnish the final three 
compounds. Analysis using the turbidimetric solubility assay revealed the best aqueous 
solubility range of this series of compounds to be 10-20 µM (moderately soluble). β-haematin 
inhibition studies were carried out on this series of compounds with a 100% hit rate found 
when compared to the Bayesian model data which lead to 30-fold enrichment when 
compared to random screening. SAR analysis showed an increase in the number of hydroxyl 
groups led to an increase in β-haematin inhibition activity. Docking studies were performed 
on these seven compounds and showed that hydrogen bonding played a role in anchoring the 
molecules in the binding pocket on the crystal surface with increased adsorption energies 
seen with an increase in the number of hydroxyl groups. Malaria parasite growth inhibition 
studies showed no compounds to be active against the NF54 and Dd2 strains at the 2 µM  
cut-off. Cellular haem fractionation studies on the carbazole indole compounds showed that 
this series of compounds acts via a mechanism that results in inhibition of haemoglobin 
uptake into the food vacuole and not via haemozoin inhibition. 
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Chapter 1: Introduction 
1.1 Historical Outline of Malaria 
Malaria is one of the oldest diseases known to man with records dating back from the sixth 
century BC described in Hindu texts. However, it was only in 400 BC that Hippocrates noticed 
enlarged spleens, malarial fevers and general poor health of people living in marsh lands. Due 
to this condition said to be originating from the marsh lands and swamps, over the next 2 500 
years the name, spoiled air or mal’aria was developed by the Romans.1,2 It was only in 1880 
when Charles Louis Alphonse Laveran first described spherical parasites containing black 
pigment in red blood cells that significant interest in the malaria parasite began to develop. 
1–4 Over more than a century there have been approximately 200 species of parasite that 
belong to the genus Plasmodium reported, with five of those infecting humans.5,6 The most 
widespread, infective and fatal of these is Plasmodium falciparum.6 
1.2 Current Malaria Scourge 
The World Health Organisation (WHO)7 malaria report describes the current malaria status of 
the world, using data collected from 91 malaria stricken countries. There were an estimated 
216 million cases in 2016 with 80% of them occurring in sub-Saharan Africa. Artemisinin-
based combination therapy (ACT) is the treatment of choice and has managed to decrease 
mortality rates with no resistance to the drug combination shown in Africa. Even though this 
treatment has substantially decreased the mortality rate, it was estimated that globally in 
2016 malaria caused 445 000 deaths, with 91% of those deaths originating in sub-Saharan 
Africa. The main challenges facing malaria treatment are funding and emerging resistance to 
current therapies which encourages research into novel treatments. Figure 1.1 shows the 
distribution of malaria cases in the world comparing the year 2000 to 2016. 
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Figure 1.1: A world map showing countries and territories with cases of malaria in 2000 
compared to 2016. The WHO can issue a certificate for a zone if it is malaria free for three 
consecutive years. These countries are coloured in blue while those that have seen zero cases 
in 2016 are coloured in yellow. Countries with one or more cases are coloured in red. 
Copyright © WHO malaria report 2017.7 
1.3 The Malaria Parasite Life Cycle 
It took almost 70 years to fully describe the malaria parasite life cycle starting from the first 
description in 1880 by Laveran.2,3 The life cycle is similar in all five species of Plasmodium that 
infect humans. It is comprised of three stages, namely the liver, blood and mosquito stages 
which are shown in the life cycle of P. falciparum in Figure 1.2. It begins with the bite of a 
female Anopheles mosquito which transfers, with its saliva, motile sporozoites which enter 
the blood stream through the human dermis and quickly enter the liver through Kupffer cells, 
to begin the liver stage. In the liver they invade the liver hepatocytes and undergo asexual 
multiplication to form about 30 000 merozoites each. The blood stage begins after about a 
week, when the merozoites are released into the blood stream and infect the erythrocytes or 
red blood cells. During a 48 hour period, trophozoites develop from rings to schizonts which 
upon maturation, rupture releasing merozoites again. The development into schizonts is 
fuelled by haemoglobin degradation and at this stage the characteristic black pigment is seen 
in people without preimmunity. This process is repeated until the victim is treated or dies. 
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This is also the stage which gives rise to all the clinical symptoms seen in malaria patients. As 
infection increases some merozoites develop into male and female gametocytes in the red 
blood cells which circulate in the blood stream and are taken up by the female Anopheles 
mosquito. Inside the mosquito these gametocytes mature into gametes after which 
fertilization occurs and an ookinete is formed. This ookinete penetrates the gut wall and 
becomes an oocyst which multiplies and forms sporozoites which travel to the mosquito’s 
salivary glands ready for infection into a human host.2,6,8–10 
 
Figure 1.2: The life cycle of Plasmodium falciparum. Reprinted with permission from 
Greenwood et al.8 Copyright © 2008 American Society for Clinical Investigation. 
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1.4 The Mechanism of Haemoglobin Degradation in P. falciparum  
The malaria parasite ingests haemoglobin from the host cytoplasm by a process called 
endocytosis using a cytostome via which it is trafficked between the parasite and the red 
blood cell. The haemoglobin is transported to the acidic food vacoule (secondary lysosome), 
also known as the digestive vacuole, with a pH between 4.8 and 5.2 via vesicles.6,11 The 
haemoglobin is digested by several proteases, plasmepsins I, II and histoaspartic protease 
releasing haem and globin. The globin is further degraded by plasmepsin IV, falcipains 2 and 
3 and falcilysin which release peptides that are further broken down by aminopeptidases to 
amino acids, of which a fraction are used by the parasite.12 These amino acids are used for 
maturation and growth of the parasite since the parasite has limited capabalities of 
synthesizing its own amino acids or acquiring them from elsewhere.11 Some studies estimate 
that up to 80% of the host haemoglobin is degraded, but this is not solely to obtain amino 
acids as only about 15% of the amino acids are used while the rest are discharged to the 
surrounding plasma.11–14 The other functions of haemoglobin degradation have been 
suggested to be to provide space for parasite growth and provide osmotic balance within the 
cell.12 Another by-product of haemoglobin degradation is haem or ferroprotoporphyrin IX 
(Fe(II)PPIX)  which is rapidly oxidised to ferriprotoporphyrin IX (Fe(III)PPIX) by oxygen in the 
acidic food vacoule. This is cytotoxic to the malaria parasite due to its capability to bring about 
lipid peroxidation especially in large amounts. Therefore the parasite has developed an 
ingenious method of detoxification by converting Fe(III)PPIX into an insoluble crystalline 
material called haemozoin via a biomineralisation process.12,15 The complete haemoglobin 
degradation pathway is summarised in Figure 1.3.  
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Figure 1.3: The degradation of haemoglobin in a parasitized red blood cell or erythrocyte 
resulting in the formation of amino acids and haemozoin. 
1.5 Chemotherapy of Malaria  
Malaria chemotherapy currently relies on four major drug classes, namely, artemisinin and 
derivatives thereof, the antifolates, the antimicrobials and the quinoline derivatives.9,16 These 
drug classes are discussed in detail in the next section.  
1.5.1 Antifolates and Antimicrobials 
During the second world war, supplies of known antimalarial drugs at the time were low and 
thus there was a large research initiative started in the United Kingdom for discovery of a new 
drug. This led to the discovery of proguanil (chlorguanide) (Scheme 1.1) which is formed via 
opening the pyrimidine ring to form a biguanide. This compound was found not to be ideal 
for acute cases of malaria due to the slow action of the drug which was also found to induce 
resistance in the parasite. This success, however did start a research initiative into pyrimidine 
derivatives. In 1951, Falco and Hitchings developed pyrimethamine (Scheme 1.1), belonging 
to the 2,4-aminopyrimides class, which was hailed an important advancement due to its 
increased activity compared to proguanil.17 However, as with proguanil, resistance to 
Erythrocyte 
Parasite Cytosol 
Acidic Food Vacuole (pH 4.8) 
Amino acids 
Vesicle 
Fe(III)-PPIX 
Haemozoin 
Peptides 
Cystostome 
Haemoglobin Fe(II)PPIX 
Fe(III)PPIX 
Haemozoin 
O2 
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pyrimethamine emerged and thus the antibiotic sulfadoxine (Scheme 1.1), was combined 
with pyrimethamine doses to provide a synergistic effect.18 The pyrimethamine-sulfadoxine 
compounds target two enzymes, namely, dihydrofolate reductase and dihydropteroate 
synthetase which are present in the folate biosynthesis pathway of the parasite.19 A study in 
1996 showed that the combination of atovaquone (Scheme 1.1), an inhibitior of the 
mitochondrial electron transport chain in the parasite, and either tetracycline (an antibiotic 
that inhibits protein synthesis) or proguanil showed cure rates of greater than 95%. 
Atavaquone cannot be given as the sole therapy as this can lead to recurrence of parasitemia. 
16,20–22 
 
Scheme 1.1: The pyrimidine based antifolate drugs proguanil, pyrimethamine and 
sulfadoxine, and the antiparasitic atovaquone.  
1.5.2 Artemisinin Derivatives 
Due to significant resistance shown to any single drug treatment, the recommended 
treatment for malaria is ACTs.7,8 ACTs combine artemisinin and a partner drug, where 
artemisinin has a fast mode of action that kills gametocytes and alleviates symptoms, while 
the longer lasting partner drug kills the rest of the parasites after the effect of artemisinin has 
worn off. This prevents susceptibility to only one antimalarial agent.8,16,23–26 Artemisinin 
(Scheme 1.2) is a sesquiterpene lactone that contains an endoperoxide bridge and was first 
extracted from the leaves of the Chinese wormwood, also known as Artemisia annua, in the 
7 
 
late 1970s to early 1980s by Tu Youyou and co-workers, which was recognised by the award 
of a Nobel Prize in Physiology and Medicine in 2015.9,26,27 Before this, the leaves of Artemisia 
annua had been used to treat chills and fevers for over 2000 years.26 Several mechanisms of 
action for this antimalarial have been debated throughout the years however, these have all 
been shown to act during the blood stage of the parasite.28,23 It has been suggested that 
cleavage of the endoperoxide bridge is catalysed by Fe(II) producing radicals that destroy the 
parasite.28,29 Two mechanisms have been proposed, namely, the reductive scisson model and 
the open peroxide model. The reductive scisson model involves Fe(II) binding to artemisinin 
and after electron transfer takes place it produces oxygen radicals that rearrange to give 
carbon radicals which are believed to alkylate malaria proteins. The open peroxide model 
proposes that ring opening is either driven by protonation in the acidic food vacoule, assisted 
by oxygen or complexation with Fe(II). Hydroperoxide is formed from heterolytic cleavage 
followed by addition of water. This hydroperoxide residue is capable of oxidising proteins.28 
Also Fenton30 degradation of the hydroperoxide produces oxygen radicals that are toxic to 
the parasite.28   
The synthesis of derivatives of artemisinin, namely, artemether, the methyl-ether derivative,  
(Scheme 1.2) and artesunate, the succinic acid analogue, (Scheme 1.2) were carried out in the 
1980s. However, all these compounds are broken down into the same metabolite, 
dihydroartemisinin, and thus these compounds are pro-drugs. 31 It has been noted that 
monotherapy with artemisinin compounds results in recurrence of parasitemia after 
treatment.26 This is mitigated with the use of ACTs and according to the WHO 409 million 
doses of ACTs where given out in 2016.  
 
Scheme 1.2: The artemisinin derivatives. 
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1.5.3 Quinolines and Derivatives 
The first malaria chemotherapy, obtained from the crushed bark of the Cinchona tree was 
discovered in 1630 by Spanish Jesuits who imported it into Europe from Peru. The bark of the 
tree was given the latin name Cinchona after a fictional tale of a countess of Cinchon who was 
cured of malaria using this crushed bark. The first attempt at isolation of the compounds 
found in this bark was in Portugal, by Gomes in 1810. After 10 years, the alkaloids, quinine 
and cinchonine, and later their diastereomers quinidine and cinchonidine were finally isolated 
by Caventou and Pelletier.6,32,33 The drug’s popularity led to the destruction of the Cinchona 
forests in Peru, therefore the Dutch and British smuggled seeds out of Peru and started their 
own plantations in Java and India. From these plantations roughly 10 million kg of quinine 
was produced annually.6 The structure of quinidine, one of the active compounds found in 
the tree bark was finally elucidated in 1908.32 
Cinchonidine and cinchonine are diastereomers and upon substitution of the hydrogen on the 
6-position of the the quinoline ring with a methoxy group, quinidine and quinine are formed. 
The four chiral alkaloid compounds isolated from the tree are shown in Scheme 1.3 with their 
respective stereochemistry.34 
 
Scheme 1.3: The structures of the alkaloids isolated from the Cinchona bark and their relative 
stereochemistry.  
9 
 
During the first World War, the Germans found themselves cut-off from the world supply of 
quinine and thus synthetic analogues needed to be discovered. The starting point of this was 
the observation by Ehrlich that methylene blue showed some effect on malaria patients and 
thus in the 1920s, Schönhofer and Wingler investigated thiazine derivatives. This led to the 
discovery of the first 8-aminoquinoline, pamaquine35 (Scheme 1.4), which showed only 
activity against avian plasmodia. Primaquine (Scheme 1.4) was synthesized as an active, less 
toxic analogue. German scientists replaced the quinoline ring by acridine while also adding a 
basic side chain. Atebrin, now called quinacrine (Scheme 1.4) was found to be most active 
against the asexual forms of P. falciparum. German scientists continued with their research 
and found that attachment of basic side chains to the 4-position of the quinoline moiety 
brought about increased activity. Following this, Andersag synthesized sontochin36 (Scheme 
1.4) and resochin in 1934 but, initial testing revealed resochin to be toxic and it was thus 
abandoned. This error was rectified 8 years later when a screen of more than 17 000 
compounds against avian plasmodia was conducted in the USA in 1943 in which resochin (now 
called chloroquine) and amodiaquine (Scheme 1.4) were shown to have increased theraputic 
activity compared to sontochin and were found to have acceptable toxicity. Clinical trials of 
chloroquine started in 1943, after which it was the antimalarial of choice for 25 years.6,10 After 
the rediscovery of chloroquine, in 1944 the first synthetic pathway that could not be used for 
commerical use for quinine, was described by Woodward and Van Doering.6 This took 36 
years after the discovery of the structure to be synthesized. Due to problems with chloroquine 
resistance, another large screen of over 300 000 compounds was carried out with the 4-
quinolinemethanols emerging as the most promising group.6,10 These compounds were 
analogues of quinine but had a strong photosensitizing action. This was rectified with the 
synthesis of mefloquine (Scheme 1.4) which has proven useful against chloroquine-resistant 
parasites.37  
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Scheme 1.4: The most influential antimalarial drugs synthesized from the 1920s till 1984. 
Throughout the years many newer antimalarial drugs have been synthesized targeting 
different stages of the life cycle of the parasite as well as different organelles in the parasite.  
Figure 1.4 shows a summary of all the antimalarial drugs currently used and their targets in 
the malaria parasite. 
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Figure 1.4: A summary of antimalarial drugs and their respective targets. Reprinted with 
permission from Greenwood et al.8 Copyright © 2008 American Society for Clinical 
Investigation. 
1.6 Resistance to Known Drugs 
According to the WHO the malaria death rate has decreased by between 27 and 44% 
depending on the region between the years 2010 and 2016 mostly due to the use of ACTs.7 
However, resistance to known antimalarial drugs has had a devastating effect on treatment 
of malaria. There is a correlation between extended use of a drug and the development of 
resistance. For example in 1961, 84 000 tons of chloroquine was supplied for inclusion in salt. 
This quickly brought about resistance in those areas where this salt was used.6    
However, the first recorded case of P. falciparum chloroquine resistance was in Thailand in 
1957 when standardised tests were introduced to assess the in vivo response to drugs in  
P. falciparum.38 After this, an attempt was made to eradicate the world of malaria by using 
chloroquine and insecticides as treatments. This pressure for the parasite to survive brought 
about rapid spread of resistance.32 However, chloroquine still remains the main treatment for 
individuals infected with P. vivax.7 Figure 1.5 shows the global distribution of chloroquine 
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resistance in 2002. This shows that even in the absence of any drug pressure after 45 years, 
the chloroquine resistant strains of P. falciparum still persist.33   
 
Figure 1.5: The global status of chloroquine and sulphadoxine-pyrimethamine resistance in 
2002 accoding to the WHO. Reprinted with permission from Ridley. 33 Copyright © 2002 
Nature.  
Even though quinine is the oldest antimalarial known to man, resistance has been slow to 
build against this drug since it is used much less frequently.6,39 Contributing factors to this is 
the bitter taste, side-effects such as hypoglycaemia and the dosage of three times daily for 
seven days.16 Resistance to the antifolate drugs, pyrimethamine and sulphadoxine, spread 
rapidly due to single point mutations in the dihydrofolate reductase and dihydropteroate 
synthase which lower the binding affinity of these drugs to the enzymes.40–43 Similary, 
atovaquone resistance results from point mutations in the gene cytB, which encodes 
cytochrome b.41,42 Mefloquine resistance has also developed rapidly due to overuse in 
Thailand, however it is still used in combination with artemisinin. Mefloquine resistance has 
been linked to the P. falciparum multidrug resistance gene (Pfmdr1). However, similar effects 
have been shown with halofantrine and quinine and thus this is most likely not the only cause 
of resistance to mefloquine.6,9,41–44 There is usually very little evidence of cross-resistance 
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between the 4-aminoquinolines and quinoline methanol compounds and thus compounds 
such as mefloquine are used on chloroquine resistant strains of P. falciparum.6,44 
Until 2008, resistance to artemisinin had not been reported. The first evidence was found in 
Cambodia, where the clearance rates were found to be more than double compared to the 
median expected for artemisinin. This was due to monotherapy with artemisinin carried out 
in this region despite literature indicating this should never be done. This resistance is due to 
the short half-life of the drug and the WHO recommends combination with drugs that have 
longer half-lives to mitigate this problem such as mefloquine.7,45  
By far the most researched mechanism of resistance is that of chloroquine due to its previous 
potency as an antimalarial drug. The main observation was that chloroquine accumulates in 
the digestive vacoule in high concentrations. This is substantially reduced in the chloroquine 
resistant strains of P. falciparum. This key finding sparked much debate about the mechanism 
of this phenomenon. However, through many years of research the actual mechanism of 
resistance was discovered.6,46,47 
The initial proposed mechanism was that of drug efflux out of the digestive vacuole in the 
resistant strains. A similar mechanism had been shown with different types of cancer cells 
and it was also shown that this drug resistance can be reversed with exposure to verapamil 
(Scheme 1.5) similar to those of drug resistant cancer cells.48,49 Several other mechanisms 
were also proposed including, increased detoxification of the chloroquine-haematin complex, 
altering chloroquine uptake by the digestive vacuole membrane or H+ flux and prevention of 
the chloroquine-haematin complex from forming.49–51 
 
Scheme 1.5: The chemical structure of the chloroquine resistance reversal agent, verapamil. 
All of these mechanisms were proved incorrect when Fidock et al 52 discovered a digestive 
vacuole transmembrane protein, aptly called P. falciparum Chloroquine Resistance 
Transporter (PfCRT), which was the primary reason for resistance. The study in 2000 showed 
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a gene containing eight point mutations in the chloroquine resistant (Dd2) strain compared 
to that of the chloroquine sensitive (HB3) strain of P. falciparum. Upon exchange of the alleles 
of the resistant to the sensitive strains, lowering of activity of chloroquine was demonstrated 
with verapamil showing reversal of  resistance as with the chloroquine-resistant strain. It was 
further observed that the most crucial mutation for resistance was the K76T mutation, an 
exchange of a lysine by a threonine amino acid at position 76.52,53 Another study by Roepe 
showed binding of PfCRT to a fluorescently tagged chloroquine analogue using spinning disk 
confocal microscopy.48,54 Juge et al in 2015 was able to demonstrate active transport of 
chloroquine by PfCRT across a proteoliposome membrane from lower pH to that of higher pH 
comparable to that of a digestive vacuole. It was also shown that verapamil was able to pass 
through the PfCRT liposome assembly and inhibit chloroquine resistance.55 
1.7 Mechanism of Action of the Quinoline Based Compounds 
Initial studies by Parker and Irvin demonstrated that chloroquine can bind DNA and thus it 
was proposed that it can inhibit DNA replication and RNA synthesis in the malaria parasite. 
56–58 This, however does not explain the fact that chloroquine kills P. falciparum at 
concentrations three times lower than those needed to be cytotoxic.6 A mechanistic clue 
came in 1970 when it was observed that chloroquine only acts against the blood stage of the 
parasite. This led to the belief that chloroquine interferes with the feeding process of  
P. falciparum. It was only in 1986 that Fitch et al 59 proposed that chloroquine interferes with 
haemozoin formation by complexing with haem. Later, Slater and Cerami complemented this 
argument in 1992 by demonstrating inhibition of β-haematin formation in vitro using 
chloroquine.60 It has been shown that haem concentrations in the digestive vacuole can be 
anywhere between 200-500 mM if not converted to non-toxic haemozoin by the parasite 
(Section 1.4). Thus this is an ideal target for malaria chemotherapy.6 
In order to attempt to verify compounds as haemozoin inhibitors before techniques for 
directly observing this had been developed, significant correlations between the haemozoin 
inhibition and parasite activity were shown. The first of these was demonstrated by Dorn et 
al 61–63 where a significant correlation between quinoline antimalarials β-haematin inhibition 
activity and NF54 P. falciparum parasite activity was shown (Figure 1.6). The assay was carried 
out using radio-labelled [14C]-haemin with eight known antimalarial drugs, namely, 
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chloroquine, halofantrine, quinacrine, amodiaquine, pyronaridine, quinine, mefloquine and 
primaquine as well as an experimental bisquinoline compound named Ro 48-6910.61  
 
Figure 1.6: The correlation of β-haematin inhibition (called haematin polymerisation) versus 
the NF54 P. falciparum parasite growth inhibtion activity of eight compounds namely, quinine 
(Q), mefloquine (MQ), quinacrine (QC), amodiaquine (AQ), chloroquine (CQ), halofantrine 
(HF), pyronaridine (PYR) and bisquinoline Ro 48-6910. Reprinted with permission from Dorn 
et al.61 Copyright © 1998 Elsevier Science.  
Another study in 1999, by Vippagunta et al 64 related the β-haematin inhibition values of 
thirteen chloroquine analogues to both the NF54 (chloroquine sensitive) and K1 (chloroquine 
resistant) parasite growth inhibition values (Figure 1.7). However, in this study the  
β-haematin inhibition values were normalised using the association constants of the drug 
with haem improving the correlation substantially. This showed the importance of the 
strength of binding of drugs to haem and how it influences parasite activity.64 
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Figure 1.7: The correlation of normalised β-haematin inhibition values using association 
constants of the drug with haem versus the parasite growth inhibition values with three 
compounds omitted due to lack of β-haematin inhibition activity. Reprinted with permission 
from Vippagunta et al.64 Copyright © 1994 American Chemical Society.  
Kaschula et al 65 also reported a correlation using chloroquine derivatives in 2002. Using an 
assay based upon differential solubility of haematin in dimethyl sulfoxide (DMSO) to calculate 
β-haematin inhibition values,66 no direct correlation was found. However, when the vacuolar 
accumulation ratio (α) was multiplied by the log(P.f IC50) a trend emerged (Figure 1.8). α was 
based on the pKa values of each compound and this ratio was divided by the α of chloroquine 
to determine the relative extent of pH trapping within the digestive vacoule of each 
compound seperately.65 Development of the pyridine ferrichrome method by Ncokazi and  
Egan 67 in 2005, which was found to be a more reliable method to measure β-haematin 
inhibition, was used to re-examine the activity of these compounds. Upon multiple 
correlation analysis using the vacuolar accumulation ratio and β-haematin inhibition values, 
a similar trend to that of the orignal Kaschula et al data was shown (Figure 1.9). There were 
similar correlations reported using non-quinoline compounds.68,69  
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Figure 1.8: a) Structure-activity relationship (SAR) showing no correlation and  b) correlation 
between log(P.f IC50 (α)) and the D10 parasite growth inhibition activity of chloroquine 
analogues. Reprinted with permission from Kaschula et al.65 Copyright © 2002 American 
Chemical Society.  
 
Figure 1.9: Multiple correlation analysis with the equation of log(1/P.f. IC50) = 
0.61(log[1/IC50(Phiβ)]) + 0.17(logVAR) + 6.98 where VAR is vacuolar accumulation ratio. 
Reprinted with permission from Ncokazi and Egan. 67 Copyright © 2005 Elsevier. 
In 2006, Roepe et al 70 reported using spinning disk confocal microscopy to observe live 
parasites in red blood cells.  These cells were dosed with chloroquine and observed over 37 
hours by measuring pixel density in z-stack (z-slice) images which were reconstructed to form 
a live image of the parasite in real time. It was shown that chloroquine inhibits haemozoin 
formation from 22 to 29 hours depending on the dose for both chloroquine sensitive and 
  b) a) 
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resistant strains (Figure 1.10). Furthermore it was observed that the use of verapamil lowered 
the IC50 of the chloroquine resistant strain, Dd2.          
 
Figure 1.10: The correlation of percent haemozoin inhibition versus percentage parasite 
growth inhibition between 25 and 30 h for chloroquine sensitive (HB3) strain (empty markers) 
with verapamil (triangle), without verapamil (squares), combination of verapamil and 
chloroquine (diamond) and the chloroquine resistant strain (Dd2) with filled markers. 
Reprinted with permission from Roepe et al.70 Copyright © 2006 American Chemical Society.  
From this study it is clear that decreased haemozoin levels in live P. falciparum cells support 
the haem detoxification pathway via haemozoin inhibition. However, this cannot validate 
haemozoin as the target as this reduction of haemozoin formation may be due to other 
factors such as reduced haemoglobin uptake. Therefore, Combrinck et al 71 devised the 
cellular haem fractionation assay in which the amount of free haem and haemozoin can be 
measured in cultured P. falciparum after exposure to known quinoline antimalarial drugs. 
Chloroquine showed the largest dose-dependant decrease in haemozoin and increase in free 
haem of all the antimalarial drugs tested with the parasite-survival curve showing the 50% 
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inhibitory concentration (IC50) of the drug at the cross-over point (Figure 1.11). It was also 
observed that there were no changes in the levels of free haem and haemozoin when dosed 
with 2.5 times the IC50 of the antifolate drugs, pyrimethamine and the pyrimethamine-
sulfadoxine combination. This was expected because these drugs are known to have a 
different mode of action. This study shows the most evidence in support of the haemozoin 
inhibition mechanism proposed by Fitch to date.      
                                                                                     
 
              
Figure 1.11: Graphs showing the effect of chloroquine dosing in P. falciparum on a) % 
haemozoin, b) % free haem and c) the % parasite survival with the % free haem. The negative 
control is pyrimethamine/sulfadoxine (SP). Reprinted with permission from Combrinck et al.71 
Copyright © 2012 American Chemical Society.  
A 
B 
C 
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1.8 β-haematin and Haemozoin 
With the knowledge that quinoline based compounds as well as other antimalarials inhibit 
haemozoin formation, it is appropriate to discuss the process by which haemozoin is formed. 
Even though this has been studied for decades the exact mechanism of haemozoin formation 
is not known.  
1.8.1 Discovery of the Structure of Haemozoin and its Synthetic Analogue, β-haematin  
The first report of haemozoin was in Italy by the renowned physician Lancisi in 1717.12,15 Later 
in 1897, Surgeon-Major Ross also noticed peculiar pigmented cells.4 Only in 1911 did W. H. 
Brown identify this pigment to consist of haem after it was originaly believed to be melanin.72 
The first isolation of haemozoin was demonstrated by Fitch et al in 1987 where the 
erythocytes were lysed and washed. Remaining proteins and lipids were broken down by 
proteases and the mixture was extracted using methanol and chloroform to yield the 
haemozoin crystals.59 In 1991, Slater et al 73 characterized haemozoin by using various 
spectroscopic techniques and comparing it to synthesized haemozoin, also known as  
β-haematin. An absorbance peak at 650 nm was observed in the UV-visible absorbance 
spectrum, characteristic of aqueous haematin which was already observed by Fitch et al 59 in 
1987. This was further confirmed with the elemental composition of haematin and the 
extracted haemozoin showing the same data. Upon dissolution of the extracted haemozoin 
in 0.1 M NaOH, the UV-visible absorbance spectrum as well as the mass spectrum were found 
to be identical to that of haematin further correlating the structure of haem to that of 
haemozoin. Haemozoin was further analysed using Fourier-transform infrared (FT-IR) 
spectroscopy where it was shown that this spectrum differed from that of haem containing 
two additional bands at 1664 and 1211 cm-1 which are characteristic of C=O and C-O 
stretching frequencies. Its was mentioned that this might arise from direct coordination of a 
carboxylate group of one molecule to the iron centre of another which was previously 
observed in an extensive series of Fe(III) monodentate complexes with coordination by 
acetate which contained a similar infrared (IR) peak at 1660 cm-1. This coordination of the 
propionate to the iron centre was only seen in the spectrum of haemozoin and not haematin. 
Using electron spin resonance (ESR) spectroscopy it was claimed that the ferric iron was in 
the low-spin state. However, this was proved incorrect later by Bohle et al 74 using Mossbauer 
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and variable-temperature electron paramagnetic resonace (EPR) spectroscopy where in fact 
this ferric iron centre is in the high-spin state. A year ealier, Bohle et al 75 also confirmed using 
powder X-ray diffraction (PXRD) patterns that haemozoin and β-haematin are identical. This 
data suggested that haemozoin takes the form of polymer chains hydrogen bonded by the 
propionate groups shown in Figure 1.12.  
 
Figure 1.12:  The Incorrect polymer structure of haemozoin proposed by Bohle et al where 
the arrows indicate direction of polymer elongation. Reprinted with permission from Bohle 
et al. 75 Copyright © 1997 The American Society for Biochemistry and Molecular Biology.  
Later, in 2000, Pagola et al 76 corrected this structure by solving the crystal structure using 
PXRD patterns obtained from synchrotron radiation by Rietvelt refinement. The structure of 
β-haematin was observed as dimers that interact via hydrogen bonding between propionate 
groups. These dimers then pack togeather via π-π interactions forming a crystal structure 
(Figure 1.13). 
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Figure 1.13: The actual crystal structure of two β-haematin dimers hydrogen bonding via the 
propionate groups. Reprinted with permission from Pagola et al.76 Copyright © 2000 Nature.  
1.8.2 Haemozoin Formation Mechanism 
There have been many hypothesized mechanisms proposed that attempt to explain the 
formation of haemozoin including, protein mediated formation77,78, enzyme catalysed60, 
spontaneous formation79 and lipid mediated62,63. Of these the most evidence points towards  
the lipid mediated mechanism whereby several studies have shown succesful formation of  
β-haematin in the presence of lipids.80,81 Haemozoin crystals have also been observed via 
microscopy and found to be in close proximity to lipids in P. falciparum.81 Recently, Kuter et 
al 82 have demonstrated that glycerolipids are responsible for the formation of haemozoin 
rather than phospholipids. The most abundant of these were found to be diacylglycerols 
rather than monoacylglycerols which was identified by using thin layer chromatography (TLC) 
analysis. With the help of extensive computational studies involving this lipid and haem as 
well as experimental findings a mechanism describing the intial stages of haemozoin 
formation was proposed (Figure 1.14). The main steps involve haem partitioning between 
lipid and aqueous phases after which haem is aggregated within the lipid, iron coordination 
occurs with the propionate groups of other haem molecules and finally crystal growth 
occurs.82  
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Figure 1.14: The proposed mechanism of haemozoin formation using the water-lipid interface 
where the dark grey band represents lipid headgroups while the light grey band represents 
lipid tails. Key steps are i) partitioning of haem into lipid, ii) aggregation of haem in lipid, iii) 
iron coordination and iv) crystal growth. Reprinted with permission from Kuter et al.82 
Copyright © 2016 the Royal Society of Chemistry.  
1.8.3 Haemozoin Inhibition Mechanism 
The mechanism of haemozoin inhibition is not certain even though it is known that 
haemozoin-inhibiting drugs cause a decrease in haemozoin and increase in free haem in the 
parasite (Section 1.7). Dorn et al 62 demonstrated that quinoline antimalarials bind to the  
µ-oxo dimer thereby reducing the amount of monomeric haem available for formation of 
haemozoin. This presence of µ-oxo dimer formation was confirmed by Kuter et al 83 who 
further observed a complex of chloroquine and Fe(III)PPIX with a stoichiometry of 2:4 using 
magnetic circular dichroism, UV-visible absorption, diffusion techniques and magnetic 
susceptibility. However, it is not certain if the complex is responsible for haemozoin formation 
inhibition. Some mechanistic suggestions indicate that this complex can bind to haemozoin 
and disrupt or terminate growth.77 Another suggestion is that the antimalarial drug in 
question could bind to the fastest growing crystal face to inhibit further growth of the crystal. 
Further computational studies by Buller et al 84 based on the crystal structure of  Pagola et al 
76 have shown chloroquine manually docking on the fastest growing face of the β-haematin 
crystal, (001), as shown in Figure 1.15. Complementing this work Olafson et al 80 have shown 
24 
 
four different adsorption sites on the β-haematin crystal but, it was also shown that 
chloroquine adsorbs preferably to the step sites on the (001) crystal face. 
 
Figure 1.15: a) The (001) face of the β-haematin crystal structure with crevices shown in green 
and b) chloroquine interacting with the (001) face of the β-haematin crystal structure. 
Reprinted with permission from Buller et al.84 Copyright © 2002 American Chemical Society.  
It should be noted that even though haemozoin inhibitors follow the same mode of action, 
resistance arises differently to each scaffold and thus cross-resistance does not occur 
a) 
b) 
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between the quinolines and other scaffolds. It is therefore still viable to still consider 
haemozoin inhibtion as a drug target. 
1.8.4 Haem-drug Complexes  
The first haem-drug complex crystal structure of halofantrine and haem was reported in 2008 
by de Villiers et al.85 This crystal structure (Figure 1.16) revealed the deprotonated hydroxyl 
group of halofantrine coordinating to the iron (III) centre and π-π stacking interactions 
between the porphyrin ring system and that of the phenanthrene ring. Using the UV-visible 
absorbance data of this complex it was shown that it was similar to that of the haem-quinidine 
and haem-quinine complexes. Consequently, similar structures were proposed. This was later 
confirmed by de Villiers et al 86 when the actual crystal structures were reported (Figure 1.16). 
   
Figure 1.16: Crystal structures of a) the halofantrine-haem complex and b) the quinine-haem 
complex. Reprinted with permission from de Villiers et al 2008 85 and 2012 86 respectively. 
Copyright © 2008 Elsevier and 2012 American Chemical Society.  
1.8.5 β-haematin Inhibition assays 
The development of assays to measure β-haematin inhibition has been crucial for 
investigating the mechanism of action of chloroquine as well as other antimalarials. IR 
spectroscopy was the first method used in 1994 by Egan et al 79 in which the presence of free 
haem was reported using high concentrations of acetate as a methodology for formation of 
β-haematin crystals. Dorn et al 63, Sullivan et al 78 and Kurosawa et al 87 all used the same 
acetate methodology, albeit with lower concentrations of acetate and radio-labelled 
haematin. Slater et al 60 also showed that the acetonitrile extract of trophozoite lysate can 
induce β-haematin formation. However, these assays did not account for the role of lipids in 
a) b) 
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the formation of haemozoin and thus Fitch et al 88 reported the use of detergents and lipids 
to mediate the formation of β-haematin. The use of neutral lipid blends is time-intensive and 
costly thus in order to mimic lipids, the use of surfactants was attempted. The main 
characteristic of surfactants is that they contain a hydrophobic tail and a hydrophilic head 
that can be charged, uncharged or zwitterionic. They consists of a broad range of detergents, 
foaming agents, dispersants and emulsifiers. In water, these molecules aggregate forming 
micelles, a spherical shape where the hydrophobic tails are contained within the sphere away 
from the hydrophillic water and the head groups point towards the water. This is only possible 
if the surfactant has reached the critical micelle concentration otherwise the surfactant forms 
a layer above the water with the hydrophilic heads closest to the surface of the water.89 
The initial attempt by Huy et al 90 in 2007 to use TWEEN® 20, a detergent, to mediate  
β-haematin formation had mixed results. The incubation time was found to be less and it was 
found to be cheaper than using neutral lipid blends. However, the results showed a  
ten-fold increase in the IC50 values of known antimalarials. Following this, Carter et al 91 
reported the use of another detergent, Nonidet-P40 (NP-40) which had comparable results 
to that of the neutral lipid blend experiments. Along with NP-40, a range of detergents, 
namely, TWEEN® 20, TWEEN® 80, CHAPS, SDS and Triton X-100 were investigated. The 
detergents ability to nucleate crystal growth was investigated and the β-haematin products 
were characterised using PXRD and IR spectroscopy. The only β-haematin crystals that 
matched those of the Bohle dehydrohalogenation β-haematin synthesis (yields ≥ 69%) were 
formed using NP-40, TWEEN® 80 and TWEEN® 20. Further concentration dose response 
experiments using known antimalarial drugs demonstrated that only NP-40 showed 
comparable results to that of the neutral lipid blend methodology after the concentration of 
NP-40 was optimised. These results are shown in Table 1.1. 
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Table 1.1: Comparison of detergents using the data collected by Carter et al 91 where NP-40 
shows the best yield and has a comparable IC50 value to that of the neutral lipid blend 
methodology. 
Lipophilic Mediator 
Mediator 
Concentration 
(µM) 
β-haematin 
yield (%) 
Chloroquine IC50 
(µM) 
Amodiaquine IC50 
(µM) 
Neutral Lipid Blend 50 75 23.07 85.26 
NP-40 30.6 74 25.73 50.99 
TWEEN® 80 14.9 69 201.8 195.7 
TWEEN® 20 9.77 71 316.3 262 
SDS 1140 10 225.4 245.6 
CHAPS 1466 7.0 n/a n/a 
Triton X-100 58.6 7.4 n/a n/a 
 
This assay was originally designed to be used for a high-throughput screening study where 
the compounds in question contained a variety of functional groups and thus the assay 
needed to be robust. In 2011, this assay was adapted for use in 384-well plates by Sandlin et 
al 92 and the colorimetric pyridine ferrichrome method developed by Ncokazi and Egan 67 was 
used to detect the amount of haem present in each well. This method was originally adapted 
from a well known way of quantifying haem in haemoglobin in which pyridine is added to the 
mixture and forms a low-spin bispyridyl complex (Scheme 1.6). This assay also forms this 
complex with free haem but not β-haematin. The absorbance spectrum of the complex 
showed a shift of the Soret band from 389 to 404 nm and sharpened it while increasing the Q 
bands intensity which indicated a change in speciation from an aggregate (most likely dimers), 
which is known to occur with haem in water, to a low-spin monomer. It was also 
demonstrated that this obeyed Beer’s law up to concentrations of 30 µM at 405 nm. The 
pyridine concentration and pH of the assay were optimised to allow only formation of the 
bispyridyl complex and allow no disruption of β-haematin which is seen at high pH. 
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Scheme 1.6: The bispyridyl-haem complex formed with the addition of pyridine to haem 
described by Ncokazi  and Egan.67 
1.9 High-throughput Screening 
High-throughput screening (HTS) is the process whereby automation enables quick assay of 
biochemical or biological activity of a large number of drug-like compounds. It has been 
widely used in the pharmaceutical industry for the discovery of hit compounds from large 
libraries of compounds such as those of Novartis 93 and GlaxoSmithKline (GSK).94 
1.9.1 Target-based Versus Phenotypic Screening 
Three types of high-throughput screening are known, namely, virtual, phenotypic and  
target-based of which only target-based and phenotypic will be discussed for the purpose of 
this thesis.95 Target-based screening is one in which, as the name suggests, the target of the 
compound is known and compounds are screened against that target. This has been the most 
popular form of screening especially for malaria based drug targets due partially to its reduced 
cost compared to phenotypic screening.95,96 
Phenotypic screening aims to measure an effect in tissue or whole cells without any 
knowledge of targets. This type of screening suffers from high cost and additional work in 
terms of target identification. However, both these screening methodologies can be 
combined by firstly performing target-based screening on the whole library of compounds, 
followed by phenotypic screening to analyse additional factors that contribute to activity such 
as cell permeability.95,96 Recently, there have been discussions to move back to phenotypic 
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screening due to improved target identification tools such as improvements in genetics and 
proteomics.96   
1.9.2 Antimalarial High-throughput Screening  
The initial HTS for β-haematin inhibitors was performed in 2000 by Kurosawa et al.87 Several 
libraries of compounds were screened, containing over 100 000 compounds for their  
β-haematin inhibition activity which used the radio-labelled haematin methodology. From 
these 100 000 compounds only 45 non-quinoline compounds were identified with four of 
these compounds, a triarylcarbinol, a piperazine, a benzophenone and an unknown scaffold 
found to be active against the P. falciparum NF54 (chloroquine sensitive) and K1 (chloroquine 
resistant) strains.  
Rush et al 97 also screened 16 000 compounds for β-haematin inhibition activity in 2009. 
However, the colorimetric pyridine ferrihemochrome methodology developed by Ncokazi and 
Egan 67 was used instead. This led to about 600 hit compounds of which 17 showed activity 
against both the 3D7 (chloroquine sensitive) and Dd2 (chloroquine resistant) strains. Both 
these screens described were target-based screens. 
The largest antimalarial HTS by far was carried out by two industrial companies (Novartis  and 
GSK) as well as an academic group (St. Jude Children’s Research Hospital) using a phenotypic 
screening method on P. falciparum between 2008 and 2010. GSK screened about two million 
compounds from their libraries of which 13 533 where confirmed to inhibit parasite growth 
by more than 80% at a concentration of 2 µM.94 This set of compounds became the Tres 
Cantos Antimalarial Set (TCAMS). The St. Jude Children’s Research Hospital screened 309 474 
compounds with the same cut-off of greater than 80% parasite growth inhibition against the 
3D7 (chloroquine sensitive) and K1 (chloroquine resistant) strains showing 561 hit 
compounds.98 Lastly, Novartis screened 1.7 million compounds of which 5 973 where found 
to active and novel enough to be considered as hit compounds.93 
1.9.3 Vanderbilt University HTS Efforts 
Following the initial pilot study containing 38 400 compounds from the Vanderbilt University 
library which was used to test the validity of the HTS methodology, a larger study was 
conducted using all of the compounds (144 330) to investigate novel β-haematin inhibiting 
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scaffolds. Compounds were first tested for β-haematin inhibition activity using the NP-40 
detergent based assay in 384-well plates with positive control amodiaquine and negative 
control DMSO used. Compounds that were found to inhibit greater than 80% of β-haematin 
formation were considered hits which identified 729 compounds with a hit rate ([hit 
compounds/total compounds] x100) of 0.5%. Hit compounds were then subjected to a so 
called “cherry picking” methodology to test for false positives. After a final cut-off of 27 µM 
was established, 530 compounds were considered hits.  
Following this, all hit compounds were tested for parasite growth inhibition activity against 
the D6 (chloroquine sensitive) strain using the SYBR Green I fluorescence-based assay first 
described by Smilkstein et al.99 171 of these hit compounds were shown to inhibit ≥ 90% 
parasitemia and considered hits with a hit rate of 32%. Dose-response analysis of these hits 
showed 73 compounds to have activities of ≤ 5 µM of which 25 exhibited nanomolar activity. 
These compounds that exhibited nanomolar activities were further tested on the C235 
(chloroquine resistant) strain of the parasite using the same conditions as before. The 
resistance index of these compounds was calculated with 21 out of 25 showing values of less 
than 3 indicating effectiveness against resistant parasites.100 The top ten of these compounds 
are shown in Table 1.2. 
 
 
 
 
 
 
 
 
 
31 
 
Table 1.2: The data collected by Sandlin et al 100 indicating the top 10 most active compounds 
against β-haematin formation and parasite growth inhibition in both the resistant and 
chloroquine sensitive strains found during the HTS. 
VU Identifier Structure 
β-haematin 
inhibition IC50 
(µM) 
D6 IC50 (µM) 
C235 IC50 
(µM) 
Resistance 
Index 
VU0098755 
 
12.6 0.11 0.13 1.2 
VU0073687 
 
6.3 0.18 0.55 2.9 
VU0001281 
 
5.7 0.19 0.17 0.9 
VU0065708 
 
16.2 0.20 0.18 0.9 
VU0096505 
 
8.8 0.24 0.22 0.9 
VU0107282 
 
17.0 0.29 0.54 1.9 
VU0114785 
 
13.4 0.35 4.82 13.9 
VU0002101 
 
14.3 0.35 0.41 1.2 
VU0028177 
 
13.3 0.35 0.46 1.3 
VU0063971 
 
8.9 0.38 0.83 2.2 
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Further analysis of a respresentative of each scaffold found in the HTS was subjected to the 
cellular haem fractionation assay to determine if haemozoin inhibition is the correct mode of 
action for these compounds. This assay was developed by Combrink et al 71 and measures the 
percentage free haem and percentage haemozoin at various concentrations of drug. A 
haemozoin inhibitor will show an increase in free haem and decrease in haemozoin. All of the 
hits tested exhibited positive results indicating that all the hits were haemozoin inhibitors.100  
Fourteen different β-haematin hit scaffolds were found in this study, 46% of which encompass 
the total β-haematin inhibitors in the study. Of the fourteen scaffolds two were analysed 
more closely, namely, the benzimidazoles and the carbazole scaffolds. The HTS results 
showed ten benzimidazole compounds to be active against β-haematin formation of which 
five where found to be active against the parasite. Similarly, the carbazole scaffold showed 
eight β-haematin inhibitors, four of which where found to be active against the malaria 
parasite. These scaffolds are also represented in the top 10 most potent hits shown in Table 
1.2 with ranks 4 and 8 representing carbazoles and benzimidazoles respectively.100 Therefore 
those hit compounds were chosen for analysis in this thesis and shown in Scheme 1.7. 
 
 
Scheme 1.7: The two scaffolds chosen from the HTS study for further analysis. 
Due to the unfavourable positive charge on the carbazole hit, it was decided to modify this 
hit using bioisosteres. Using the online resource, SwissBioisoteres, enabled the choice of 
indoles instead of the quinoline group. Swissbioisosteres indicated that 17 out of the 19 
compounds on record with this ring system change retained the same activities, while two 
showed a better activity and one showed a lower activity. Therefore, the quinoline group was 
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changed to an indole group as shown in Scheme 1.8. The following sections will discuss these 
scaffolds in reference to known literature drugs. 
 
 
Scheme 1.8: New proposed carbazole based hit analogue. 
1.10 Benzimidazole Scaffold in the Literature 
Benzimidazoles are a well-known chemical moiety that was first synthesized by Hoebrecker 
and subsequently by Wundt and Landenberg from the years of 1872 to 1873 which now forms 
part of a diverse family of bioactive compounds that have a broad range of medicinal uses. 
101–103 These medicinal properties include, but are not limited to, antiparasitic, antimicrobial, 
potential anticancer, anti-inflammatory, analgesic, antihypertensive, antioxidant, antiulcer, 
anti-HIV and antimalarial activity amongst others (Scheme 1.9).103–111 This wide variety of 
medicinal applications explains the prevalence of interest in this scaffold as well as syntheses 
involving the benzimidazole scaffold throughout literature.103  
Since the late 1980s, there have been numerous reports of benzimidazole compounds 
inhibiting the growth of Plasmodium parasites. In 1990, Dieckmann-Schuppert and Franklin 
112 reported benzimidazole compounds that interact with tubulin to inhibit tubulin 
polymerisation. The same authors also reported attempts at using albendazole, a known 
benzimidazole drug that is used in the treatment of hookworms, against the malaria parasite. 
This was not feasible as high concentrations of the drug were needed to be effective.113 
Mayence et al, 113 in 2011 reported bis(oxyphenylene)benzimidazole compounds that were 
found to be active against P. falciparum. Similarly, there were reports of amidino  
bis-benzimidazoles and N-aryl-2-aminobenzimidazoles reported by Worachartcheewan et al 
114 and Ramachandran et al 115 respectively that demonstrated activity against P. falciparum. 
However, none of these reports show haemozoin inhibiting benzimidazole compounds apart 
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from the recent work by Chibale et al 116 which showed weak β-haematin inhibitory activities. 
This leaves an interesting research gap for the benzimidazole hit compound shown in Scheme 
1.7. 
 
Scheme 1.9: Some prominent drug compounds containing the benzimidazole scaffold 
indicating their wide medicinal applications.117 
1.11 Carbazole Scaffold in the Literature 
Carbazole was first isolated by Graebe and Glazer in 1872 from coal tar.118 In 1965, the first 
carbazole alkaloid, murrayanine, was isolated from the leaves of the Murraya koenigii Spreng 
tree in India.119 Following this, there has been a keen interest in carbazole-containing 
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compounds due to their various biological applications which mainly include anticancer 120,121, 
antimicrobial 122,123 , neuroprotective and recently antimalarial activity.124 Scheme 1.10 shows 
some compounds mentioned in literature that have potent activities against their relevant 
targets. 
 
 
Scheme 1.10: Carbazole-containing compounds that showed potent activities for treatment 
of various diseases. 
Shortly after murrayanine was discovered and synthesized, investigations into the carbazole-
containing compounds for antimalarial studies were carried out. Brown et al 125 investigated 
the potential for heteroaryl carbinols to exhibit antimalarial activity in 1971, but all the 
compounds were shown to be inactive. Following this in 2007, a patent was filed for the 
discovery of novel carbazole-containing compounds that were shown to inhibit haemozoin 
formation via the supposed inhibition of the haem detoxification protein which is theorized 
to catalyse haemozoin formation in the parasite. Molette et al 122 demonstrated the activity 
of a series of amino-alcohol carbazoles, similar to the hit compound found during HTS, with 
promising in vitro and in vivo results. The most active of those compounds is shown in Scheme 
1.11. Wang et al 126 performed a HTS on a library of 126 compounds docking them in silico in 
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the P. falciparum specific binding site, PfHsp90. The best compound found during this screen 
was an amino-alcohol carbazole compound shown in Scheme 1.11. This compound showed 
good binding to the amino acid residues while showing no specific binding to the human 
analogue of PfHsp90. This compound also showed potent activity against P. falciparum. 
 
Scheme 1.11: The amino-alcohol carbazole derivatives that were demonstrated to be the 
most active against P. falciparum in each literature study. 
Given that the benzimidazole and carbazole hit compounds chosen from the HTS are backed 
up by a rich source of data from literature, indicating their potential as druggable compounds 
together with their potent activities shown in the HTS, these compounds were considered 
ideal candidates for further investigation in this project. 
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1.12 Aims and Objectives 
1.12.1 Aims 
Due to the dire need for new scaffolds of antimalarials that are able to overcome growing 
resistance, while retaining haemozoin formation as the drug target of choice, the aims of the 
project were to synthesize derivatives of the hit compounds chosen from the Vanderbilt HTS 
using Bayesian statistical models to narrow down the choice of compounds, probe the 
mechanistic action of these derivatives and discover any possible structure-activity 
relationships. 
1.12.2 Objectives 
More in depth lists of objectives for each chapter are shown in the introduction of each 
chapter with a summarised version shown below. 
In order to achieve the aims of this project the following specific objectives needed to be 
achieved: 
 Enumerate derivatives of the benzimidazole scaffold and predict β-haematin 
inhibition and malaria parasite growth inhibition values using Bayesian statistics for 
both scaffolds.  
 Select derivatives for synthesis based on these results and synthesize a series of 
derivatives for each scaffold. 
  Analyse all the synthesized compounds for biological activities and compare it to the 
predicted Bayesian results.  
 Perform molecular docking on all compounds to determine any correlations with  
β-haematin inhibition activity. 
 Perform the cellular haem fractionation to verify the haemozoin target of these 
scaffolds. 
 Investigate all SAR of these compounds to enable further optimisation of these 
scaffolds in the future. 
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Chapter 2: Bayesian Studies 
2.1 Introduction 
HTS has been one of the primary tools used by the pharmaceutical industry for years as it uses 
large libraries screened against single targets to discover hits. Despite its success in the 
industry there is always a search for a more cost effective way to determine the appropriate 
chemical characteristics, pharmacokinetics and pharmacodynamic properties of potential 
hits.127 HTS also suffers from lack of chemical diversity as large databases generally only focus 
on a small chemical space.128 Machine learning techniques, such as Bayesian classifiers and 
molecular docking helps to screen a whole array of compounds in silico and predict their 
activities as well as give a better understanding of the interaction of these compounds with 
targets such as the β-haematin surface. This allows focus to be drawn onto different chemical 
spaces, eliminating most of the false-positives that are found in HTS screens and shortens 
time needed for synthesis.129,130 
2.2 Bayesian Probability Method 
2.2.1 Bayesian Statistics 
Machine learning approaches have been used for a variety of chemoinformatic applications 
in the literature, including the aiding of drug design by predicting molecular properties or 
compound activity.131,132 Some of the more frequently used statistical algorithms include 
random forests, vector machines and naïve Bayesian, however, naïve Bayesian has only 
recently been applied to antimalarial activity predictions.127,131 Bayesian statistics can be used 
to build a statistical model from a large data set of compounds with both active and inactive 
compounds present such as from a HTS data set (priors) to predict properties such as 
adsorption, distribution, metabolism and excretion (ADME) as well as activities against the 
malaria parasite.127,132,133 
2.2.2 Bayes’ Theorem 
The statistical model used in this study makes use of Bayes’ theorem, first published in 1763 
by Thomas Bayes, to predict molecular properties based on Equation 2.1: 134 
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𝑃(𝐴|𝑀)  =
𝑃(𝑀|A)𝑃(𝐴)
𝑃(𝑀)
              Equation 2.1 
For the purpose of this thesis, A is the activity of a compound and M is the molecular feature 
that contributes to the activity. Therefore P(A) is the probability of any compound being active 
in the training set, P(M) is the probability of the molecular feature being present in any 
molecule in the training set, P(A|M) is the probability that the molecular feature contributes 
to activity in a test molecule and P(M|A) is probability that the molecular feature is present 
in an active compound in the training set.  
2.2.3 Bayesian Model in Discovery Studio 
The Bayesian model approach in Accelrys Discovery studio software uses prior data, in this 
case HTS data, with knowledge of inactive and active compounds according to a 
predetermined cut-off set by the user to create a training set.127,135,136 Any compound that is 
below the user determined threshold is earmarked as “bad” (inactive) and any compound 
above the threshold is earmarked as “good” (active).127,129,133,137 The system learns to 
distinguish features of active compounds using input descriptors such as LogP, molecular 
weight, number of hydrogen bond donors, number of hydrogen bond acceptors, number of 
rotatable bonds, number of ring systems, fractional polar surface area, extended connectivity 
fingerprints of depth 6 and the number of aromatic rings.127,131,137 The model records the 
frequency of these features in the ‘”good” compounds and assigns them a weighting using 
the Laplacian-adjusted probability estimate (see Section 2.2.4).127,133,137 A Receiver Operating 
Characteristic (ROC) score is given to the user once the model is completed which indicates 
the performance of the model and is calculated from the area under the curve of the true 
positives rate versus the false positives rate.  A ROC score of 1 means a perfect model and 
that of 0.5 means that no enrichment is achieved.127,129,137 An external compound (test 
compound) can be run in the model and its data can then be added to the model to improve 
the ROC score. This can be done several times with active and inactive compounds as the 
model improves with a more diverse array of compounds.137 For this work a prebuilt  
β-haematin inhibition model (cut-off 100 μM) and a prebuilt parasite growth inhibition model 
(cut-off 2 μM) with ROC scores of 0.915 and 0.991 respectively  were used which was reported 
by Wicht et al.127   
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2.2.4 Laplacian-corrected Probability Estimator 
In order to adjust for an uncorrected probability of a certain feature of a molecule, a 
Laplacian-corrected estimator is used as some molecular features appear more often than 
others which can skew the data. The derivation is given by means of an example from Xia 
Xiaoyang et al and Discovery Studio.135,137 
Assuming a number of compounds T is available in a given training set of which X are active 
then the baseline probability of a random compound chosen being active would be 
𝑃(𝑎𝑐𝑡𝑖𝑣𝑒) = 𝑋/𝑇. If Y of those T compounds contained a certain molecular feature Z and 
only S of those molecules were shown to be active, then the probability of a compound being 
active changes to 𝑃(𝑎𝑐𝑡𝑖𝑣𝑒|Z) = 𝑆/𝑌. The estimate for that feature Z becomes unreliable if 
the number of molecules in the training set with the feature Z is low. This means, for example, 
if only one compound in the training set contains molecular feature Z and happens to be 
active then 𝑃(𝑎𝑐𝑡𝑖𝑣𝑒|Z) =
1
1
= 1, which is vastly overconfident for that molecular feature. 
This means that the feature has been undersampled, but most molecular features do not 
relate to active molecules in the training set so for these cases 𝑃(𝑎𝑐𝑡𝑖𝑣𝑒) = 𝑃(𝑎𝑐𝑡𝑖𝑣𝑒|Z). 
Adding a sample of N molecules with the molecular feature Z to the training set, we now have 
the expected number of molecules being active is 𝑃(𝑎𝑐𝑡𝑖𝑣𝑒) ∗ 𝑁. With the inclusion of these 
new molecules to the training set, correcting the estimate of the probability, the equation 
changes to:  
𝑃𝑐𝑜𝑟𝑟(𝑎𝑐𝑡𝑖𝑣𝑒|Z) =
(𝑆+P(active)∗N)
𝑌+𝑁
  
This correction factor now stabilises the estimator as the number of compounds Y+N 
approaches N, the probability of the molecular feature now converges to just P(active) which 
is the expected value of most of the features as most features do not contribute to activity in 
a molecule. Finally, the estimator is divided by P(active) and then the logarithm is taken 
thereafter to produce Equation 2.2. 
log 𝑃𝑓𝑖𝑛𝑎𝑙(𝑎𝑐𝑡𝑖𝑣𝑒|Z) = log
𝑃𝑐𝑜𝑟𝑟(𝑎𝑐𝑡𝑖𝑣𝑒|Z)
𝑃(𝑎𝑐𝑡𝑖𝑣𝑒)
               Equation 2.2 
This is done to normalise the equation and to completely predict the probability of the 
molecule being active from the molecular features. Most molecular features will give a 
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LogPfinal that is approximately zero but some features that are common in active molecules 
LogPfinal will be positive. Similarly, if the molecular features are common in inactive 
compounds in the training set LogPfinal will be negative.135,137 
2.2.5 Pipeline Pilot 
Pipeline Pilot was developed in 2004 by SciTegic, later a subsidiary of Accelrys and was the 
first software that allows its user to fully automate analysis, data management and reporting 
protocols at the click of a button. This is done by a number protocols linked together as the 
user sees fit, to create a workflow of jobs which can be reused by other users later or extended 
to include more processes.138 Pipeline Pilot is compatible with all functions available in the 
Discovery Studio package and was used for this study. 
2.3 Bayesian Goals 
The goals of this chapter were to:  
 Produce a workflow of protocols in Pipeline Pilot to: 
 Enumerate all possible in silico benzimidazole compounds from the available 
starting materials in the Sigma-Aldrich catalogue. 
 Predict β-haematin inhibition and hence select active compounds in silico. 
 Predict the resulting active compounds using the malaria parasite growth 
inhibition model and select the active compounds in silico. 
 Select the active compounds according to predicted aqueous solubility. 
 
 Investigate six proposed carbazole indole derivatives in silico using both the  
β-haematin inhibition model and malaria parasite growth inhibition model. 
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2.4 Results and Discussion 
2.4.1 Benzimidazole Bayesian Methodology 
The benzimidazole hit compound from the HTS has three possible points of derivatization 
(Figure 2.1) that were explored in this study. The three ring systems in Figure 2.1 (red, green 
and blue) can lead to an enormous number of enumerated in silico compounds, thus it was 
decided to use the Sigma-Aldrich database of available chemicals as a basis to explore in silico 
derivatives. 
 
Figure 2.1: The three proposed areas of derivatization. 
A protocol created in Pipeline Pilot (Scheme 2.1) was used in Discovery Studio to automate 
all the processes described below. This made it possible to create a workflow to narrow down 
the search for the optimum series of compounds to synthesize by using various filters after 
each step. Using this methodology 325 728 compounds were enumerated through a 2-step 
reaction from an input of 26 o-phenylenediamine derivatives, 24 p-aminobenzoic acid 
derivatives and 522 aromatic carboxylic acids. After enumerating this new in silico library of 
compounds, the next step in the workflow was to subject them to the β-haematin inhibition 
model created by Wicht et al.127 All predicted inactive compounds (19 904), determined by 
the model cut-off of -4.920, were filtered out and the predicted active compounds (305 824) 
were filtered using the parasite growth inhibition activity model with a cut-off of -8.580 also 
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created by Wicht et al.127 These predicted inactive compounds (2 148) were filtered out and 
the predicted active compounds (303 676) were sorted by aqueous solubility level with a  
cut-off of 1 or less, available as part of the Discovery Studio ADMET predictions function.  
35 124 Compounds were predicted to have a moderate to low solubility whilst 268 552 were 
predicted to have little to no solubility in aqueous medium at 25 °C. Only 68 compounds of 
the 35 124 compounds were predicted to have a solubility value of 3 (moderate). This was a 
warning of the limitations of these compounds with any aqueous based chemistry and any 
assays that might need to be done on this series. 
 
 
Scheme 2.1: An example of the Pipeline Pilot protocol used. 
Benzimidazole ring formation reaction 
Amide bond formation reaction 
β-haematin inhibition protocol 
Parasite growth inhibition protocol 
Second parasite growth inhibition 
protocol 
Aqueous solubility descriptor 
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2.4.2 Benzimidazole Derivatives: Rationalisation 
Reviewing the soluble active dataset, absence of substitution on the middle ring system 
(green in Figure 2.1) was found to be a defining feature. The only deviation from this result 
was the presence of mono nitro substituted derivatives and a change from a benzene to 
pyridine ring system. Upon analysis of the predicted β-haematin inactive compounds, 100% 
of the compounds in that subset of data contained one to four substituents on that ring 
system. In light of these results it was decided to avoid substituents on that ring system and 
focus on the other two positions of the molecule. This narrowed down the search even further 
and ensured a simpler synthesis of these compounds.  
The other dominant features found in the soluble active compounds subset was the presence 
of mono and disubstituted nitro and halogen benzimidazole substituents, the presence of  
5-membered ring systems after the amide bond (blue in Figure 2.1) and mono and 
disubstituted benzene and pyridine ring systems (blue in Figure 2.1). Selection of compounds 
with these features allowed for concentration of effort on the effect of the position of 
substitution on the various ring systems. It is also common practise to synthesize the hit 
compounds from the HTS study to ensure that this hit was not a false positive as all the data 
from the HTS was input into the Bayesian models so any compounds with a similar fingerprint 
would be heavily influenced by the hit and termed as active.  
From these observations, the number of choices of compounds to synthesize was narrowed 
down from 35 124 to 36. Due to unforeseen synthetic difficulties described in Chapter 3, 
formation of compounds substituted on the benzimidazole ring (red in Figure 2.1) was not 
possible, therefore only the amide linked ring system (blue in Figure 2.1) was derivatized. 
Table 2.1 contains all the compounds chosen for this study and their appropriate predicted  
β-haematin and parasite growth inhibition activity. These compounds were predicted to have 
a lower aqueous solubility than their nitro and halogenated analogues, so it was expected 
that solubility issues would arise with these compounds, but their β-haematin inhibition and 
parasite growth inhibition scores far surpassed the cut-off values for these models and so 
they were considered ideal candidates for this study. 
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Table 2.1: Selected compounds for synthesis based on Bayesian results 
Ar (compound number) 
β-haematin inhibition 
score 
Parasite growth inhibition 
score 
Phenyl (2) 25.6979 61.3259 
m-Bromophenyl (3) 28.1166 57.2935 
m-Trifluoromethylphenyl (4) 32.6362 75.2685 
3-Bromopyridyl (5) 38.4248 72.6119 
p-tert Butylphenyl (6) 25.4777 63.8076 
2,4-Dichlorophenyl (7) 24.0156 49.3979 
o-Methoxyphenyl (8) 19.9991 43.3265 
3-Trifluoromethylpyridyl (9) 36.4715 81.8491 
o-Nitrophenyl (10) 21.0876 30.0400 
3,5-Dinitrophenyl (11) 40.5853 47.2409 
2,6-Dichloropyridyl (12) 29.5242 65.4908 
o-Chlorophenyl (13) 19.5834 45.2802 
m-Chlorophenyl (14) 31.0259 58.6210 
p-Chlorophenyl (15) 25.1454 56.5011 
3-Pyridyl (16) 30.6674 78.3569 
Thiophenyl (17) 19.3296 55.1323 
Furanyl (18) 14.9506 48.2215 
Pyrrole (19) 27.4973 67.9852 
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2.4.3 Benzimidazole Fragments 
An in silico investigation of the hit benzimidazole fragments was performed using the 
previously described Bayesian models to predict their activities. This provided a 
rationalization for the change in predicted activity with the removal of key functional groups. 
The compounds derived from the hit compound are shown in Figure 2.2 and are comprised 
of the smallest fragment on either side of the molecule built sequentially until the compounds 
lack just one ring system. The Bayesian statistics results for the β-haematin model showed all 
but one compound to be predicted as active but many compounds were found to be close to 
the cut-off value as shown in Table 2.2. This prediction indicated that these compounds would 
either be expected to have low, or no β-haematin inhibition activity.  
 
Figure 2.2: Benzimidazole fragment compounds derived from the hit compound in the centre. 
The results of the parasite growth inhibition model predicted that five out of the seven 
compounds would be active, with three of the compounds close to the cut-off indicating high 
confidence in just two predicted active compounds. Both compounds 1 and 23 contained the 
benzimidazole and middle benzene ring system, supporting the previous decision to focus 
synthetic efforts on the carbonyl containing ring system. 
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Table 2.2: The Bayesian statistic results of the benzimidazole fragment study with predicted 
active compounds shown in red and predicted inactive compounds shown in black. 
Compound Number β-haematin inhibition score 
Parasite growth inhibition 
score 
1 22.8883 56.9520 
21 12.7431 -8.57182 
21a -5.34745 -10.6894 
22 6.81007 -8.25818 
22a 8.04823 -12.8326 
23 19.8929 60.8754 
23a 1.03421 4.55447 
 
2.4.5 Carbazole Indole Derivatives 
Bayesian statistics can provide some insight into the role of hydrogen bonding of the hit 
compound with the β-haematin crystal surface. Enumerating compounds by sequentially 
removing hydroxyl groups from the hit compound until it was devoid of hydroxyl groups is a 
case in point with respect to the carbazoles (Figure 2.3). This generated only three different 
compounds, but using the hit data it was unclear which enantiomer was active therefore all 
enantiomers and racemic compounds were enumerated for this study.  
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Figure 2.3: Enumerated carbazole indole compounds from the neutral hit analogue (33). 
Predicted activities (Table 2.3) were computed using both the Bayesian β-haematin inhibition 
and the parasite growth inhibition model, as with the benzimidazole compounds. 
Interestingly, only compounds 33-35 were predicted to be active for the β-haematin inhibition 
and compounds 30-35 where predicted to be active in the parasite growth inhibition model 
however, the numerical values are low for these compounds termed to be active. 
Remembering that the cut-off of the β-haematin inhibition model is -4.920, the difference of 
the active values is 9.645 units and with the parasite growth inhibition model cut-off value of 
-8.580, the difference is 3.198 and 0.386 units. This implies that the data is unreliable and 
thus warrants further investigation.  
 
 
 
Compound with no hydroxyl groups 
Compounds with one hydroxyl group 
Compounds with two hydroxyl groups  
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Table 2.3: The Bayesian statistic results of the carbazole indole study using both models with 
predicted active compounds shown in red and predicted inactive compounds shown in black.  
Compound Number β-haematin inhibition score 
Parasite growth inhibition 
score 
29 -7.4793 -10.3333 
30 -5.29619 -8.19434 
31 -5.29619 -8.19434 
32 -5.29619 -8.19434 
33 4.72502 -5.38157 
34 4.72502 -5.38157 
35 4.72502 -5.38157 
 
One drawback found using Bayesian predictions for this subset of compounds is that the 
models cannot distinguish any differences between these chiral molecules and thus the 
values for the racemic mixture and both enantiomers are identical. This is because the 
Bayesian models use sets of molecular fingerprints to predict activity, but in the Bayesian 
model used there were no molecules with a chiral fingerprint so it cannot differentiate 
between these chiral centres. 
2.5 Summary and Conclusions 
In this study 325 728 unique benzimidazole compounds were enumerated using the  
Sigma-Aldrich catalogue of starting materials with the hit benzimidazole compound a basis 
for derivatization. These compounds underwent two stages of activity predictions using  
pre-existing Bayesian models, filtering out predicted inactive compounds at each stage.  
19 904 compounds were predicted to be inactive in the β-haematin inhibition model from the 
initial 325 728 compounds, after which 2 148 compounds were predicted to be inactive in the 
parasite growth inhibition model. The 303 676 predicted active compounds underwent an 
aqueous solubility prediction producing 268 552 moderately soluble compounds. 18 of these 
compounds were selected for synthesis based on these results and it was decided to 
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derivatize only one ring system. The hit benzimidazole subunits were also investigated in a 
similar fashion showing six out of seven compounds predicted to have β-haematin inhibitory 
activity while five out of the seven compounds were predicted to have parasite growth 
inhibitory activity. This was also carried out on seven carbazole indole compounds, predicting 
four out of seven compounds to be inactive against the β-haematin inhibition model and one 
out of seven compounds inactive against the parasite growth inhibition model.    
Implementing the Bayesian statistical techniques in this study has greatly enriched the 
knowledge base on this scaffold regarding choices and positions of functional groups. 
Bayesian statistics has also improved our throughput, enumerating 325 728 compounds in 
silico without the need for synthesis. As with all techniques, there are limitations with this 
methodology as the results depend on the training set of each model and its ability to 
recognize certain fingerprints, thus from this study the enantiomers of the chiral carbazole 
indole scaffold were predicted to be the same. Further investigation into these scaffolds was 
considered necessary using experimental and other computational techniques. 
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Chapter 3: Synthesis Aspects 
3.1 Introduction 
The Bayesian predictions in Chapter 2 invited the synthesis of the compounds identified, in 
which first a retrosynthetic analysis of both the hit compounds as well as the relevant 
literature methodologies for the transformations involved and their mechanisms will be 
discussed. Thereafter, the actual synthesis results with the appropriate characterisation 
techniques will be discussed, which will be followed by an extension into series generation 
for structure-activity studies. The derivatives synthesized were not necessarily meant to be 
drug candidates but ones to reinforce knowledge of the mechanism of action of these 
compounds and to validate previously discussed predicted activities from the Bayesian 
statistics. 
3.2 Scaffold 1: Benzimidazoles 
3.2.1 Benzimidazole Chemical Properties 
The benzimidazole moiety has two nitrogen atoms contained as an activated imine and a 
mildly acidic amine due to resonance connection between the two. Both functionalities are 
involved in H-tautomerism (Scheme 3.1) and in water this process is reported139,140 as being 
an intermolecular process between the benzimidazole imine of one molecule and the 
benzimidazole amine of another molecule, which results in the nitrogen atoms becoming 
chemically equivalent. Any mono-substitution on the A-ring, however, introduces an 
asymmetry that results in a non-equivalence in the H-tautomers. Similarly, N-substitution 
with A-ring mono-substitution also results in constitutional isomers being produced.140 
 
Scheme 3.1: Tautomerism of the benzimidazole ring system.140 
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3.2.2 Benzimidazole Hit Compound Retrosynthetic Analysis 
The benzimidazole hit compound can be disconnected back to a 4-(1H-benzo[d]imidazol-2-
yl)aniline intermediate which can be further disconnected back to p-aminobenzoic acid and 
o-phenylenediamine as shown in Scheme 3.2. The forward reactions therefore consisted of 
two separate condensation reactions to form the benzimidazole ring and the amide bond 
respectively. These observations led to a literature survey of both of these reactions, which 
are now reviewed in context.  
Scheme 3.2: Retrosynthetic analysis of the benzimidazole hit compound. 
3.2.3 Benzimidazole Ring Synthesis 
The benzimidazole ring system is traditionally prepared using the Phillips-Ladenburg reaction, 
which involves reacting a 1,2-diaminobenzene with a carboxylic acid using aqueous 
hydrochloric acid at high temperature or pressure.141,142 This method gives poor yields when 
preparing 2-arylbenzimidazoles from aromatic carboxylic acids, which led Leavitt, Hein and 
Alheim in 1956 to improve the reaction using polyphosphoric acid (PPA) as an alternative 
promoter. This in turn resulted in a significant increase in yield, making it still one of the main 
methods used today for this target.143,144 Modern approaches have expanded on this to 
include various Lewis acids, but in the present work it was decided to use the methodology 
laid out by Leavitt et al in view of its simplicity for accessing bulk quantities of the desired 
benzimidazole, together with the fact that the reagents were already available in-house.103,144  
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So and Heeschen145 have shown by various nuclear magnetic resonance (NMR) studies that 
the mechanism for the formation of the benzimidazole ring system firstly, involves the 
formation of a mixed anhydride from the aromatic acid and PPA, which forms a dynamic 
equilibrium with the free benzoic acid group and PPA polymer such that the proportion of 
mixed anhydride increases with temperature. This can be visualised via NMR spectroscopy. It 
should be also noted that the percentage of mixed anhydride increases with initial 
phosphorus pentoxide (P2O5) content in the PPA, in which a P2O5 content of 77% or greater 
was needed for any mixed anhydride to be formed. Under these acidic conditions, the  
o-phenylenediamine exists as an equilibrium between its protonated and neutral forms 
(Scheme 3.3), the latter being the reactive species that combines with the mixed anhydride 
in a nucleophilic acyl substitution reaction (SNAc) to form intermediate A.145 The acidic 
medium promotes ring closure via another SNAc mechanism involving nucleophilic attack of 
the other primary amine, which is also unprotonated, on the electrophilic carbon of the 
protonated carbonyl group. Finally, elimination of water furnishes the 2-arylbenzimidazole.145 
Scheme 3.3 below summarises these events: 
 
Scheme 3.3: Reaction mechanism for formation of the benzimidazole product. 
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The key intermediate for producing the first series of compounds was the 2-arylbenzimidazole 
intermediate containing a para amino group in the 2-phenyl group, which could be 
disconnected back to p-aminobenzoic acid and o-phenylenediamine as shown in Scheme 3.4. 
The PPA methodology described above was used to form this intermediate. The amino group 
of the p-aminobenzoic was considered to be sufficiently deactivated nucleophilically due to 
resonance stabilisation by the carboxylic acid as shown in Scheme 3.4 and hence wasn’t 
protected first. This would have lengthened the synthesis to the target, but its participation 
in substitution could not be discounted (to form a polypeptide polymer) so this possible 
complication was flagged. 
 
Scheme 3.4: The initial key target scaffold. 
3.2.4 Amide Bond Formation 
Following the synthesis of the 2-arylbenzimidazole key intermediate, formation of the amide 
bond, for which several methods are available, was the next and final step needed to reach 
the target compounds. The amide bond functionality is found in a whole host of molecules, 
most importantly as the peptide linkage in proteins, which are essential for life as they play 
important roles in a multitude of biological processes such as transport, immune protection 
and enzymatic catalysis. A survey of the Comprehensive Medicinal Chemistry database 
revealed that amide bonds occur in more than 25% of all known drugs, which is not surprising 
as they are known to be stable, neutral and have hydrogen bonding capabilities.146,147 Amide 
bond formation between an amine and acid is formally called a condensation reaction 
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because of the expulsion of water during the reaction, which needs to be removed for the 
reaction equilibrium to proceed favourably to product. Indeed, mixing of the amine and acid 
forms a stable salt shown in Scheme 3.5, which prevents any condensation reaction from 
occurring. However, heating the reaction to temperatures greater than 160 °C allows the 
amine to override the inherent weak electrophilicity of the acid for the addition step of the 
reaction to occur, but such a high temperature is invariably incompatible with other 
functionalities. Reducing the activation energy for nucleophilic attack to occur requires an 
activation in the form of converting the hydroxyl group of the acid into a suitable leaving 
group.147 
 
Scheme 3.5: Thermodynamics of amide bond formation. 
The literature contains a plethora of methodologies for achieving such activation, and these 
can be broken down into four main categories: namely carbodiimides, N-hydroxysuccinimide 
(NHS) esters, mixed anhydrides and acyl chlorides.147 The carbodiimide methodology is mainly 
used in the synthesis of peptides as the other methodologies pose a danger of hydrolysis, 
racemisation and the cleavage of protecting groups. The latter will therefore be discussed 
first as an example to demonstrate the lowering of the activation energy for the amide 
formation reaction. The first carbodiimide mentioned in the literature was  
N,N’-dicyclohexylcarbodiimide (DCC), which in view of difficulties in removing its reaction  
by-product dicyclohexylurea during purification, has been largely replaced by second-
generation diimides such as N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), 
diisopropyl carbodiimide (DIC) and (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate) (HATU). However, all of these follow a similar 
mechanism147–149 and 1-hydroxybenzotriazole (HOBt) is invariably added to limit O- to  
N-acyl transfer as well as limit racemisation in the case of -amino acids. Firstly, the carboxylic 
acid reacts with the carbodiimide in an acid catalysed process (via transfer from the carboxylic 
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acid) to form an O-acylisourea mixed anhydride intermediate that lowers the activation 
energy needed for subsequent nucleophilic attack. This intermediate first reacts with the 
oxygen of HOBt to form the Bt ester, which is then rapidly substituted by the amine via a SNAc 
mechanism to furnish the product (Scheme 3.6).147 The reaction can be carried out in a range 
of solvents, including water, dimethylformamide (DMF) and pyridine, in which EDC is probably 
the most commonly used reagent as it gives a water soluble urea by-product.147  
 
Scheme 3.6: Amide coupling reaction mechanism using DDC and HOBt. 
The second methodology listed involves an esterification reaction that was first described by 
Steglich in 1978 involving 4-dimethylaminopyridine (DMAP) as an acyl-transfer catalyst.150 
This involves the formation of an NHS ester using DCC coupling described before. The NHS 
ester intermediate is then reacted with an amine to form the desired amide bond found in 
Scheme 3.7.150 
 
Scheme 3.7: The use of Steglich’s esterification reaction to form an amide bond. 
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The third methodology listed involves the use of anhydrides, which are known to readily react 
with nucleophiles such as amines. These anhydrides are formed by heating the acid directly 
or via reaction of two equivalents of acid with one equivalent of DCC. This is then followed by 
a SNAc reaction with an amine to furnish the amide bond shown in Scheme 3.8. 
Scheme 3.8: Formation of an amide bond via the anhydride methodology. 
However, only the half acid is used and thus large wastage occurs.147 To alleviate this problem 
a mixed anhydride can be used where the second carboxylic moiety is cheap and easy to 
couple via its acid chloride.151 An example is the pivalolyl group in which the bulk of the  
t-butyl group ensures a regioselective coupling (Scheme 3.9).147 
Scheme 3.9: Mixed anhydride reaction mechanism using pivaloyl chloride. 
Acylation using an acid chloride is still one of the simplest and effective methodologies so long 
as one is not worried about hydrolysis, racemisation or environmental concerns (small scale). 
Many acid chlorides are commercially available, and if not, can be prepared from the acid 
using one of many chlorinating agents. These include oxalyl chloride, phosphorus 
pentachloride, phosphorus trichloride, phosphorus oxychloride or thionyl chloride.147,152 
Notably, though, care should be taken when working with these reagents as they release toxic 
hydrogen chloride (HCl) gas. 
The mechanism for the formation of an acid chloride using thionyl chloride is well known 
throughout the literature. Initially, the reaction begins with the reaction of the acid with 
thionyl chloride to form a chlorosulfite ester in the form of a protonated carbonyl group 
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(oxocarbenium ion). The latter activates the addition of chloride to generate the tetrahedral 
intermediate that is believed to break down in an entropically favoured, concerted fashion to 
expel SO2 and HCl gas with formation of the acid chloride. Overall, the conversion constitutes 
a SNAc reaction as shown in Scheme 3.10.147,152 
 
Scheme 3.10: Acid chloride formation mechanism. 
Once the acid chloride is formed, the appropriate amine can be coupled in yet another SNAc 
reaction to form the amide bond, in which a base is required to neutralise the HCl produced. 
Mild, non-nucleophilic bases are required here to avoid nucleophilic attack on the chloride by 
the base (eg. hydroxide does not qualify).152 In this regard, amine bases are popular such as 
triethylamine (Et3N), Hünig's base (i-Pr2NEt) or pyridine. Of these, pyridine is the most 
favourable as it acts as an acyl-transfer agent, which increases the rate of the reaction. 
Together with its ability to improve the solubility of substrates, pyridine makes for a popular 
choice of solvent in these types of reactions.147 The transfer aspect of pyridine is interesting 
(see Scheme 3.7) and is represented below in Scheme 3.11. 
Scheme 3.11: Acetylation reaction mechanism using pyridine. 
Pyridine undergoes a SNAc reaction with the acid chloride faster than the primary amine 
owing to its nitrogen’s strong Lewis basic and soft character. This results in an N-acyl-
pyridinium salt, which is more electrophilic than the acid chloride. Thereafter, a fast amine 
attack ensues with regeneration of pyridine, which, following proton transfer affords the 
amide and pyridinium hydrochloride as a by-product.147,152 With so many methodologies 
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available the suitability of reagents, conditions, the yield, formation of unwanted side 
products, purification and the selectivity of the reagents needed to be considered.147 
Ultimately, the acid chloride methodology was decided upon for the purpose of this thesis. 
3.3 Scaffold 2: Carbazole Indoles 
3.3.1 Retrosynthetic Analysis of the Carbazole Indole Compound 
Similar to the benzimidazole case previously, the proposed carbazole hit analogue could be 
disconnected back to 7-hydroxyindole and an epoxide, which may then be disconnected back 
to epichlorohydrin and carbazole as shown in Scheme 3.12. The forward direction therefore 
consisted of an SN2 reaction between the carbazole and epichlorohydrin followed by a 
regioselective epoxide opening to realize the target compounds. The IC50 values measured for 
the original hit compound were obtained using the racemate, therefore separate 
enantiomers of the hit analogue were synthesized and evaluated. As with the benzimidazole 
hit compound, various aspects of the carbazole moiety will now be discussed.  
 
Scheme 3.12: Retrosynthetic analysis for the carbazole indole hit compound. 
3.3.2 Carbazole Subunit 
Carbazoles are important heterocycles in medicinal chemistry, consisting of a 5-membered 
pyrrole core fused symmetrically with two benzene rings,124 making it an indole ring with a 
benzene ring fused onto the 2,3-positions. The classical method for the preparation of the 
carbazole moiety is through the dehydration of 1,2,3,4-tetrahydrocarbazoles prepared by the 
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Fischer-Borsche or the Graebe-Ullmann synthesizes. However, a more recent methodology 
involves the use of transition metal catalysis (iron, palladium or molybdenum).118 For the 
purposes of this thesis all carbazole reagents were purchased, and the term carbazole refers 
to 9H-carbazole moiety, with its reactivity based on the nucleophilic nature of the 
deprotonated nitrogen anion.118,124 
3.3.3 Indole Subunit 
Indoles are an important bicyclic heterocycle that consist of a pyrrole ring fused to a benzene 
ring at the α, β-positions. They occur in proteins as the amino acid tryptophan and in indole 
alkaloids such as LSD. The indole ring system is a widely encountered pharmacophore in 
medicinal chemistry.153 The prevalence of indole chemistry can be seen with nine different 
named reactions for the synthesis of this pharmacophore in which the Fischer indole synthesis 
is the most famous.154 The reactivity of this substrate in context again lies in the nucleophilic 
nature of the deprotonated nitrogen anion and for the purpose of this thesis, the indole ring 
systems were purchased.153,154 
3.3.4 Epoxidation using Epichlorohydrin 
Epoxides are generally formed by oxidising an alkene using a peroxy acid, most commonly  
m-chloroperoxybenzoic acid (m-CPBA), but for attachment of a three-carbon chain epoxide 
to a secondary amine, epichlorohydrin is the more effective choice.152 Epichlorohydrin can be 
purchased as a racemic mixture or as chirally pure enantiomers, therefore it is possible to 
form the different enantiomer target products. However, it is considered to be a carcinogen, 
so extreme caution must be taken during use.155 Interestingly, based on the reaction of 
unsymmetrical (substituted) epoxides during substitution, nucleophilic attack occurs at the 
epoxide carbon rather than directly on the carbon bearing the chloride. With strong, relatively 
soft nucleophiles the epoxide opening reaction involves an SN2 mechanism in which the 
nucleophile attacks the least hindered side of the epoxide, opening it up and forming an 
oxygen anion. This anion attacks the carbon adjacent to the chlorine, eliminating a chloride 
and forming the desired product with regeneration of the epoxide and with retention of 
configuration of the C-O bond at  the stereogenic centre, as shown in Scheme 3.13.152 
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Scheme 3.13: Epichlorohydrin substitution mechanism. 
3.3.5 Protection of the Alcohol 
After forming the intermediate compound, a methodology for regioselective alkylation (using 
the epoxide) on the amino nitrogen rather than the phenolic hydroxyl oxygen of  
7-hydroxyindole needed to be established. Base catalysis to afford the indole N-anion was 
envisaged as necessary for this reaction in view of the low nucleophilicity of the indole 
nitrogen, which meant that protection of the relatively acidic hydroxyl group was required. 
The chemical literature contains a large number of reagents for alcohol protection, but in 
context two groups stood out as likely candidates owing to their ease of introduction and 
removal.152 These were a benzyl ether and a N-tert-butoxycarbonyl (Boc) carbonate, for which 
relevant mechanisms are shown in Schemes 3.14a and 3.14b. Both involve different types of 
substitution (SN2 and SNAc respectively) mechanisms involving the oxide anion of the 
indole.152 The benzyl protection methodology was chosen for the purposes of this thesis due 
to the stability of this group in basic conditions and at high temperatures.  
 
Scheme 3.14: a) Boc protection mechanism, b) Benzyl protection mechanism. 
3.3.6 Epoxide Opening 
With the protection of the alcohol in hand, various aspects of the epoxide opening needed to 
be considered. While nucleophilic attack at the chiral carbon (more substituted) of a chiral 
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epoxide of a terminal alkene is known to be promoted under Lewis acidic conditions in view 
of the secondary carbocation character in the transition state, the requirement here for 
attack at the less-hindered carbon meant that base catalysis via an SN2 manifold was required 
(refer to Scheme 3.15 for both mechanisms).152 The rate of an SN2 reaction decreases with 
the steric bulk of the nucleophile, which suggested that a bulky nucleophile was not ideal.152 
Additionally, it is important to note that such an SN2 reaction (at the least hindered epoxide 
carbon) would retain stereogenicity at the C-O bond of the chiral centre, which was an 
important aspect of the synthetic design. 
 
 
Scheme 3.15: Acid and base mediated epoxide opening mechanisms where LA represents 
lewis acid. 
3.4 Synthetic Goals 
The goals of this chapter were to: 
 Synthesize and characterize the eighteen benzimidazole compounds identified by the 
Bayesian statistics. 
 Synthesize and characterize the seven benzimidazole substructures from the Bayesian 
study. 
 Synthesize and characterize the seven carbazole indole compounds from the Bayesian 
study. 
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3.5 Results and Discussion 
3.5.1 Scaffold 1: Benzimidazoles 
3.5.1.1 Synthesis of the Benzimidazole Intermediate 
Formation of 1 was carried out on a 40 mmols scale using the reaction conditions detailed in 
Scheme 3.16 following the previously established methodology of Chua et al.156 After reaction 
completion, which was verified by TLC analysis, NaHCO3 was used to neutralize the acid in a 
mini work-up, the mixture was transferred into a beaker quickly using warm water, followed 
by several washes. This mixture was cooled using an ice bath and slowly neutralized using 
NaHCO3 so as to minimise reaction vigour (CO2 evolution). It was imperative that the reaction 
was not overly basified so as to avoid substantial losses of deprotonated product into the 
water. Column chromatography was not required as recrystallization of the solid obtained 
(via filtration) using methanol was used to achieve a yield of 61% with an HPLC purity of  
≥ 95%.  
 
Scheme 3.16: Reaction conditions for the formation of the benzimidazole product (1). 
The synthesis of the benzimidazole product was confirmed by its 1H nuclear magnetic 
resonance (NMR) spectrum using deuterated dimethyl sulfoxide (DMSO-d6) as a solvent to 
ensure visualisation of the primary amine peak as shown in Figure 3.1. As expected, two 
doublets typical of a 1,4-disubstituted system, accounted for H-11, H-12, H-14 and H-15, while 
two multiplets accounted for the benzimidazole ring system. One is reminded here that rapid 
N-H tautomerism renders the benzimidazole A-ring protons symmetrically equivalent in 1H 
NMR. A two-proton broad singlet at 5.54 ppm confirmed the presence of the primary amino 
group, and this signal could be used as a diagnostic marker for this moiety. Similarly, the 13C 
NMR spectrum showed eight distinct signals as expected, four for each aromatic ring based 
on the above mentioned symmetry grounds. Definitive assignment of the 13C NMR spectrum 
resonances could not be ascertained for compound 1. 
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Figure 3.1: The 1H NMR spectrum of the benzimidazole intermediate (1) in DMSO-d6. 
Following the successful formation of 1, attempts were then made to synthesize a variety of 
derivatives of 1 using the same methodology described but using various substituted  
o-phenylenediamine derivatives (1a-1g), shown in Scheme 3.17, so as to functionalise the  
A-ring. 
 
Scheme 3.17: The reaction conditions for the attempt at synthesizing compound 1 
derivatives. 
H-12, H-14 
H-1, H-2 
H-3, H-6 
H-11, H-15 
NH2 
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All of the substituted o-phenylenediamine reactants (1a-1g) degraded (formed a black 
precipitate) during the reaction, presumably due to the high temperatures (220 °C) required 
for these reactions to proceed in the presence of PPA (strong acid). These reactants (1a-1g) 
were found to be stable in PPA at room temperature and so a temperature study was carried 
out on all of the diamine reactants 1a-1g using the reaction conditions detailed in Scheme 
3.17 (i.e. with the PPA) to determine the optimum temperature for reaction. The melting 
point of each diamine (1a-1g) was taken as a starting temperature for initial reaction. The 
reactions were analysed using TLC every hour to determine reaction progress and the 
degradation point of each compound. If no reaction had occurred the temperature was 
increased by 10 °C. This was carried out until the compound degraded or a maximum 
temperature of 220 °C was reached. All compounds fully degraded before they reached  
220 °C, with no distinct product visualised. Therefore, it was concluded that the formation of 
condensation products (1h-1n) was not possible using these conditions, and thus this route 
was abandoned.  
3.5.1.2 Acid Chloride and Amide Bond Formation Results 
After the disappointing results from the temperature study, attention was redirected to the 
C-ring by preparing a library of amides of intermediate 1. However, it was first imperative to 
consider access to the acid chlorides. This was achieved either by reacting the relevant acid 
with thionyl chloride or accessing the acid chloride commercially directly from commercial 
sources. Using 3-bromobenzoic acid as a pilot study, the acid chloride was formed by refluxing 
the acid in thionyl chloride overnight to ensure complete conversion. TLC could be used to 
monitor the progress of the reaction by quenching a drop of the mixture with MeOH to form 
the methyl ester. Progress could be monitored comparing residual acid versus the ester due 
to the polarity difference on the TLC plate. Once the esterification was complete, the excess 
thionyl chloride was reduced under pressure and the newly formed acid chloride was used 
within an hour with no further purification.  
Initial reaction of 3-bromobenzyl chloride (1.5 eq.) and 1 (1.0 eq.) was performed by stirring 
the mixture in anhydrous tetrahydrofuran (THF), with excess pyridine, at room temperature. 
However, formation of an unwanted side product was identified, whose 1H NMR and 13C NMR 
spectra both showed the presence of two amide functionalities rather than the desired one, 
66 
 
as well as an additional aromatic ring system. This resulted in the structure being assigned as 
3a, as shown in Scheme 3.18.  
 
Scheme 3.18: Trial acid chloride coupling reaction. 
These results reflected that the reaction was driven by the electrophilicity of the  
N-acylpyridinium ion, which could promote acylation at both types of nitrogen (the free 
amino and the heteroaromatic N). Evidently, the soft but nucleophilic amidine of the 
imidazole ring of the benzimidazole is reactive enough to be acylated. However, TLC analysis 
suggested that formation of compound 3 via pathway 1 was faster in that compound 3 formed 
first.  
Using this reasoning the number of equivalents of 3-bromobenzyl chloride was thus lowered 
to one, still using room temperature as the reaction temperature. However, this now resulted 
in an incomplete conversion in which a portion of diacylated product was still visible on TLC. 
Column chromatography separation of 1 from any of the products (3 and 3a) was not fully 
possible due to the small retention factor (Rf) difference between the compounds as well as 
their propensity to ‘drag’ on the column.  
Despite these results, it was decided to next examine the effect of temperature on the 
reaction. This was achieved by varying the reaction temperature of four separate reactions, 
using 1.5 eq. of 3-bromobenzoyl chloride and 1.0 eq. of 1. The first reaction at room 
temperature yielded the same results as before with a 1:1 ratio of 3a to 3 visualised on TLC. 
The reaction at 0 °C achieved the same result with a 1:1 mixture of 3a and 3 visualised on TLC. 
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Using the same methodology as before, but further lowering the temperature to -78 °C, 
yielded no reaction as the pyridine froze. The last attempt at -40 °C was successful, with 
formation of only compound 3 visualised on TLC. However, residual 1 was also visualised on 
TLC which was also undesirable. In order to mitigate this problem, two further reactions were 
attempted increasing the original 1.5 eq. of 3-bromobenzoyl chloride used in the reaction. An 
increase to 1.8 eq. still yielded the same results as with the 1.5 eq. Finally, increasing the 
equivalents of 3-bromobenzoyl chloride to 2.0 resulted in full conversion with no formation 
of 3a visualised via TLC. The optimised reaction conditions are shown in Scheme 3.19.  
 
Scheme 19: Optimised reaction conditions for full conversion to compound 3. 
The product was too polar for conventional extraction, therefore the bulk of the pyridine was 
azeotropically removed with toluene at 60 °C on a rotary evaporator. The remaining residual 
pyridine was reduced under pressure before subjecting the crude mixture to column 
chromatography using MeOH and DCM mixtures. It was assumed that the HCl produced in 
the reaction stayed on the column as pyridinium hydrochloride. Further purification for 
biological evaluation purposes was achieved by recrystallizing product 3 from methanol and 
water mixtures to constant melting point of 324 - 325 °C.  
The 1H NMR spectrum of 3 is shown in Figure 3.2. This showed two multiplets at 7.20 ppm 
and 7.63-7.79 ppm accounting for 2H and 3H respectively, the latter corresponding to the  
A-ring protons and H-21. Following this, a signal at 7.81 ppm accounted for 1H with a J value 
of 7.8 Hz which was assigned to H-22. Two other multiplets were seen at 7.98 and 8.19 ppm, 
integrating for 3H each and were assigned to H-12, H-14 and H-20 and H-11, H-15 and H-24 
respectively. The diagnostic signal for the amide proton H-16 was found at 10.54 ppm 
integrating for 1H. Finally, the assignment of H-9 at 12.80 ppm implied no formation of 3a.  
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Figure 3.2: The 1H NMR spectrum of compound 3 in DMSO-d6. 
The 13C NMR spectrum of 3 is shown in Figure 3.3, where the carbonyl carbon signal at  
164.1 ppm was diagnostic of the formation of the amide bond. Overall, eighteen resonances 
(singlets) were observed with a 7:4:6 split (benzimidazole: C: D) plus the carbonyl, revealing 
that desymmetrization of the benzimidazole A ring system was observed implying a slow 
benzimidazole H-tautomerism on the NMR time scale. A reminder of this tautomerism is 
shown in Scheme 3.20 to illustrate this.  
H-16 
H-9 
H-1, H-2 
H-3, H-6, H-21 
H-22 
H-12, H-14, H-20 
H-11, H-15, H-24  
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Figure 3.3: The 13C NMR spectrum of compound 3 in DMSO-d6. 
 
Scheme 3.20: Tautomerism of the benzimidazole ring system of compound 3. 
This overall methodology was followed for all the derivatives for this study and is depicted in 
Scheme 3.21 except for the recrystallizing solvent used. The reaction times differed slightly 
depending on the acid chloride used, although no correlation could be found between the 
reaction times and the nature of the substituents on the acid chloride based on its electron-
withdrawing or donating groups. Rather, the insolubility of the acid chloride emerged as the 
main determinant, with the insoluble acid chlorides (5, 9, 12 and 16) producing the longer 
reaction times, which changed from two to three hours.  
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Scheme 3.21: Synthesized benzimidazole derivatives. 
3.5.1.3 NMR Analysis and Other Characterisation of the Benzimidazole Derivatives 
The library depicted in Scheme 3.21 was characterized using 1H NMR, 13C NMR, correlation 
spectroscopy (COSY) and heteronuclear single-quantum correlation (HSQC) NMR 
spectroscopy. DMSO-d6 was used as a solvent for all of the NMR experiments, so as to 
solubilize the polar compounds and to visualize the amine peaks. In spite of the abundance 
of aromatic signals, a significant amount of information could be extracted from the NMR 
data. Firstly, the 1H NMR spectra for all eighteen compounds were similar, showing the 
benzimidazole core containing two multiplets at ≈ 7.2-7.3 ppm and ≈ 7.6-7.7 ppm, 
respectively and were assigned as the benzimidazole ring system protons. While the two 
doublets at ≈ 8.0-8.1 ppm and ≈ 8.2-8.3 ppm, respectively were assigned to the  
1,4-disubstituted phenyl system protons. Importantly, though, diagnostic 1H NMR peaks for 
the formation of these compounds was provided by aromatic ring proton peaks from the acid 
chloride, as well as the disappearance of the primary amine at around 5.54 ppm in the starting 
material, which was replaced by a secondary amide peak found at ≈ 10 ppm, signifying the 
formation of the amide bond. Similar to compound 3, the benzimidazole NH was visualized at 
≈ 12.8 ppm signifying no formation of side products such as 3a. These features can all be 
found in the 1H NMR spectra for 5 and 12 shown in Figures 3.4 and 3.5. 
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Figure 3.4: 1H NMR spectrum of 5 in DMSO-d6. 
 
 
Figure 3.5: 1H NMR spectrum of 12 in DMSO-d6. 
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As expected, the 13C NMR spectra for compounds 2-19 revealed the diagnostic carbonyl 
carbon peak for the amide at ≈ 161 ppm as well as new carbon peaks accounting for the 
addition of the new aromatic ring system. Interestingly, while the 13C NMR spectra for 
compounds 3, 4, 5, 7, 10 and 12 showed seven carbon peaks for the benzimidazole ring 
system other compounds 2, 6, 8, 9, 11, 13, 14, 15, 16, 17, 18 and 19 showed just four. As 
before, this was attributed to differences in the rates of NH-tautomerism, but a correlation 
between structure and number (as a relative tautomerism rate) could not be established. 
These subtleties are illustrated in Figures 3.6 and 3.7 for 14 (symmetrization) and 10 
(desymmetrization) respectively.  
 
Figure 3.6:  The 13C NMR spectrum of 14 in DMSO-d6, showing symmetrization of the A-ring 
carbon signals (shown in red). 
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Figure 3.7: The 13C NMR spectrum of 10 in DMSO-d6, showing desymmetrization of the A-ring 
carbon signals (shown in red). 
Other methods of characterization used for these compounds included high resolution mass 
spectrometry (HRMS), IR spectroscopy, melting point analysis (to within one degree of the 
previous melting point), and high-performance liquid chromatography (HPLC) to at least 95% 
purity with compound 3 shown as an example in Figure 3.8. 
C-6 C-3 C-1, C-2 
C-4, C-5 
74 
 
 
Figure 3.8: C18 HPLC trace of compound 3 at 254 nm. 
Given the formation of 3a, it was decided to include a similar compound in this part of the 
study to determine the effect of removing the NH hydrogen bond in the B-ring on the  
β-haematin and parasite growth inhibitory activities. Therefore, 20 was formed using 
compound 3 (1.0 eq.), THF, pyridine and benzoyl chloride (9.0 eq.) at room temperature for 
18 hours, as shown in Scheme 3.22. Upon complete disappearance of 3, monitored via TLC 
analysis, a standard work-up procedure was used involving acidifying the reaction mixture to 
pH 4 using HCl to remove most of the pyridine from the organic layer. 20 was then extracted 
using MeOH and chloroform mixtures. The crude mixture was then subjected to column 
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chromatography using MeOH and DCM mixtures to afford 20 in 39% yield, which was followed 
by recrystallization using acetone and water to yield a crystalline solid. 
 
Scheme 3.22: Reaction conditions for the formation of compound 20. 
The 1H NMR spectrum of product 20, shown in Figure 3.9, showed the same proton signals as 
those of compound 3 but with the addition of five extra aromatic ring protons, accounting for 
the E-ring. The diagnostic carbonyl carbon peak for 20, at 168.9 ppm could be seen in the 13C 
spectrum (Figure 3.10). The 13C NMR spectrum of 20 also showed the expected four additional 
carbon peaks accounting for the E-ring carbons as well as twenty three resonances overall, 
based on a fully desymmetrized A-ring due to benzimidazole N-substitution. Further 
confirmation of compound 20 was given by virtue of a correct HRMS HRMS-ES+ Calculated: 
496.0661 [M+H]+ for C27H19 BrN3O2, Observed: 496.0654. 
 
Figure 3.9: The 1H NMR spectrum of 20 in DMSO-d6, with the E-ring proton signals shown in 
red. 
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Figure 3.10: The 13C NMR spectrum of 20 in DMSO-d6, with the E-ring carbon signals shown 
in red. 
3.5.1.4 Benzimidazole Fragment Synthesis 
An important issue in any SAR investigation is to evaluate the biological activity of hit 
fragment structures so as to ascertain at what structural point activity gets switched on. 
Although many such fragments were predicted by the Bayesian model to be inactive against 
malaria parasite growth inhibition yet active against β-haematin inhibition, it was deemed 
necessary to synthesize these compounds in order to verify these results. As with the previous 
syntheses, the methodologies were well known and are described herein by discussing each 
compound in turn. Scheme 3.23 shows the seven fragment targets that were purchased (21a, 
22a and 23a) or synthesized (1, 21, 22 and 23) in this study, in which the synthesis of 1 has 
already been described. 
C-26 
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C-28 
 
C-29, C-33 C-30, C-32 
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Scheme 3.23: The fragment compounds either purchased or synthesized.  
Compound 23 was formed via a standard acylation of 1 by refluxing 1 (1.0 eq.) in acetic 
anhydride (1.1 eq.) and toluene for two hours at 115 °C. Chemoselective mono-acylation was 
achieved by controlling the number of reagent equivalents as well as not adding pyridine as 
a base and acyl-transfer catalyst. The latter resulted in a much slower reaction that required 
heat to proceed and in which the benzimidazole was presumably just too non-nucleophilic for 
acylation to occur.  
In this case, it was possible to purify the product by simply washing the resulting solid with 
hot ethyl acetate and toluene to remove excess anhydride and acetic acid by-product. Its  
1H NMR spectrum showed exactly the same peaks as 1, except for the new acetyl group 
methyl singlet at 2.09 ppm. Similarly, the 13C NMR spectrum showed a new peak at 24.1 ppm 
accounting for the methyl carbon and a peak at 168.6 ppm resonating for the amide carbonyl. 
In this case, three A-ring resonances for the benzimidazole carbons in the 13C NMR spectrum 
demonstrated a symmetrical ring system due to fast H-tautomerism. 
Similarly, compounds 21 and 22 were both synthesized using the acid chloride methodology 
already discussed, but with no risk for formation of a diacylation product. The reaction 
conditions for both reactions are shown in Scheme 3.24.  
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Scheme 3.24: Reaction conditions for the formation of compounds 21 and 22. 
For the formation of compound 22, the methylamine hydrochloride salt was neutralized using 
triethylamine (Et3N) to liberate the free amine. After reaction completion, both compounds 
21 and 22 were found to be non-polar enough for standard extraction procedures using either 
chloroform / MeOH mixtures (22) or DCM (21) after acidification using 1M HCl to pH 7. This 
was followed by column chromatography and recrystallization using DCM (21) or acetone (22) 
to yield the pure products, with purities of greater than 95% according to HPLC. The 1H NMR 
spectrum of 21 showed six separate resonances accounting for the two aromatic rings 
systems, as well as an amide peak at 10.47 ppm as expected. The 13C NMR spectrum showed 
ten expected carbon signals. Similarly, the 1H NMR spectrum of compound 22 showed three 
proton resonances accounting for the pyridine ring system, a peak at 7.96 ppm accounting 
for the secondary amide proton and a methyl doublet at 2.93 ppm. Its 13C NMR spectrum 
showed the expected seven carbon peaks. As with the initial benzimidazole series, all 
compounds were also characterized using IR spectroscopy, melting point analysis and C18 
HPLC purity analysis (Figure 3.11). 
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Figure 3.11: C18 HPLC trace of compound 21 at 254 nm. 
3.5.2 Scaffold 2: Carbazole Indoles 
3.5.2.1 Synthesis of Carbazole and Indole Intermediates 
To reach the goal of synthesizing the seven carbazole indole compounds, the synthesis of the 
four key intermediates (24, 25, 26 and 27) needed to be realized. The three epoxide 
intermediates (24, 25 and 26), shown in Scheme 3.25, were synthesized using a previously 
established methodology reported by Kimura et al157, via alkylation of the respective 
epichlorohydrin stereoisomer with the carbazole anion derived from using sodium hydride as 
the base, the latter resulting in a colour change from light yellow to dark purple. Following 
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the addition of the epichlorohydrin, the reaction proceeded over sixteen hours to allow for 
complete conversion. The products were purified using column chromatography and 
recrystallized in ethanol to form long needle-like crystals. 
 
Scheme 3.25: Reaction conditions for the formation of compounds 24, 25, and 26. 
As expected, the 1H NMR (Figure 3.12) and 13C NMR spectra of compounds 24, 25 and 26 were 
found to be identical, revealing four resonances due to symmetry of the two rings accounting 
for all the carbazole aromatic protons, two double doublets accounting for the enantiotopic 
protons H-17, while two double doublets accounted for the enantiotopic protons H-14 and a 
characteristic epoxide multiplet accounted for H-15. The 13C NMR spectra revealed nine 
carbon singlets, six for the two identical phenyl ring systems and three for the alkyl chain, 
confirming successful synthesis of the epoxide derivatives.  
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Figure 3.12: The 1H NMR spectrum of 25 in acetone-d6 with red arrows indicating the 
enantiotopic protons and the zoomed in area of H-15.  
A similar SN2 alkylation approach was used to synthesize compound 27 as shown in Scheme 
3.26, using 1,3-dibromopropane (1.2 eq.) as the electrophile. Again, the carbazole anion was 
used, although this time NaH was used as the limiting reagent (0.9 eq.) to avoid elimination 
of the terminal bromide post-alkylation. Unfortunately, the reaction still furnished a 50:50 
mixture of the desired bromide 27, as well as its elimination product 27a, which was 
confirmed by 1H NMR spectroscopy. No double-alkylation product was observed though. 
Compound 27a was observed presumably due to residual base in the reaction mixture, 
implying that the NaH had not been fully consumed in spite of it being the limiting reagent as 
well as, what was considered to be adequate time for deprotonation of 30 minutes at 0 °C 
followed by 30 minutes at ambient temperature. This was a minor setback, though as both 
carbazole and 1,3-dibromopropane are cheap and readily available and thus it was not 
deemed necessary to optimise this reaction. Chromatographic separation of 27 and 27a was 
achieved using solely hexane. The 1H NMR spectrum of 27 was very similar to that of 24, 25 
H-17
 H-15 
H-15 
H-14
 H-15 
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and 26 as it showed four aromatic proton resonances for the carbazole ring system. Three 
unique resonances as two triplets and a pentet accounted for the alkyl chain of 27.  
 
Scheme 3.26: The reaction conditions for the formation of 27 and the mechanism for the 
formation of 27a. 
The preparation of compound 28, as shown in Scheme 3.27, was also an essential 
requirement of achieving the three final compounds. Compound 28 was prepared using the 
same SN2 mechanistic approach as the other four intermediate compounds described above. 
Less than one equivalent of sodium hydride was used, which ensured formation of a mono-
benzylated ether product using benzyl bromide as an electrophile. This was done since the 
phenolic hydroxyl group of 7-hydroxyindole is known to be more acidic than its secondary 
amine. The 1H NMR spectrum of 28 showed six aromatic peaks as five for the indole ring 
system, and a multiplet integrated for five protons which accounted for the phenyl ring. The 
presence of a peak at 5.12 ppm, integrated for two protons, confirmed the presence of a 
benzylic methylene group. The absence of a hydroxyl peak at 4.54 ppm and the presence of 
the secondary amine peak at 8.38 ppm indicated successful chemoselective protection on the 
hydroxyl group only.  
 
Scheme 3.27: Reaction conditions for the formation of 28. 
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3.5.2.2 Synthesis of Carbazole Indole Compounds 
With intermediates 24-27 discussed above now in hand, synthesis of the target compounds 
was carried out involving substitution by an indole anion. The same reaction procedure for 
synthesis of 24-27 except at higher temperature (70 °C rather than the initial room 
temperature) was used for the formation of compounds 29, 30, 31 and 32 as shown in Scheme 
3.28. The higher temperature presumably reflected the reduced electrophilicity of the 
epoxide (Cl replaced by carbazole) as well as the steric presence of the carbazole.  
 
Scheme 3.28: Reaction conditions for the formation of compounds 29, 30, 31 and 32. 
As with all NaH reactions, the reaction mixture was quenched in each case with a saturated 
NH4Cl solution, and extracted using EtOAc. The compounds 29, 30, 31 and 32 were each 
purified using column chromatography, but an unknown yellow oil was present in each crude 
sample after column chromatography that could not be separated, as both compounds had 
the exact same Rf values. The problem was solved by taking advantage of the oily nature of 
this impurity as well as the crystalline nature of the products by washing the residues with 
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pentane followed by recrystallization with pentane. This yielded final compounds 29, 30, 31 
and 32 with moderate yields (51-72%) and, importantly, purities ranging between 93.0 and 
99.7% according to HPLC using a C18 column was observed. Compounds 31 and 32 were 
further subjected to chiral OD HPLC, with enantiomeric excess (ee) of each compound 
calculated using the racemic mixture (30) as a reference. The ee of 31 and 32 were found to 
be 90 and 80% respectively, with the chiral OD HPLC trace for 31 shown in Figure 3.13. The 
peak at 15 min was rationalized as a solvent peak. Even though these ee values are not ideal, 
they were expected to give a strong indication of which enantiomer is the most biologically 
active after further testing.  
 
Figure 3.13: The chiral OD HPLC trace of compound 31. 
As expected, the 1H NMR spectra of the racemic mixture (Figure 3.14) and enantiomers (30, 
31, 32) were identical, with ten resonances accounting for the both the carbazole and indole 
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ring systems. However, proton signals were overlaid onto each other, making it difficult to 
properly distinguish between the aromatic signals. Additionally, diagnostic peaks from the  
C-3 spacer included a broad singlet at 1.99 for the hydroxyl group, two multiplets, integrated 
for two protons each accounting for the protons H-14 and H-16, and a multiplet integrated 
for one proton accounting for H-15. 
 
Figure 3.14: 1H NMR spectrum of 30 in chloroform-d with the red arrows indicating zoomed 
in areas. 
The 13C NMR spectrum showed seventeen carbon peaks containing the three diagnostic alkyl 
peaks at 47.2, 50.4 and 70.6 ppm respectively, and the remaining fourteen peaks which 
accounted for the aromatic carbons. 
The aromatic region of the 1H NMR spectrum of 29 revealed a similar pattern as for 30-32, 
but the absence of the stereogenic hydroxyl-bearing centre made the spectrum much simpler 
in the aliphatic region, with just two triplets and one pentet observed. The 13C NMR spectrum 
of 29 was also found to be similar, with seventeen carbon peaks, in which the alkyl carbons 
were shifted upfield at 29.4, 40.5 and 44.0 ppm respectively due to the lack of the electron-
withdrawing secondary alcohol group. All compounds were also characterized using IR 
spectroscopy, melting point analysis, HPLC and HRMS, with the HRMS analysis for compound 
29 shown in Figure 3.15 as an [M+H]+ molecular ion using electrospray positive ionization. 
OH 
H-14 and H-16 
H-15 
Aromatic protons 
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Figure 3.15: The HRMS analysis of compound 29 using electrospray positive ionization. 
Since the formation of the intermediate compounds 33a, 34a and 35a from benzyl ether 28 
followed the same mechanistic approach as that of formation of compounds 29, 30, 31 and 
32, it was decided to use the same methodology (Scheme 3.29). Although, at 70 °C the 
reaction showed no formation of product which was attributed to the large benzyl protecting 
group of compound 28, providing steric hindrance. 
 
Scheme 3.29: Reaction conditions for the first attempt at formation of compounds 33a, 34a 
and 35a using the previously established methodology. 
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This was addressed by increasing the temperature to 130 °C and changing to DMF as a solvent. 
However, this choice also proved to be problematic as the starting material degraded at high 
temperature under basic conditions according to TLC. Hence, N-methyl-2-pyrrolidone (NMP) 
was used as a replacement solvent with some success but this too had limitations in that the 
reaction failed to achieve full conversion. After further optimization attempts using NMP, 
including increasing the temperature from 130 to 200 °C, the number of NaH equivalents from 
one to two and using longer reaction times (up to one week) there was still no improvement 
in the yield. Ultimately, the final reaction conditions settled on are shown in Scheme 3.30. It 
was decided not to purify these compounds to the usual standards (≥ 95% purity at this stage, 
but rather deprotect the benzyl groups first before fully characterizing. Therefore, a minimum 
purification (removal of excess starting materials and NMP) was carried out in each case 
whereby, the reaction mixture was quenched with a saturated NH4Cl solution and extracted 
using EtOAc. The organic residue was washed nine times with water to remove all the NMP 
and purified using column chromatography. 
 
Scheme 3.30: The reaction conditions used for the synthesis of intermediates 33a, 34a and 
35a. 
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Following this, the benzyl protecting groups of 33a, 34a and 35a were each cleaved 
hydrogenolytically using 10 mol% of Pd-C and hydrogen gas in anhydrous methanol to furnish 
the final compounds 33, 34 and 35 as shown in Scheme 3.31. The reaction mixtures were each 
filtered through Celite©, taking care not to let the Pd-C residue run dry for fear of ignition. 
The residues were purified using column chromatography, and as with the previous 
compounds 29-32, the yellow oily impurity was removed by washing the residues with 
pentane. The remaining solids were recrystallized using DCM to yield compounds 33, 34 and 
35, with chemical purities of greater than 95% according to HPLC on a C18 column. The yields 
(35-45% over two steps) for this subset of compounds were relatively poor, due to incomplete 
conversion and difficult purification.  
 
Scheme 3.31: Reaction conditions for the benzyl deprotection reactions to furnish the final 
compounds 33, 34 and 35 with yields given for over two steps. 
The 1H and 13C NMR spectra of compounds 33-35 were identical and needed to be carried out 
in methanol-d4 due to low solubility in other solvents. Since the visualization of the hydroxyl 
groups was not possible using 1H NMR in this solvent, IR spectroscopy was used instead, in 
which two separate hydroxyl peaks (OH phenolic and OH aliphatic) indicated deprotection 
and therefore formation of the desired compounds as revealed in Figure 3.16 for compound 
33.  
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Figure 3.16: The ATR-FTIR spectrum of 33 with the two hydroxyl peaks indicated by the red 
arrows. 
The 1H NMR spectra of 33-35 each showed nine separate resonances accounting for the 
aromatic protons, and five resonances which corresponded to the four diastereotopic protons 
H-15 and H-17 together with H-16 for the stereogenic centre as shown in Figure 3.17. The  
13C NMR spectra of 33-35 showed the expected 17 singlet resonances accounting for all 
carbons present in the molecules. As with the other subsets of compounds, 33-35 were also 
characterised using IR spectroscopy, melting point analysis and HRMS, with an HRMS analysis 
for compound 35 using electrospray positive ionization shown in Figure 3.18. 
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Figure 3.17: The 1H NMR spectrum of 34 in methanol-d4 with the zoomed in alkyl region 
shown in red. 
 
Figure 3.18: The HRMS analysis of compound 35 using electrospray positive ionization. 
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Compounds 35 and 34 were further subjected to chiral OD HPLC with the ee of each 
compound calculated using the racemic mixture (33) as a reference. The ee of 34 and 35 were 
found to be 80% and 44% respectively with the HPLC trace of 35 shown in Figure 3.19. The 
stereoselectivity of 34 and 35 was found to be worse than that of 31 and 32, presumably due 
to the increased temperature required for reaction completion, although a precise 
mechanism for racemisation was not clear. These ee values were far from perfect, especially 
that of compound 35; however, they were considered to offer an insight for preliminary 
biological studies where the objective was to identify the most active enantiomer. C18 HPLC 
analysis of compounds 33-35 also showed chemical purities of ≥ 95%. 
 
Figure 3.19: The chiral OD HPLC trace of compound 35. 
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3.6 Summary and Conclusions 
A synthetic template, 1, was synthesized using PPA, 4-aminobenzoic acid and  
o-phenylenediamine using known literature methodology for intended elaboration into a 
library of benzimidazole-tethered amides. All attempts at formation of A-ring derivatives of 1 
using the same methodology failed due to degradation, in spite of temperature optimization 
studies. By comparison, the amino group of 1 could be used to synthesize a library of 
compounds 2-19 via acid chloride methodology with pyridine as a base and an acyl-transfer 
agent, with THF as the solvent. This process was optimised using two equivalents of acid 
chloride at a temperature of -40 °C to avoid formation of any diacylated product. A diacylated 
product, 20, was also synthesized to compare biological activities with the parent compound, 
3. The benzimidazole fragment compounds were either purchased (21a, 22a, 23a), preformed 
(1) or synthesized using the acid chloride methodology (21, 22) or standard acetylation 
methodologies (23). 
Formation of carbazole epoxide intermediates (24, 25 and 26) was achieved via a NaH  
(1.0 eq.) mediated SN2 reaction using both chiral and racemic epichlorohydrin reagents  
(1.0 eq.) individually, and carbazole (1.0 eq.), with moderate yields of 41 to 50%. Formation 
of intermediate 27 involved changing the electrophile to 1,3-dibromopropane, with a 
reduction in the number of equivalents of NaH used in the hope of limiting formation of 27a 
via elimination of bromide. However, this was to no avail, implying unreacted NaH was still 
present in the reaction mixture upon addition of the 1,3-dibromopropane. These 
intermediates (24, 25, 26, 27) were subjected to a further NaH (1.0 eq.) mediated SN2 reaction 
using indole (1.0 eq.) as the nucleophile to furnish compounds 29, 30, 31 and 32 with 
moderate yields of 54 to 72%. A problematic yellow oily residue present in compounds 31, 32 
and 33 made purification difficult, which was removed by washing and recrystallization of the 
residues with pentane. The enantiomeric excesses for 31 and 32 were found to be 90 and 80% 
respectively, which was good enough for taking through to biological testing so as to give an 
indication of enantiomer relative activity.  
The benzyl protection of 7-hydroxyindole via a NaH mediated SN2 reaction furnished 
intermediate 28. Using 28 as a reagent, while modifying the NaH reaction conditions by 
changing the solvent from THF to NMP and increasing the reaction temperature from 70 to 
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130 °C, successfully produced intermediates 33a, 34a and 35a. Benzyl group hydrogenolysis 
of 33a, 34a using Pd-C, MeOH and in a hydrogen atmosphere furnished compounds 33, 34 
and 35, with yields of 33 to 45% over two steps. The enantiomeric excess of 34 and 35 was 
found to be 80 and 44% respectively with loss of enantio-purity attributed to the harsh 
reaction conditions used.  
Discounting intermediates, a total of twenty three benzimidazole compounds were 
synthesized using no more than two steps, with moderate to excellent yields and chemical 
purities of ≥ 95%. A variety of derivatives incorporating different functional groups was 
synthesized for SAR and QSAR analysis. Also discounting intermediates, a total of seven 
carbazole indole compounds were synthesized using either a two or three-step synthesis, 
with moderate to low yields and chemical purities ≥ 95%. All characterization data confirmed 
identity of all synthesized compounds and all compounds were soluble enough in DMSO or 
via sonification for biological testing.  
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Chapter 4: Benzimidazole Structure-Activity Relationships:  
β-haematin Inhibition, Parasite Growth Inhibition and Molecular 
Docking 
4.1 Introduction 
After synthesizing both series of benzimidazole compounds, the next logical step was to 
analyse their β-haematin inhibiting and biological activities to verify the Bayesian statistical 
predictions. The β-haematin inhibition and parasite growth inhibition activity of the hit 
compound (Figure 4.1), 5, was already reported in the Vanderbilt high-throughput screen. 
Therefore, the aim of this section was to replicate that data and determine the activities of 
all other synthesized compounds in both benzimidazole series. 
 
 
 
Figure 4.1: The reported activities of the hit benzimidazole compound, 5. 
Structure-activity relationships (SARs) have been used widely in the literature to predict 
biological or binding data based on physiochemical properties of compounds from a scaffold 
that contains previous activity data.138 This allows the user to predict biological activities  
pre-synthesis, making it a more efficient and rational process, thus saving in terms of cost and 
time. Molecular docking is also a useful computational tool to predict interactions with 
molecules and crystal or protein surfaces and can help confirm the synthesized compounds 
interaction with the target, in this instance the β-haematin crystal surface.158 All these 
techniques are discussed and used in this chapter. 
 
 
β-haematin IC50: 14.3 µM 
Parasite growth inhibition IC50: D6 strain 348 nM, C235 strain 412 nM 
95 
 
4.2 Benzimidazole Structure-Activity Relationships and Molecular Docking 
Goals 
The goals of this chapter were to:  
 Perform the NP-40 β-haematin inhibition assay on all benzimidazole compounds. 
 Use Materials Studio to perform docking studies on the first subset of benzimidazole 
compounds (2-19). 
 Subject all benzimidazole compounds to parasite growth inhibition studies on the 
NF54 strain and analyse the data. 
 Subject selected benzimidazole compounds to parasite growth inhibition studies on 
the Dd2 strain and determine their cytotoxicity. 
 Subject selected compounds to the haem fractionation assay. 
 Using the data from the above studies, attempt to establish a QSAR for compounds  
2-19. 
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4.3 Results and Discussion 
4.3.1 β-haematin Inhibition Studies 
The NP-40 detergent mediated assay, modified from Carter et al, was used for all these 
studies. Modifications to improve the solubility of the benzimidazole compounds by 
substituting 70 µL of water with acetone was necessary to obtain reproducible results. This 
substitution of solvents has been shown to have no interference in the assay and is in 
accordance with the published data by Carter et al.92 Compounds 2-19 shown in Scheme 4.1 
were tested, with the results shown in Table 4.1 accompanied by the Bayesian predictions 
from Chapter 2.  
Scheme 4.1: The synthesized benzimidazole compounds tested for β-haematin inhibition 
using the NP-40 detergent based assay. 
Of the eighteen compounds tested, fourteen were found to be active in the β-haematin 
inhibition assay using the cut-off of 100 µM for β-haematin inhibition activity with a typical 
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sigmoidal dose response curve shown in Figure 4.2. This indicated that 78% of the Bayesian 
predictions were correct. Compound 7 was also found to be very close to the cut-off. 
Compared to random screening using the β-haematin Bayesian model containing 2 113 active 
compounds and 64 118 inactive compounds, a 24-fold enrichment was thus achieved.127   
Table 4.1: The β-haematin inhibition results of compounds 2-19 and the accompanying 
Bayesian prediction from Chapter 2. 
Compound β-haematin inhibition IC50 (µM) 
Bayesian β-haematin inhibition 
score 
2 Inactive 25.6979 
3 24.5 ± 4.2 28.1166 
4 28.1 ± 1.7 32.6362 
5 32.0 ± 1.4 38.4248 
6 Inactive 25.4777 
7 Inactive 24.0156 
8 38.9 ± 1.5 19.9991 
9 16.6 ± 0.3 36.4715 
10 28.9 ± 1.6 21.0876 
11 13.3 ± 0.5 40.5853 
12 16.8 ± 0.4 29.5242 
13 38.2 ± 1.4 19.5834 
14 25.1 ± 1.1 31.0259 
15 Inactive 25.1454 
16 35.6 ± 1.7 30.6674 
17 42.4 ± 2.1 19.3296 
18 84.1 ± 2.4 14.9506 
19 46.6 ± 1.7 27.4973 
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Figure 4.2: A sigmoidal dose response curve showing β-haematin activity of 9 and the 
amodiaquine standard. 
One goal of this study was to determine which fragments of the hit compound, 5, are essential 
for β-haematin inhibitory activity. The fragment compounds purchased (21a, 22a and 23a) 
and synthesized (1, 21, 22 and 23) as well as the diacylated product, 20 are shown in Scheme 
4.2. These compounds were subjected to the same assay and the results are shown in Table 
4.2 along with the Bayesian predictions from Chapter 2. All compounds except 20 were found 
to be experimentally inactive in contrast to the predictions of six active and one inactive 
compound. This is not surprising as the Bayesian scores for all compounds except two are 
very close to the cut-off score for an IC50 below 100 µM and hence have low confidence. 
Compound 20 was found to be experimentally somewhat more active than its parent 
compound, 3, with an IC50 of 15.6 ± 0.5 µM compared to 3 with an IC50 of 24.5 ± 4.2 µM. 
Compound 1 was found to be a false positive on the basis of the β-haematin inhibition activity 
prediction while compound 23 had a β-haematin inhibition value of 120.6 ± 6.9 μM which is 
close to the cut-off and accounts for the second highest Bayesian prediction score. Despite all 
the false positive predictions, this data gave a 14.3% hit rate for these compounds. When this 
is compared to random screening using the β-haematin inhibition Bayesian model, a 4-fold 
enrichment was achieved. These two significant enrichments achieved for the benzimidazole 
compounds (24-fold) and fragment studies (4-fold) show how powerful the Bayesian 
technique and specifically the β-haematin Bayesian model is as this technique not only saves 
time but valuable resources when performing hit to lead analysis. 
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Scheme 4.2: The synthesized benzimidazole fragments. 
Table 4.2: The β-haematin inhibition results of the benzimidazole fragment compounds and 
the accompanying Bayesian prediction, with the above the cut-off score for IC50 < 100 µM in 
red.  
Compound β-haematin inhibition IC50 (µM) 
Bayesian β-haematin inhibition 
score 
1 Inactive 22.8883 
20 15.6 ± 0.5  - 
21 Inactive 12.7431 
21a Inactive -5.34745 
22 Inactive 6.81007 
22a Inactive 8.04823 
23 120.6 ± 6.9 19.8929 
23a Inactive 1.03421 
 
4.3.2 Benzimidazole β-haematin Inhibition SAR 
When analysing compounds 2-19 for SARs, clear trends emerged. By considering the  
β-haematin activities of compounds 13, 14 and 15, which are all mono-chlorinated 
compounds, the effect of substituent position on the phenyl ring system was made evident. 
Compound 13 (o-chloro) showed moderate β-haematin activity of 38.2 ± 1.4 µM, while 
compound 14 (m-chloro) showed good activity (25.1 ± 1.1 µM) and compound 15 (p-chloro) 
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no activity (above 100 µM). Upon examination of the other para-substituted compounds 6 
and 7, both compounds showed similar inactivity in the β-haematin inhibition assay. The same 
holds true for the ortho-substituted compounds 8 (o-methoxy) and 10 (o-nitro), with 
moderate β-haematin activities of 38.9 ± 1.5 µM and 28.9 ± 1.6 µM. It is evident that the 
electron withdrawing nitro group is preferred over the electron releasing methoxy group. This 
phenomenon can also be seen when examining the meta-substituted compounds 3  
(o-bromo), 4 (o-trifluoromethyl) and 11 (3,5-dinitro) with good β-haematin inhibition 
activities of 24.5 ± 4.2 µM, 28.1 ± 1.7 µM and 13.3 ± 0.5 µM noting that all substituents are 
electron withdrawing. Compound 11 with the two electron withdrawing nitro groups showed 
the best β-haematin inhibition activity of the series. Nitro groups are more strongly electron 
withdrawing than halogens. The conclusions that can be drawn from this series are: electron 
withdrawing groups (EWG) result in increased β-haematin inhibition activity over electron 
releasing groups (ERG) and the more electron withdrawing the group, the better the activity. 
It can also be noted that the order for increasing β-haematin inhibition activity for various 
substituent positions on the ring system are as follows: para < ortho < meta.  
The type of ring system was also shown to influence the β-haematin inhibition activity of 
these compounds. To analyse this, a comparison between compounds 2 (phenyl) and 16 
(pyridyl) was made. The difference between these two compounds can be seen immediately 
with compound 2 showing complete inactivity and compound 16 showing a moderate  
β-haematin inhibition activity of 35.6 ± 1.7 µM. This trend is also seen when comparing 
compounds 4 (o-trifluoromethylphenyl) and 9 (o-trifluoromethylpyridyl) with respective  
β-haematin activities of 28.1 ± 1.7 µM and 16.6 ± 0.3 µM. The modification of a 6-membered 
ring system to a 5-membered ring system showed moderate to poor activity when comparing 
compounds 17 (thiophene), 18 (furan) and 19 (pyrrole) with β-haematin inhibition activities 
of 42.4 ± 2.1 µM, 84.1 ± 2.4 µM and 46.6 ± 1.7 µM respectively to compound 16 with an 
electron poor pyridyl ring with a β-haematin inhibition activity of 35.6 ± 1.7 µM. However, 
these modifications are all superior to the electron rich phenyl ring system with compound 2 
being inactive (> 100 µM). Thus the order for increasing β-haematin inhibition activity for 
various ring systems is as follows: phenyl < furan < pyrrole < thiophene < pyridyl. All these 
findings are summarised in Scheme 4.3. 
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Scheme 4.3: The SAR trends found for the benzimidazole series for β-haematin inhibition with 
good/ preferred groups in green, moderate groups in blue and poor groups in red.  
4.3.3 Molecular Docking 
To gain more insight into the observed SARs, molecular docking was attempted. Molecular 
docking is the process whereby a molecule is positioned in an active site in such a way as to 
try to achieve maximum binding affinity and molecular interactions between the two sites. 
158–161 This is usually used to determine ligand-protein interactions but can in principle also be 
used for interactions with a crystal surface.158 This model can assist in identifying the key 
interactions between the ligand and active site for biological activity as well as assist in 
verifying a proposed mechanism of action for certain drug-like molecules.158  
Even though one of the first suggestions of molecular docking came from Crick, it was only in 
the mid-1980s that the field of molecular docking started to develop.159 The first widely used 
docking programme was simply called DOCK and was developed by Kuntz et al.159 However, 
even with the development of docking programmes, the process of docking is not simple. 
Ideally, one has to consider several enthalpic and entropic factors which play key roles in 
binding, the mobility of the active site and ligands and interactions with other molecules in 
solution such as water, although approximations often have to be made.161 There are three 
key considerations for any docking study: the representation of the system of interest, the 
conformational searching algorithm and the scoring function.159 Three families of scoring 
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functions exist namely: force-field based, knowledge based and empirical. Similarly, three 
conformational algorithms exist namely: systematic methods (incremental construction and 
conformational search), simulation methods (energy minimisation and molecular dynamics) 
and random methods (Monte Carlo, Tabu search and Genetic Algorithms).138,160 This makes 
each docking programme unique and thus different docking programmes will be more 
efficient for different systems. Solving a docking problem for a certain system requires the 
use of a fast and efficient searching algorithm coupled with a fast enough scoring function 
that can easily discriminate between native or non-native conformations of the ligand and 
binding site and is unique to the system in question.159  
4.3.3.1 Materials Studio 
Of all the docking programmes available including AutoDock, FlexX, FRED, Glide, GOLD and 
DOCK, the Materials Studio package 162 is the only one specifically designed to be able to 
compute adsorption calculations with different surfaces. The package is able to handle crystal 
surfaces with promising results.138 This makes it ideal for docking studies using a series of 
small molecules adsorbed onto a β-haematin crystal structure. The Materials Studio package 
contains many functions but for this work only the Forcite geometry optimisation, adsorption 
locator with simulated annealing (Forcite anneal) functions and energy calculations were 
necessary. 
A Forcite geometry optimisation is a single point energy calculation that determines the 
minimum energy of the molecule in question. The adsorption locator uses an input substrate 
(in this case β-haematin crystal structure) and an input adsorbent (benzimidazole). The 
simulation uses the Monte Carlo method to determine the optimum orientation of the 
absorbent on the substrate.163 The calculation also uses simulated annealing to find a 
minimum energy structure. These two techniques are simultaneously used through multiple 
cycles to allow for more accurate results.163 Annealing is a technique where the molecule in 
question is heated to high temperatures and subsequently cooled over cycles to find the 
optimum configuration.163 As with all computational systems there are limitations using this 
methodology for docking. The most noteworthy of these limitations is the exclusion of solvent 
during calculations (calculations are carried out in a vacuum slab). This can be problematic in 
terms of direct comparison to working under physiological conditions, as water can interact 
with both the molecule and β-haematin crystal surface changing the outcome of 
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intermolecular interactions. This is however unavoidable as including water in these 
simulations would increase the computational time to the extent of making the simulation 
impractical. This is exacerbated by having to investigate different crystal faces for each 
compound. The other limitation to this methodology is that the entropy of the system is not 
considered as only the energy of the β-haematin crystal and compound are investigated. In 
order to investigate this entropy change would require more sophisticated techniques adding 
to time and resource costs.   
4.4.3 Docking Results and Discussion 
Confirmation of the benzimidazole compounds as β-haematin inhibitors led to the 
investigation of the binding configurations and energies on the fastest and second fastest 
growing β-haematin crystal faces,84 (001) and (011), using molecular docking techniques. 
Materials Studio was used for all docking computations which allowed the use of a  
β-haematin crystal surface based on the reported crystal structure84 and modified CVFF  
force-field84 produced by the de Villiers group (unpublished work). 
Compounds 2-19 were drawn in Chemdraw Ultra 12.0.2 and imported into Materials Studio 
where the geometry of the compounds were optimised using a Forcite geometry optimisation 
calculation. These optimised compounds were adsorbed onto both of the pre-built  
β-haematin crystal surfaces using the adsorption locator. The lowest energy adsorption 
results for each compound and crystal face were subjected to a Forcite annealing calculation 
to obtain the lowest plausible energy configuration of the system. An energy calculation was 
performed on this β-haematin crystal and compound complex. This was used to obtain the 
adsorption energy for each compound on each crystal face using equation 4.1:  
Eads (kcal.mol-1) = E final – E initial 
                = E (crystal + inhibitor) – E (crystal) – E (inhibitor)            Equation 4.1 
The adsorption results are shown in Table 4.3 alongside the experimental β-haematin 
inhibition results discussed earlier.  
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Table 4.3: The adsorption energies obtained from the molecular docking on both β-haematin 
crystal faces of compounds 2-19. 
Compound 
β-haematin inhibition 
IC50 (µM) 
Adsorption energy 
(kcal/mol) (001) 
Adsorption energy 
(kcal/mol) (011) 
2 Inactive -59.80 -57.23 
3 24.5 ± 4.2 -61.35 -62.20 
4 28.1 ± 1.7 -68.73 -69.95 
5 32.0 ± 1.4 -60.73 -61.67 
6 Inactive -61.24 -60.26 
7 Inactive  -68.21 -64.62 
8 38.9 ± 1.5  -60.98 -60.42 
9 16.6 ± 0.3 -64.60 -68.39 
10 28.9 ± 1.6  -71.45 -64.34 
11 13.3 ± 0.5 -84.11 -74.30 
12 16.8 ± 0.4 -66.40 -66.41 
13 38.2 ± 1.4 -64.62 -62.35 
14 25.1 ± 1.1 -63.79 -62.62 
15 Inactive -66.83 -64.58 
16 35.6 ± 1.7 -60.59 -58.62 
17 42.4 ± 2.1 -60.84 -58.48 
18 84.1 ± 2.4 -61.71 -58.08 
19 46.6 ± 1.7 -61.33 -57.49 
 
Analysis of this data lead to a simple correlation of the β-haematin inhibition IC50 values with 
the adsorption energy on the (011) β-haematin crystal face, shown in Figure 4.3. This suggests 
that the (011) β-haematin crystal face was the most important crystal face for the 
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benzimidazole compounds to adsorb onto in order to inhibit β-haematin formation and 
therefore this was the topic for further analysis. In order to justify this correlation, an in-depth 
analysis of the intermolecular interactions between this series of compounds and β-haematin 
was performed. 
 
Figure 4.3: Experimental β-haematin IC50 versus the adsorption energy for the (011)  
β-haematin crystal face. 
Using intermolecular interaction distances for hydrogen bonding, which were taken to be 
optimally between 2.36 and 3.69 Å,164 and π-π interactions distances which were optimally 
taken to be between 3.3 and 3.8 Å, 165 molecular docking results could be rationalised.  
Examining the predicted structures of the experimental β-haematin non-inhibitors 2, 6, 7 and 
15 it was seen that these compounds showed π-π interactions as well as hydrogen bonding 
with the β-haematin crystal surface (Figure 4.4). Compound 2 showed two π-π interactions 
both with distances of 3.7 Å. Compared to literature standards this is near the upper limit and 
thus termed weak. Compound 2 also contained a short hydrogen bond between the amide 
hydrogen and a propionate group of the (011) β-haematin crystal face with a bond distance 
of 2.68 Å. Compound 6 contained one π-π intermolecular interaction and a short hydrogen 
bond with respective distances of 3.6 Å and 2.20 Å. The other π-π distance was found to be 
-80 -70 -60 -50
0
10
20
30
40
50
60
Adsorption energy (011) (kcal/mol)

-h
a
e
m
a
ti
n
 i
n
h
ib
ti
o
n
 I
C
5
0
 (

M
)
r2 = 0.70 
P = 0.0004 
106 
 
much greater than the upper limit from literature at 4.1 Å. Compound 7 was found to be 
similar to compound 6 with one π-π interaction with a distance of 3.6 Å and a short hydrogen 
bond with a bond distance of 2.37 Å. Compound 15 showed two very weak π-π interactions 
with distances of 3.8 Å which is the upper limit according to literature. This compound also 
showed a short hydrogen bond with a bond distance of 2.12 Å.  
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Figure 4.4: Docked structures of compounds 2, 6, 7 and 15 (top to bottom) on the (011) crystal 
face of the β-haematin crystal with π-π interactions shown in green and hydrogen bonding 
shown in light blue. 
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A similar behaviour compared to the inactive compounds was found with compound 18 
(Figure 4.5). This compound showed only one π-π interaction and one short hydrogen bond 
with respective bond distances of 3.6 Å and 2.41 Å. This is not surprising as the β-haematin 
inhibition IC50 of this compound was found to be 84.1 ± 2.4 µM which is close to the cut-off 
value of 100 µM. 
 
Figure 4.5: Docked structure of compounds 18 on the (011) crystal face of the β-haematin 
crystal with π-π interactions shown in green and hydrogen bonding shown in light blue. 
All other active compounds in this series showed similar behaviour with one to two π-π 
interactions and a hydrogen bond. Two examples, compounds 3 and 5, are shown in Figure 
4.6 to illustrate this observation. Compound 3 showed two π-π interactions with bond 
distances of 3.8 Å and 3.7 Å with a moderate hydrogen bond with bond distance of 2.98 Å. 
Similarly, two π-π interactions are shown with compound 5 with both bond distances of  
3.7 Å and one moderate hydrogen bond with bond distance of 2.94 Å. 
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Figure 4.6: Docked structures of compounds 3 and 5 (top to bottom) on the (011) crystal face 
of the β-haematin crystal.  
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A clear trend could not be seen between the β-haematin inhibition inactive compounds and 
β-haematin inhibitors in the series. This led to consideration of the same compounds 
adsorbed on the (001) β-haematin crystal face even though it was known from the previous 
correlation that the (011) β-haematin crystal face was the most important in terms of these 
adsorption energies. 
Examining the predicted structures of the experimental β-haematin inhibition inactive 
compounds 2, 6, 7 and 15, it was seen that these compounds showed little to no 
intermolecular interactions with the (001) β-haematin crystal surface (Figure 4.7). Compound 
2 showed no π-π interactions as the distances of 5.2, 4.3 and 4.0 Å were much greater than 
the maximum π-π interaction distances of 3.8 Å. This compound did however contain an 
anomalously close hydrogen bonding contact with a bond distance of 2.0 Å which is lower 
than the lower limit for hydrogen bonding of 2.36 Å. In contrast, compound 6 had no 
hydrogen bonds but did contain one weak π-π interaction between the benzimidazole ring 
and the porphyrin ring system with a distance of 3.7 Å compared to the maximum distance of 
3.8 Å according to literature. Compound 7 contained one intermolecular interaction with the 
β-haematin surface in the form of a short hydrogen bond with a value of 2.49 Å. This 
interaction was near the lower limit of literature with a value of 2.36 Å. The π-π interaction 
indicated in Figure 4.6 of compound 7 could be considered very weak as it falls on the upper 
limit of 3.8 Å. Compound 15 contains one weak π-π intermolecular interaction between the 
p-chloro substituted ring system and the porphyrin ring system with a distance of 3.5 Å. This 
compound also contains a short hydrogen bond with the bond distance of 2.8 Å.  
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Figure 4.7: Docked structures of compounds 2, 6, 7 and 15 (top to bottom) on the (001) crystal 
face of the β-haematin crystal showing few to no interactions with the β-haematin surface. 
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Compound 18 (Figure 4.8) showed only one π-π interaction with a interaction distance of  
3.7 Å and no hydrogen bonding. This supported the assumption that 18 was too weak a  
β-haematin inhibitor to be included in the correlation study as it contained the same number 
of π-π interactions as the inactive compounds which were not included in the previous 
correlation. 
 
Figure 4.8: Docked structures of compounds 18 on the (001) crystal face of the β-haematin 
crystal. 
By contrast the experimentally active β-haematin inhibitors contained between two and 
three moderate to strong intermolecular interactions with the β-haematin crystal surface 
(Figure 4.9). Two π-π interactions were visualised between the m-bromo-substituted ring 
system and the porphyrin ring system as well as the benzimidazole ring system and the 
porphyrin ring system with respective bond distances of 3.8 and 3.5 Å for compound 3. 
Compound 3 also contained a short hydrogen bond with a bond distance of 2.19 Å. Similarly, 
compound 5 contained two π-π interactions with distances of 3.5 and 3.7 Å and a hydrogen 
bond with bond distance of 2.17 Å.  
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Figure 4.9: Docked structures of compounds 3 and 5 (top to bottom) on the (001) crystal face 
of β-haematin showing more favoured intermolecular interactions of at least two π-π 
interactions and a hydrogen bond per molecule. 
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A summary of the π-π interactions are shown in Table 4.4. This indicated that any compound 
with two or less π-π interactions on a combination of both β-haematin crystal faces showed 
inactivity. The only outlier to this is compound 15 which showed three π-π interactions, 
however those interactions are extremely weak as both interactions on the (011) crystal face 
were found to have values of 3.8 Å which is the upper limit according to literature. These 
observations justified the exclusion of compounds 2, 6, 7, 15 and 18 from the correlation of 
adsorption energies of the (011) β-haematin crystal face and the β-haematin inhibition IC50 
values on the basis that a minimum number of specific interactions are also required. 
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Table 4.4: The number of π-π interactions for each of the β-haematin crystal faces of 
compounds 2-19 with inactive compounds and outliers shown in red. 
Compound 
No. of π-π interactions 
on (011) β-haematin 
crystal face 
No. of π-π interactions 
on (001) β-haematin 
crystal face 
Total No. of π-π 
interactions 
2 2 0 2 
3 2 2 4 
4 1 2 3 
5 2 2 4 
6 1 1 2 
7 1 0 1 
8 1 2 3 
9 2 2 4 
10 2 1 3 
11 2 1 3 
12 2 1 3 
13 2 1 3 
14 2 2 4 
15 2 1 3 
16 2 1 3 
17 2 1 3 
18 1 1 2 
19 2 1 3 
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4.4.4 Malaria Parasite Growth Inhibition Studies 
Following the investigations into the β-haematin inhibition of the benzimidazole compounds 
using the various tools described above, compounds 2-19 were tested for parasite activity in 
vitro. The malaria parasite growth inhibition activity assay was carried out by collaborators 
using the lactate dehydrogenase assay instead of the SyBr Green assay as previously 
discussed, which used cultured NF54 chloroquine sensitive malaria parasites and were tested 
in triplicate.166,167 The results are shown in Table 4.5 alongside the predicted Bayesian score.  
Of the eighteen predicted inhibitors of malaria parasite growth, only two were found to be 
experimentally inactive using a cut-off of 20 µM. This meant that 89% of the compounds were 
predicted correctly by the Bayesian model corresponding to a 45-fold enrichment compared 
to random screening using the malaria parasite growth inhibition Bayesian model containing 
817 active compounds and 41 729 inactive compounds.127 If, however, a cut-off of 2 µM (used 
because the compounds were predicted using a pre-built Bayesian model) was used, as was 
the case with the Bayesian predictions, nine out of the eighteen compounds would be termed 
active and with a hit rate of 50%. When compared to random screening using the same 
Bayesian model a 26-fold enrichment was achieved. This false positive data was generated 
because the Bayesian model recognises any compound with a benzimidazole fingerprint as 
active, so with the new input of this data the Bayesian model would be improved. Thus, not 
only was the Bayesian screening highly successful using the β-haematin inhibition model, but 
also for the malaria parasite growth inhibition model. 
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Table 4.5: The malaria parasite growth inhibition IC50 results of compounds 2-19 using the 
NF54 strain of P. falciparum and the accompanying Bayesian prediction from Chapter 2. 
Compound 
NF54 malaria parasite growth 
inhibition IC50 (µM) 
Malaria parasite growth 
inhibition score 
2 Inactive 61.3259 
3 1.3 ± 0.2 57.2935 
4 1.34 ± 0.07 75.2685 
5 0.41 ± 0.03 72.6119 
6 2.0 ± 0.1  63.8076 
7 7.2 ± 0.2  49.3979 
8 5.50 ± 0.6 43.3265 
9 0.8 ± 0.5 81.8491 
10 12.3 ± 2.7 30.0400 
11 0.67 ± 0.07 47.2409 
12 0.53 ± 0.13 65.4908 
13 15.0 ± 0.3 45.2802 
14 1.21 ± 0.06 58.6210 
15 Inactive 56.5011 
16 11.6 ± 2.6 78.3569 
17 7.2 ± 0.7 55.1323 
18 5.9 ± 0.8 48.2215 
19 1.2 ± 0.4 67.9852 
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4.4.5 Benzimidazole Malaria Parasite Growth Inhibition SAR 
As with the β-haematin inhibition SAR, a comparison of 13 (o-chloro), 14 (m-chloro) and 15 
(p-chloro) showed a trend for position of substitution. Compound 15 again showed poor 
activity with a parasite growth inhibition activity of greater than 20 µM, while compound 13 
showed moderate activity with an IC50 of 15.0 ± 0.3 µM and compound 14 showed good 
activity with an IC50 value of 1.21 ± 0.06 µM. This followed the same trend as the β-haematin 
inhibition activity of para < ortho < meta. However, upon examination of compound 6  
(p-tert-butyl), an IC50 of 2.0 ± 0.1 µM was obtained. This indicated that not all para-substituted 
ring systems showed poor activity. In fact, this biological activity was superior to all ortho-
substituted compounds in the series. When a comparison between compound 8 (o-methoxy) 
and 10 (o-nitro) was made, a conclusion was drawn that the electron releasing groups actually 
showed an increased activity compared to electron withdrawing groups. Therefore, the final 
conclusion that was drawn for the position of substitution trend for malaria parasite growth 
inhibition was as follows: para ≈ ortho < meta. 
Upon investigating the optimal type of ring system, a comparison between 2 (phenyl) and 16 
(pyridyl) was informative. Compound 2 had an IC50 value greater than the 20 µM cut-off while 
compound 16 had an IC50 value of 11.6 ± 2.6 µM. This trend also holds when comparing the 
substituted compounds 3 (m-bromophenyl) and 5 (m-bromopyridyl) with respective IC50 
values of 1.3 ± 0.2 µM and 0.41 ± 0.03 µM. Similarly, this was seen with compounds 4  
(m-trifluoromethylphenyl) and 9 (m- trifluoromethylpyridyl) with respective IC50 values of 
1.34 ± 0.07 µM and 0.8 ± 0.5 µM respectively. Both these sets of compounds also showed a 
promising activity shift to the nM range, although their activities are not close to that of the 
chloroquine standard used (12.51 ± 0.63 nM). When the two six-membered ring system 
values were compared to the five-membered ring series of compounds 17 (thiophene), 18 
(furan) and 19 (pyrrole) with respective IC50 values of 7.2 ± 0.7 µM, 5.9 ± 0.8 µM and  
1.2 ± 0.4 µM, the most active compounds in this comparison were definitely the 5-membered 
ring systems. Thus, the activity trend for the differing ring systems when comparing malaria 
parasite growth inhibition IC50 values was as follows: phenyl < pyridyl < thiophene < furan  
< pyrrole. All these findings are summarised in Scheme 4.4. 
120 
 
Scheme 4.4: The SAR trends found for the malaria parasite growth inhibition IC50 of the 
benzimidazole series with preferred groups in green, moderate groups in blue and poor 
groups in red. 
4.4.6 Parasite Growth Inhibition Studies in the Dd2 Strain and Cytotoxicity  
A selection of the most active compounds from the NF54 testing were further tested on the 
chloroquine resistant strain of malaria parasite, Dd2, using the same assay conditions to 
determine if cross-resistance was evident for this series of compounds. The results are shown 
in Table 4.6 alongside the NF54 results for comparison. 
The Dd2 results showed a slight decrease in activity of compounds 5 (m-bromo) and 9  
(m-trifluoromethyl) with IC50 values of 0.96 ± 0.04 µM and 1.10 ± 0.37 µM respectively 
compared to the NF54 results of 0.41 ± 0.03 µM and 0.8 ± 0.5 µM. The opposite was true for 
compounds 11 (3,5-dinitro) and 12 (2,6-dichloro) which showed small increases in activity 
going from IC50 values of 0.67 ± 0.07 µM and 0.53 ± 0.13 µM respectively in the NF54 strain 
to values of 0.31 ± 0.02 µM and 0.34 ± 0.03 µM respectively in the Dd2 strain. This was clearly 
seen with the resistance indexes (RIs) of compounds 5 and 9 greater than one and while 
compounds 11 and 12 showing values of less than one. Using this data it can be seen that for 
inhibition of the Dd2 strain, a disubstituted compound is preferred to a monosubstituted 
compound. None of the compounds exhibit cross-resistance, since the RI values are all small. 
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Table 4.6: The malaria parasite growth inhibition IC50 results of compounds 5, 9, 11 and 12 
using the Dd2 strain of P. falciparum and the accompanying NF54 IC50 results. 
Compound 
Dd2 malaria parasite 
growth inhibition IC50 
(µM) 
NF54 malaria parasite 
growth inhibition IC50 
(µM) 
Resistance Index 
(RI) 
5 0.96 ± 0.04 0.41 ± 0.03 2.34 
9 1.10 ± 0.37 0.80 ± 0.50 1.38 
11 0.31 ± 0.02 0.67 ± 0.07 0.45 
12 0.34 ± 0.03 0.53 ± 0.13 0.64 
 
The cytotoxicity of compounds 5, 9, 11 and 12 was determined against the Chinese Hamster 
Ovarian (CHO) cell line, with the results shown in Table 4.7. All compounds were shown to be 
selective against P. falciparum with the selectivity index (SI) ranging from 31.82 to 664.77 in 
the chloroquine resistant strain and 43.75 to 461.24 in the chloroquine sensitive strain. 
Table 4.7:  The cytotoxicity results from the CHO cell line of compounds 5, 9, 11 and 12 with 
the selectivity indexes to the Dd2 and NF54 strain of P. falciparum. 
Compound 
CHO 
cytotoxicity 
(µM) 
Dd2 malaria 
parasite growth 
inhibition IC50 
(µM) 
Selectivity 
Index (SI) 
Dd2 
NF54 malaria 
parasite growth 
inhibition IC50 
(µM) 
Selectivity 
Index (SI) 
NF54 
5 189.11 ± 4.17 0.96 ± 0.04 196.99 0.41 ± 0.03 461.24 
9 35.00 ± 4.39 1.10 ± 0.37 31.82 0.80 ± 0.50 43.75 
11 206.08 0.31 ± 0.02 664.77 0.67 ± 0.07 307.58 
12 183.87 ± 8.67 0.34 ± 0.03 540.79 0.53 ± 0.13 346.92 
 
4.4.7 Malaria Parasite Growth Inhibition Studies Using a Fragment Approach 
The fragment compounds were also tested against the NF54 strain of P. falciparum despite 
their lack of β-haematin inhibition activity. The diacylated product (20) was also included in 
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this study. The results are shown in Table 4.8 along with the Bayesian predictions for the 
compounds. 
All fragment compounds were found to be inactive in comparison to their Bayesian 
predictions of two inactive compounds. Thus, in the case of this subset of compounds, the 
Bayesian model predicted 71% of the data correctly with a 36-fold enrichment compared to 
random screening using the malaria parasite growth inhibition Bayesian model. From this 
data it can be concluded that the whole molecule is required for biological activity as the 
removal of any group from the molecule leads to biological inactivity in the malaria parasite. 
Compound 20 also showed a two-fold diminished malaria parasite growth inhibition activity 
when compared to its parent compound, 3, indicating that a substituent on the N atom of the 
benzimidazole ring is not favoured for parasite activity.  
Table 4.8: The malaria parasite growth inhibition IC50 results of the fragment compounds and 
20 using the NF54 strain of P. falciparum accompanied by the Bayesian predictions from 
Chapter 2. 
Compound 
NF54 malaria parasite growth 
inhibition IC50 (µM) 
Malaria parasite growth 
inhibition score 
1 Inactive 56.9520 
20 2.6 ± 0.6 - 
21 Inactive -8.57182 
21a Inactive -10.6894 
22 Inactive -8.25818 
22a Inactive -12.8326 
23 Inactive  60.8754 
23a Inactive 4.55447 
 
4.4.4 Cellular Haem Fractionation Assay  
Following the investigation of the initial benzimidazole series using the NP-40 assay, it was 
known that the vast majority of these compounds were β-haematin inhibitors. However, this 
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does not necessarily mean that they will inhibit haemozoin formation in the cell. Without 
additional data there was uncertainty that the compounds were able to enter the food 
vacuole. Yet another scenario might be that the compounds had a stronger activity against 
another target and thus killed the cell in that way without affecting haemozoin formation.  In 
order to confirm that these compounds do indeed inhibit haemozoin formation in the cell, 
four compounds, 3, 5, 6 and 13 were tested by colleagues using the cellular haem 
fractionation assay developed by Combrinck et al.71,168 This allowed for the measurement of 
free haem and haemozoin levels in the malaria parasite after dosage at chosen multiples of 
the IC50 of each compound. The results for all the compounds showed similar behaviour to 
compound 3 shown in Figure 4.10.  
The measurements showed that with an increase in concentration of compound 3 there was 
an evident decrease in both the percentage haemozoin and mass of haemozoin in the malaria 
parasite as well as a large increase of free haem compared to the control. This is consistent 
with the proposed mechanism of action being haemozoin inhibition, where more toxic free 
haem is available to kill the malaria parasite due to the compounds inhibiting the growth of 
haemozoin. 
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Figure 4.10: The percentage and amount of free haem and haemozoin after incubation with 
compound 3. 
4.4.5 QSAR Study 
A QSAR study on the benzimidazole compounds was conducted using Molecular Modelling 
Pro Plus (MMPPlus) v 7.0.2.169 The main input for this study was the experimentally 
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determined malaria parasite growth and β-haematin inhibition data obtained from the 
previously discussed studies. Using this and physio-chemical parameters calculated by 
MMPPlus a feasible multiple correlation was obtained, shown in Figure 4.11. 
 
Figure 4.11: Experimental -Log(Pf IC50) versus the predicted -Log(Pf IC50) obtained from the 
multiple correlation of various terms according to equation 4.2. 
-Log(Pf IC50) = (1/β-haematin IC50)(28,73) + number of hydrogen bond donors(3,71) + 
molecular depth(1,43) - 8,90                           Equation 4.2 
This correlation was found to be significant using the F-test at the 99% confidence level  
(F-stat = 9.84 > F-crit = 5.56) and the two-tailed t-test at 90% confidence level for each 
parameter (t = 5.12, 1.87, 2.56, 3.46 > t-crit = 1.76). The multiple correlation showed that for 
an increase in P. falciparum activity there was an increase in β-haematin inhibition activity, 
an increase in the number of hydrogen bond donors and an increase in the molecular depth 
of the molecule (the amount of space the molecule takes up in terms of height). Looking at 
the terms individually, in order to obtain a more active compound against malaria parasite 
growth, the compound was required to have hydrogen bond donors. As shown by the haem 
fractionation study, the biological activity is linked to their ability to inhibit β-haematin 
formation. The molecular depth of these compounds remains quite consistent and is the least 
influential term in the equation. This equation was found to be dominated by the  
1/β-haematin IC50 which signifies the importance that β-haematin inhibitory activity plays in 
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this set of compounds and cements the understanding that these compounds act via 
haemozoin inhibition.  
4.5 Summary and Conclusions 
In this study all the synthesized benzimidazole compounds were tested using the NP-40 
detergent mediated β-haematin inhibition assay. The initial series showed promising results 
with fourteen out of eighteen compounds termed active. Comparing this to the Bayesian 
predictions, 78% of the compounds were correctly predicted with a 24-fold enrichment 
compared to random screening. SAR of the benzimidazole scaffold in terms of β-haematin 
inhibition showed three trends. A preferred meta-substitution pattern was seen and electron 
withdrawing groups were preferred over electron releasing groups. There was also a 
preference over which ring system was favoured for β-haematin inhibition activity as follows: 
phenyl < furan < pyrrole < thiophene < pyridyl. All compounds in the fragment study were 
found to be inactive in contrast to the Bayesian predictions where only one out of seven 
predictions was correct, leading to a hit rate of 14% with a 4-fold enrichment compared to 
random screening.  
Docking studies were carried out on all the benzimidazole compounds to investigate the 
correlation between β-haematin inhibition activity and adsorption energies. A correlation 
between β-haematin inhibition activity and adsorption energies on the (011) β-haematin 
crystal face was found. This indicated that the (011) β-haematin crystal face was the most 
important in terms of adsorption for this series of compounds with respect to inhibition. In 
order to justify this correlation, the intermolecular interactions of the compounds with the 
both β-haematin crystal faces was studied. This showed that compounds with less than three 
π-π interactions were deemed inactive. Compounds 2, 6, 7, 15 and 18 all showed this trend. 
Hydrogen bonding was also a factor considered in this study but could not explain inactivity 
as all compounds contained at least one hydrogen bond.   
P. falciparum growth inhibition studies were carried out on all compounds using the 
chloroquine sensitive NF54 strain with selected active compounds also tested on the 
chloroquine resistant Dd2 strain and for cytotoxicity. Using a cut-off of 20 µM, sixteen out of 
the eighteen initial benzimidazole compounds were deemed active with 89% (16/18 
compounds) of the compounds correctly predicted by the Bayesian statistics leading to a  
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45-fold enrichment compared to random screening. However, if the cut-off was lowered to  
2 µM, as with the initial Bayesian model, only 50% (9/18 compounds) of the compounds were 
correctly predicted still with a substantial 26-fold enrichment compared to random screening. 
The results from the NF54 strain showed that meta-substituted compounds were favoured 
and both para-substituted and ortho-substituted compounds showed lower activity. Electron 
releasing substituents were favoured in contrast to the finding from the β-haematin inhibition 
studies. The trend for selection of ring systems was found to be as follows: phenyl < pyridyl  
< thiophene < furan < pyrrole.  
The Dd2 results showed a slight decrease in activity in the monosubstituted compounds while 
the disubstituted compounds showed a small increase in activity. None showed evidence of 
cross-resistance with chloroquine. The fragment compounds were all shown to be inactive 
against the NF54 strain with 71% (5/7 compounds) correctly predicted by Bayesian statistics 
showing a 36-fold enrichment compared to random screening. Compound 20 saw a 2-fold 
diminished malaria parasite growth inhibition activity compared to its parent, 3. 
The haem cellular fractionation assay confirmed that the benzimidazole compounds were 
indeed haemozoin inhibitors and were able to get into the cell and food vacuole with a 
decrease in haemozoin and an increase in free haem shown. A QSAR study showed that the 
P. falciparum growth inhibition activity values of these benzimidazole compounds can be 
predicted using the number of hydrogen bond donors, the molecular depth of the molecule 
and most importantly the β-haematin inhibition activity.  
Using the Bayesian model to pre-screen compounds was found to be extremely successful 
and enabled the quick selection of reliable hit compounds and derivatives thereof. Although 
the benzimidazole compounds did not show a dramatic improvement in biological activity 
compared to the hit compound, the findings are none the less important. It is now possible 
to predict the β-haematin inhibition values by using simulated adsorption energies on the 
(011) β-haematin crystal face. With these calculated β-haematin values, predictions can be 
made for parasite activities of new compounds before synthesis. In this way the tedious 
synthetic steps are mitigated until worthy candidates are discovered using computational 
techniques.  
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Chapter 5: Carbazole Indole Molecular Docking and Structure-
Activity Relationships for β-haematin and Parasite Growth Inhibition 
5.1 Introduction 
The initial carbazole scaffold was first discovered in the Vanderbilt high-throughput screen 
and showed promising biological results (Figure 5.1). However, due to the unfavourable 
positive charge on the quinoline nitrogen, modifications were made to this scaffold as 
discussed in Chapter 1. The seven synthesized carbazole indole compounds were investigated 
for β-haematin inhibition, β-haematin adsorption energies using molecular docking, aqueous 
solubility and biological activity.  
 
β-Haematin IC50 16.2 µM 
Parasite Growth inhibition IC50: D6 200 nM , C235 180 nM 
Figure 5.1: The biological results for the hit carbazole compound from the Vanderbilt  
high-throughput screen. 
The main focus point for this series of compounds was to investigate how the β-haematin 
inhibition, biological data and adsorption energies changed by altering the hydrogen bonding 
capabilities of the molecules through sequential removal of hydroxyl groups from the hit 
compound analogue (Scheme 5.1). However, as this set of compounds contain a chiral centre 
all enantiomers needed to be analysed to determine which, if any were active compounds. 
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Scheme 5.1: The Synthesized carbazole indole compounds 29-35 with differing number of 
hydroxyl groups investigated in this chapter. 
5.2 Carbazole Indole Molecular Docking and Structure-Activity Relationships 
Goals 
The goals of this chapter were to:  
 Perform the NP-40 β-haematin inhibition assay on all seven carbazole indole 
compounds and compare the results to the Bayesian statistics predictions. 
 Subject all seven carbazole indole compounds to parasite growth inhibition tests on 
the NF54 and the DD2 strains and compare the results to the Bayesian statistics 
predictions. 
Compounds with two hydroxyl groups  
Compounds with one hydroxyl group 
Compound with no hydroxyl groups 
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 Use Materials Studio to perform docking studies on all of carbazole indole compounds 
and investigate interactions with the β-haematin crystal surfaces. 
 Subject two compounds to the haem fractionation assay. 
 Subject two compounds to the turbidimetric solubility assay to test for aqueous 
solubility. 
 Using the data from the above studies, attempt to find a QSAR for compounds 29-35. 
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5.3 Results and Discussion 
5.3.1 Turbidimetric Solubility Assay  
Two of the most important features of compounds in terms of medicinal chemistry are their 
solubility and pKa values.170 The measurement of solubility ranges can be performed using a 
turbidimetric solubility assay. This assay requires a 96 well plate where half the wells 
incorporate a compound at various concentrations in DMSO as a solvent to act as a baseline 
reading. Similarly, the other half of the 96 well plate incorporates a compound at various 
concentrations using a phosphate buffered saline solution as a solvent. In this way the 
turbidity of the wells can be measured using a UV-visible spectrophotometer at a longer 
wavelength than usual for organic molecules, 620 nm, to prevent interference from UV active 
compounds.171 This is possible as precipitation in the wells can be measured due to the 
increased light scattering from the precipitated molecules in the well, thus increasing the 
absorbance value of the well.172 According to literature, compounds with a solubility of less 
than 1 µM are conventionally termed highly insoluble, those with solubility values between 1 
and 100 µM are termed moderately soluble and compounds with solubility values greater 
than 100 µM are termed highly soluble.171  
Thus, the turbidimetric solubility assay was performed on compounds 29, 32 and 35 in order 
to determine the aqueous solubility ranges of the compounds. This assay was not performed 
on the benzimidazole compounds as it was known that all compounds in the benzimidazole 
series showed solubility ranges of less than 1 µM from other assays performed on those 
compounds and observations during the synthesis of the benzimidazole compounds. The 
turbidimetric solubility assay curves are shown in Figures 5.2, 5.3, 5.4 and 5.5 for 
hydrocortisone and compounds 29, 32 and 35 respectively. The x-axis of the graphs has been 
modified in order to clearly visualise at what concentration ranges turbidity occurs. Thus 1 on 
the x-axis represents a concentration of 0.0 µM, 2 a concentration of 5.0 µM, 3 a 
concentration of 10.0 µM, 4 a concentration of 20.0 µM, 5 a concentration of 40.0 µM, 6 a 
concentration of 80.0 µM, 7 a concentration of 160.0 µM and 8 a concentration of 200.0 µM. 
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Figure 5.2: Corrected absorbance at 620 nm for hydrocortisone versus the adjusted 
concentration scale. 
Hydrocortisone was used as a positive standard for this assay as it is highly soluble in both 
DMSO and aqueous medium with a solubility range of greater than 200 µM. 
 
Figure 5.3: Corrected absorbance at 620 nm for 29 versus the adjusted concentration scale. 
Compound 29 exhibited a solubility of less than 5 µM as the deviation from the baseline 
begins between 1 (0.0 µM) and 2 (5.0 µM) on the x-axis. This compound was thus termed 
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highly insoluble to insoluble as there is no certainty that the concentration is greater than  
1 µM. 
 
Figure 5.4: Corrected absorbance at 620 nm for 31 versus the adjusted concentration. 
Compound 31 exhibited a solubility range of between 5 to 10 µM. This was due to the 
deviation from the baseline occurring between 2 (5.0 µM) and 3 (10.0 µM) on the x-axis. 
Therefore, this compound was termed moderately aqueous soluble. This increased solubility 
was due to the addition of a hydroxyl group on the alkyl chain of the molecule compared to 
compound 29. 
 
Figure 5.5: Corrected absorbance at 620 nm for 35 versus the adjusted concentration. 
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Compound 35 exhibited a solubility range of between 10 and 20 µM. This was due to the 
deviation of the curve from the baseline between the values of 3 (10.0 µM) and 4 (20.0 µM) 
on the x-axis. When compared to compound 31, the solubility was increased due to the 
additional hydroxyl group present in the molecule, however, 35 was also termed moderately 
soluble.  
5.3.2 β-haematin Inhibition Studies 
As for the benzimidazole compounds in Chapter 4, the NP-40 detergent mediated β-haematin 
inhibition assay was modified for use on the carbazole indole compounds. Compounds 29-35 
were tested using these conditions with the results shown in Table 5.1 alongside the Bayesian 
statistics results from Chapter 2 for purposes of comparison.  
Table 5.1: The β-haematin inhibition results of compounds 29-35 and the accompanying 
Bayesian prediction from Chapter 2 with active compounds shown in red. 
Compound β-haematin inhibition IC50 (µM) 
Bayesian β-haematin inhibition 
score 
29 Inactive -7.4793 
30 97.4 ± 10.6 -5.29619 
31 102.6 ± 2.7 -5.29619 
32 96.6 ± 8.1 -5.29619 
33 22.5 ± 2.4 4.72502 
34 18.0 ± 3.2 4.72502 
35 23.6 ± 2.3  4.72502 
 
Analysing the data from the table, it can be seen that compounds 29-32 (compounds with no 
or one hydroxyl) can be termed inactive or very poorly active using the 100 µM cut-off, with 
the values given for comparison. A clear trend can be seen with these compounds where the 
β-haematin inhibition activity increases with the number of hydroxyl groups from zero 
(inactive) to one (inactive or poorly active) to two hydroxyls (active). Comparing the Bayesian 
predictions and experimental data, the two correlate completely with all seven compounds 
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correctly predicted leading to 100% hit rate with this series of compounds. This was a 30-fold 
enrichment compared to random screening of the β-haematin inhibition Bayesian model 
containing 2 133 active compounds and 64 118 inactive compounds. This showed that the 
Bayesian model performs for at least two scaffolds and is a crucial technique for the discovery 
of these compounds and derivatives thereof.  
5.3.3 Docking Studies 
Attempts were made to use molecular docking to explain the trend in β-haematin inhibition 
by using the intermolecular interactions approach used on the benzimidazole compounds. 
Using the same methodology as the benzimidazole compounds, the adsorption energies are 
given in Table 5.2.  
Table 5.2: The adsorption energies obtained from the molecular docking on both β-haematin 
crystal faces of compounds 29, 31, 32, 34 and 35. 
Compound 
β-haematin inhibition 
IC50 (µM) 
Adsorption energy 
(kcal/mol) (001) 
Adsorption energy 
(kcal/mol) (011) 
29 Inactive - - 
31 96.6 ± 8.1 -72.84 -54.81 
32 102.6 ± 2.7 -66.44 -60.87 
34 18.0 ± 3.2 -56.58 -59.92 
35 23.6 ± 2.3  -64.58 -59.13 
 
Using again the literature intermolecular interaction distances for hydrogen bonding, which 
were taken to be optimally between 2.36 and 3.69 Å,164 and π-π interactions distances which 
were optimally taken to be between 3.3 and 3.8 Å,165 the molecular docking results could be 
rationalised. The racemic compounds (30, 33) were not simulated in this study as they are 
just mixtures of the enantiomers already simulated (31, 32, 34, 35). Adsorption energies could 
not be obtained for 29 as the compound does not stay inside the β-haematin pocket during 
simulated annealing. From investigating the pre-annealing docking structure of compound 
29, (Figure 5.6) it can be seen that there are no hydrogen bonding capabilities for this 
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compound nor any feasible π-π interactions (4.6 Å and 4.8 Å is much greater than the 
literature maximum value of 3.8 Å). This correlates with the experimental inactivity of this 
compound. Examining the docked structures for compounds 31 and 32 (Figure 5.7), one long 
hydrogen bond can be seen between the hydroxyl group and a propionate group of the  
β-haematin crystal structure with a bond distance of 3.59 Å. The π-π interaction distances are 
too long with a value shown of 4.0 Å.  
 
Figure 5.6: Docked structure of compound 29 on the (001) crystal face of the β-haematin 
crystal showing no intermolecular interactions with the β-haematin surface.  
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Figure 5.7: Docked structure of compound 31 on the (001) crystal face of the β-haematin 
crystal showing one hydrogen bond and no π-π intermolecular interactions. 
Compounds 34 and 35 (Figure 5.8) show the same results as 31 and 32 except the hydroxyl of 
the indole functionality is involved in the hydrogen bond rather than alkyl hydroxyl. The short 
hydrogen bond (2.38 Å) between this functionality and the propionate group of the  
β-haematin crystal is shorter than compounds 31 and 32, likely leading to a stronger bond 
(3.59 Å vs. 2.38 Å). This probably explains the increased experimental β-haematin inhibition 
activity. 
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Figure 5.8: Docked structure of compound 35 on the (001) crystal face of the β-haematin 
crystal showing one hydrogen bond and no π-π intermolecular interactions. 
It should also be noted that there are no significant intermolecular interactions with these 
compounds and the (011) β-haematin crystal face. An example of this is shown in Figure 5.9 
where the π-π distances of 4.4 and 4.1 Å are much greater than the maximum value from 
literature of 3.8 Å. Therefore the (001) β-haematin crystal face was deemed the most 
important crystal face for these compounds. 
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Figure 5.9: Docked structure of compound 35 on the (011) crystal face of the β-haematin 
crystal showing no intermolecular interactions. 
There was no significant correlation found between the energy of interaction with the  
β-haematin crystal faces and the experimental β-haematin inhibition data due to insufficient 
data points. 
5.3.4 Malaria Parasite Growth Inhibition Studies 
Following the success of the β-haematin inhibition study and the molecular docking, the 
carbazole indole compounds were subjected to malaria parasite growth inhibition studies. 
These compounds were sent to collaborators and subjected to the same assay conditions as 
described in Chapter 4. The results of this study are shown in Table 5.3 with the relevant 
Bayesian statistics for comparison purposes. 
All compounds in this series were shown to inhibit the parasite growth of the NF54 strain of 
the malaria parasite using a 20 µM cut-off, compared to the one inactive compound predicted 
by the Bayesian model. This led to a hit rate of 86%, but when compared to random screening 
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of the compounds in the malaria parasite growth inhibition Bayesian model containing 817 
active and 41 729 inactive compounds, a 44-fold enrichment was achieved. However, the 
original Bayesian model contained a 2 µM cut-off so when compared to this all compounds 
are deemed to be inactive.  
Table 5.3: The malaria parasite growth inhibition IC50 results of compounds 29-35 using the 
NF54 strain of P. falciparum and the accompanying Bayesian prediction from Chapter 2 with 
predicted active compounds shown in red. 
Compound 
NF54 malaria parasite growth 
inhibition IC50 (µM) 
 Malaria parasite growth 
inhibition score 
29 14.15 ± 4.74 -10.3333 
30 8.03 ± 2.94 -8.19434 
31 6.82 ± 1.21 -8.19434 
32 5.75 ± 0.66 -8.19434 
33 8.86 ± 0.10 -5.38157 
34 3.47 ± 0.10 -5.38157 
35 7.64 ± 0.54 -5.38157 
 
Compound 29 (no hydroxyl groups) showed the lowest malaria parasite growth inhibition 
activity of the series, while compounds 30-32 (one hydroxyl group) showed similar activities 
to compounds 33-35 (two hydroxyl groups). Of the different subgroups (30-32 and 33-35), the 
racemic compounds showed the lowest activity while 34 was found to be the most active 
compounds of the series. 
Since all compounds showed some malaria parasite growth inhibition activity against the 
NF54 strain, it was prudent to analyse this series against the chloroquine resistant strain of  
P. falciparum, Dd2. The results of this are shown in Table 5.4 together with the NF54 results 
and resistance index. Compounds 29 (no hydroxyl groups) and 30-32 (one hydroxyl group) 
saw an increase in malaria parasite growth inhibition activity in the Dd2 strain of  
P. falciparum. The opposite trend was seen in compounds 33-35 (two hydroxyl groups). This 
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is clear when examining the resistance index where compounds 29-32 showed a resistance 
index of less than one compared to compounds 33-35 which showed a resistance index of 
greater than one. None of the compounds exhibited significant cross-resistance with 
chloroquine. 
Table 5.4: The Dd2 malaria parasite growth inhibition IC50 results of compounds 29-35 and 
the accompanying NF54 malaria parasite growth inhibition IC50 results.  
Compound 
Dd2 malaria parasite 
growth inhibition IC50 
(µM) 
 NF54 malaria parasite 
growth inhibition IC50 
(µM) 
Resistance Index 
(RI) 
29 5.42 ± 1.01 14.15 ± 4.74 0.38 
30 2.84 ± 0.36 8.03 ± 2.94 0.35 
31 4.32 ± 0.36 6.82 ± 1.21 0.63 
32 2.76 ± 0.10 5.75 ± 0.66 0.48 
33 11.29 ± 0.90 8.86 ± 0.10 1.27 
34 8.04 ± 0.50 3.47 ± 0.10 2.32 
35 20.60 ± 7.73 7.64 ± 0.54 2.69 
 
The cytotoxicity of compounds 29-35 was determined against the CHO cell line, with the 
results shown in Table 5.5. All compounds were shown to be selective against P. falciparum 
with the selectivity index (SI) ranging from 5.46 to 75.43 in the chloroquine resistant strain 
and 14.73 to 47.79 in the chloroquine sensitive strain. 
In general, the malaria parasite growth inhibition activities results are poor in comparison to 
the original hit compound which showed low nanomolar values. This indicated that either the 
switch from the quinoline ring system to the indole ring system or the removal of the positive 
charge lowered activity substantially.  
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Table 5.5: The cytotoxicity results from the CHO cell line of compounds 29-35 with the 
selectivity indexes to the Dd2 and NF54 strain of P. falciparum. 
Compound 
CHO 
cytotoxicity 
(µM) 
Dd2 malaria 
parasite 
growth 
inhibition 
IC50 (µM) 
Selectivity 
Index (SI) 
Dd2 
 NF54 malaria 
parasite growth 
inhibition IC50 
(µM) 
Selectivity 
Index (SI) 
NF54 
29 > 300.00 5.42 ± 1.01 > 55.35 14.15 ± 4.74 > 21.20 
30 202.78 ± 97.14 2.84 ± 0.36 71.40 8.03 ± 2.94 25.25 
31 218.15 ± 13.37 4.32 ± 0.36 50.50 6.82 ± 1.21 31.99 
32 208.19 ± 7.34 2.76 ± 0.10 75.43 5.75 ± 0.66 36.21 
33 183.21 ± 15.24 11.29 ± 0.90 16.23 8.86 ± 0.10 20.68 
34 165.82 ± 35.41  8.04 ± 0.50 20.62 3.47 ± 0.10 47.79 
35 112.53 ± 20.62 20.60 ± 7.73 5.46 7.64 ± 0.54 14.73 
 
5.3.5 Cellular Haem Fractionation Assay 
Following the biological analysis of the carbazole indole series, compounds 32 and 34 were 
sent to collaborators from the Egan research group for cellular haem fractionation analysis. 
The results for compound 32 are shown in Figure 5.10. Analysis showed that the percentage 
haemozoin remained constant throughout the study but the haemozoin iron content showed 
a large decrease. By contrast there was little to no change in the percentage free haem or 
haem iron content. This strongly indicated that this compound acts against a target that 
results in the inhibition of the uptake of haemoglobin into the food vacuole. This behaviour 
has previously been reported with other compounds such as atovaquone and 
hexahydroquinoline.168,173  
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Figure 5.10: The percentage and iron content values of haem, and haemozoin after incubation 
with compound 32. 
Surprisingly, the same phenomenon occurred with compound 34 as shown in Figure 5.11. The 
percentage free haem increased, but the iron content of free haem in the cell remained 
constant as did the percentage haemozoin while the iron content of haemozoin in the cell 
decreased to about half the control value.  The β-haematin inhibition IC50 of this compound 
was found to be 18.0 ± 3.2 µM, therefore it can be concluded that this series of compounds 
is probably not able to enter food vacuole or acts on a different target before reaching 
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concentrations adequate to inhibit haemozoin formation. Haemozoin inhibition is evidently 
not the mode of action of these compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: The percentage and iron content values of haem and haemozoin after incubation 
with compound 34. 
This shows how important this type of analysis is, as even though a compound is able to inhibit 
β-haematin formation, this might not be its ultimate mode of action.  
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5.4 Summary and Conclusions 
In this study all the synthesized carbazole indole compounds were tested using the 
turbidimetric solubility assay. This revealed that an increase in hydroxyl groups increased the 
water solubility of the compounds. However, the compounds were only found to be 
moderately soluble with a maximum concentration range of 10 to 20 µM.  
All synthesized carbazole indole compounds were also tested using the NP-40 detergent 
mediated β-haematin inhibition assay using the same procedure as used for the 
benzimidazoles. The series showed promising β-haematin inhibitory results with all 
compounds deemed active. Comparing this to the Bayesian predictions, a 100% hit rate was 
achieved proving yet again the utility of the method. When this was compared to random 
screening, a 30-fold enrichment was achieved. SAR analysis of this series revealed that an 
increase in the number of hydroxyl groups in the molecule increased the β-haematin 
inhibition activity. 
Docking studies were also carried out on this series of compounds with the results showing 
that compound 29, which was experimentally inactive in the β-haematin inhibition study, had 
no intermolecular interaction with both the fastest and second fastest growing β-haematin 
crystal surfaces. In contrast all the other compounds in the series contained one hydrogen 
bonding interaction with the (001) β-haematin crystal surface. This hydrogen bond was 
shorter for compounds 34 and 35. It was also found that all compounds in the series did not 
interact with the (011) β-haematin crystal surface and thus the (001) β-haematin crystal 
surfaces was deemed the most important for this series of compounds.  
P. falciparum growth inhibition studies were carried out on all compounds using the NF54 and 
Dd2 strains. Using a cut-off of 20 µM, all compounds were shown to inhibit the parasite 
growth of the NF54 strain. This led to an 86% hit rate compared to the Bayesian results with 
one compound incorrectly predicted. This was found to be a 44-fold enrichment compared to 
random screening using this model. However, using a cut-off of 2 µM all compounds were 
found to be inactive. Analysing the Dd2 results, compounds 29-32 were found to be more 
active when compared to the NF54 strain results with a resistance index of less than one. The 
opposite was found to be true for compounds 33-35.  
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Haem fractionation results showed that the haemozoin iron content showed a large decrease 
while there was no change in the free haem levels or haem iron content. This indicated that 
these compounds have the effect of inhibiting the uptake of haemoglobin into the food 
vacuole, a phenomenon already seen in literature with other compounds. They are not 
haemozoin inhibitors and have an unknown mechanism of action. 
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Chapter 6: Conclusions and Future Work 
6.1 Conclusions 
A drastic increase in malaria parasite resistance has caused decreased efficacy of well-known 
antimalarials such as chloroquine, mefloquine, amodiaquine and many others. There have 
also been reports of ACT resistance, even though efforts to minimise this are being 
implemented by the WHO. These challenges pose serious health risks globally thus resulting 
in a dire need for new, effective antimalarials comprising of novel scaffolds. To this end, a HTS 
at Vanderbilt University identified 171 compounds which were shown to be β-haematin 
inhibitors as well as inhibit greater than 90% parasitemia in P. falciparum. These 171 
compounds were sorted by scaffold, of which the benzimidazole and carbazole scaffolds were 
selected for this project. One of the key factors for this choice was the two hit compounds, 
one for each scaffold, which appeared in the top ten most active compounds in the Vanderbilt 
HTS. 
In this project, both the benzimidazole and carbazole scaffolds were further studied to 
discover SARs and probe possible mechanisms of action for the potential drug-like 
compounds using the hit compounds discussed as starting points for analysis.  
Discovery Studio was used in conjunction with Pipeline Pilot and previously established 
Bayesian statistical models to enumerate and filter an in silico library consisting of 
benzimidazole derivatives, based on the hit compound, according to firstly β-haematin 
inhibition activity, followed by malaria parasite growth inhibition activity and finally aqueous 
solubility using the Sigma-Aldrich catalogue for purchasable reagents. After vigorous 
screening and compound elimination, 19 compounds were selected for a 2-step synthesis via 
a condensation reaction using PPA at 220 °C, followed by an acylation reaction using an 
optimised acid chloride methodology (2.0 eq. acid chloride, 1.0 eq. 1, - 40 °C). A smaller series 
of seven benzimidazole compounds was also subjected to the same Bayesian models but 
using predetermined structures based on fragments from the original hit benzimidazole 
compound as well as a diacylated compound, 20. These fragment compounds and 20 were 
either purchased or synthesized using similar acylation methodologies. 
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The benzimidazole compounds showed clear SAR trends for β-haematin inhibition and are 
summarised in Scheme 6.1. The overall preferred system for β-haematin inhibition was 
observed to be a pyridyl ring system with a meta-EWG substituent. In silico molecular docking 
of the 19 benzimidazole compounds on both the (001) and (011) β-haematin crystal faces 
revealed the (011) face to be the dominant face for adsorption according to a correlation with 
β-haematin inhibition activity and adsorption energies. This prompted an investigation into 
the intermolecular interaction between these compounds and both the β-haematin crystal 
faces which demonstrated that compounds must have a minimum of three π-π interactions 
between the compound and the crystal faces to be a β-haematin inhibitor.  
Scheme 6.1: A summary of the SAR trends found for the benzimidazole series for β-haematin 
inhibition with good/ preferred groups in green, moderate groups in blue and poor groups in 
red. 
Clear SAR trends observed from malaria parasite growth inhibition IC50 values are shown in 
Scheme 6.2. The ideal benzimidazole compound observed consisted of a 5-membered 
heteroaromatic ring system. meta-ERG substituents were found to be favoured on the  
6-membered aromatic ring systems which is contradictory to the SAR trend found for  
β-haematin inhibition and thus a balance between these two trends must be found for a 
compound to have potent activity. None of the compounds exhibited cross-resistance when 
tested against the chloroquine resistant strain with disubstituted compounds found to be 
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more active against the chloroquine resistant strain of P. falciparum. All benzimidazole 
fragment compounds were found to be inactive when tested in the parasite growth inhibition 
assay. Thus, it was concluded that all functional groups, not just the benzimidazole 
functionality, are required for in vitro activity. 
Scheme 6.2: The SAR trends found for the malaria parasite growth inhibition IC50 of the 
benzimidazole series with preferred groups in green, moderate groups in blue and poor 
groups in red. 
Cellular haem fractionation studies confirmed that the mode of action of the benzimidazole 
compounds is haemozoin inhibition with an increase in free haem and a decrease in 
haemozoin shown in the parasite. A multiple correlation study further showed for an increase 
in malaria parasite growth inhibition activity the β-haematin activity, number of hydrogen 
bond donors and molecular depth must also increase. 
Seven carbazole indole compounds were selected with varying hydrogen bonding ability to 
analyse the influence of this on β-haematin inhibition as well as parasite growth inhibition 
activities. These activities were first predicted using the same Bayesian statistical models in 
Material Studio as with the benzimidazole compounds. The carbazole indole compounds were 
synthesized either via a 2-step or 4-step synthetic pathway, the former involving a NaH 
mediated SN2 alkylation using carbazole and an epichlorohydrin stereoisomer or  
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1,3-dibromopropane, followed by another NaH mediated SN2 reaction to open the epoxide 
or eliminate bromine and furnish the desired compounds. The 4-step synthetic sequence was 
similar, but in addition to the previous steps mentioned also involved benzyl protection of  
7-hydroxyindole prior to epoxide opening followed by deprotection using hydrogen gas and 
Pd-C. Solubility studies were performed on these compounds using the turbidimetric 
solubility assay. This was possible due to their increased aqueous solubility compared to the 
benzimidazole compounds. The best carbazole indole compound was found to be moderately 
aqueous soluble with a solubility range of 10-20 µM. 
β-haematin inhibition analysis on the carbazole indole compounds demonstrated that there 
was a definite trend in activity from no hydroxyl groups (inactive), one hydroxyl group (poor 
activity) and two hydroxyl groups (active). Docking analysis of the carbazole indole 
compounds demonstrated that these compounds only interact via hydrogen bonding with the 
(001) β-haematin crystal face. It was shown that hydrogen bonding interactions form the basis 
of β-haematin inhibition activity in the carbazole indole compounds as there were no π-π 
interactions shown between these compounds and both the β-haematin crystal surfaces. A 
similar trend was shown in the malaria parasite growth inhibition study, where the compound 
without any hydroxyl group was shown to be inactive while the other six compounds showed 
moderate activities. These in vitro activities where substantially weaker than the original hit 
compound and thus either the quinoline ring system, the positive charge or a combination of 
the two are essential for activity. In vitro testing on the chloroquine resistant strain showed 
no cross resistance with the compounds with two hydroxyl groups showing a decrease in 
activity compared to the chloroquine sensitive strain. Cellular haem fractionation studies 
demonstrated that haemozoin inhibition is not the mode of action of the carbazole indole 
compounds but rather follows similar behaviour to atovaquone. 
Analysis of all the predicted Bayesian activities for both scaffolds demonstrated a 4-fold to 
44-fold enrichment compared to random screening within the respective Bayesian model. 
This showed the benefits of using these Bayesian models to screen compounds before 
attempting to synthesize the respective compounds.   
In this project, two novel non-quinoline containing scaffolds were investigated revealing their 
fairly simple synthetic pathways. The scaffold characteristics relating to β-haematin 
inhibition, adsorption onto the β-haematin crystal surfaces, parasite growth inhibition 
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activities, free haem levels and ultimately the mechanism of action was revealed. This data 
provides insight into these scaffolds so that future drug design can be guided.  
6.2 Future Work 
The benzimidazole hit compound found during the HTS was still found to be the most active 
of the series even after investigation into other derivatives. However, now that SAR for this 
scaffold has been established further attempts to increase the activity of this scaffold can be 
made. The interplay between the SAR for β-haematin inhibition and the SAR for malaria 
parasite growth inhibition should be investigated. Mainly, the question of whether a  
5-membered ring system or a pyridyl ring system is best should be further investigated. 
Further derivatives guided by the new SAR input in the Bayesian models should be attempted 
especially looking at substituted 5-membered rings in light of the in vitro SAR demonstrated 
in this project. One of the main challenges with this scaffold was the overall low aqueous 
solubility of the compounds. Attempts to improve this solubility with the addition of 
hydrophilic functional groups will enable simpler synthesis as well as better ADME properties 
of this scaffold. 
Only seven compounds were synthesized for the carbazole indole compounds. Due to this 
small series, SAR trends other than hydrogen bonding were not possible, therefore it would 
be beneficial to expand on this study by exploring various other derivatives of this scaffold. 
As with the benzimidazole scaffold, the Bayesian models, which are now further enriched with 
the data from this project, would assist in the choice of derivatives. Optimisation or a new 
synthetic route are needed to improve the enantiomeric excess of these compounds in order 
to make these compounds viable for further testing. This preliminary study also demonstrated 
that these compounds do not act via haemozoin inhibition but rather have a different mode 
of action. It would be interesting to investigate the original hit compound, even though it 
contained an unfavourable positive charge, to show if the initial carbazole quinoline scaffold 
also showed the same results. Furthermore, it has been shown that this carbazole scaffold is 
an ideal candidate for a drug discovery programme due to its potent activity shown in the HTS 
as well as reasonable aqueous solubility demonstrated in this project which will more likely 
be significantly improved with a charged compound. For these reasons an in-depth study of 
this scaffold is needed. 
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Due to the complex nature of P. falciparum resistance and treatment, all resources and data 
available must be used to aid in the design and discovery of novel antimalarial compounds to 
ensure that, hopefully in the near future the scourge of malaria can finally be eradicated. 
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Chapter 7: Experimental  
7.1 General Synthetic Methods 
All reagents were purchased from commercial sources (Sigma-Aldrich, Kimix, and Protea 
chemicals). All solvents except anhydrous pyridine were distilled before use. Tetrahydrofuran 
in particular was distilled under nitrogen using sodium wire and benzophenone. Calcium 
chloride was used as a drying reagent in drying tubes. Thin layer chromatography was 
performed using aluminium-backed silica gel 60 F254 plates, which were purchased from 
Merck and visualised using a UV lamp, anisaldehyde spray (a mix in a 1:1 (v/v) ratio of 10% 
H2SO4 in ethanol solution and 5% anisaldehyde in ethanol solution) or a ninhydrin spray  
(300 mg Ninhydrin in 97 mL absolute ethanol and 3 mL of glacial acetic acid). Column 
chromatography was carried out using silica gel 60 (mesh 68 – 280 µm) purchased from Fluka 
and a Biotage Isolera One flash chromatography system. Nuclear magnetic resonance 
experiments were recorded using a Bruker or Varian Unity 300, 400 or 600 MHz instrument. 
Chemical shifts () were recorded relative to residual DMSO-d6 ( 2.50 in 1H NMR and  39.52 
in 13C NMR), chloroform-d ( 7.26 in 1H NMR and  77.16 in 13C NMR), methanol-d4 ( 4.87 in 
1H NMR and  49.00 in 13C NMR) or acetone-d6 ( 2.05 in 1H NMR and  206.26 in 13C NMR). 
All chemical shifts were reported in ppm and all J values were reported in Hz. Melting points 
were obtained using a Reichert-Jung Thermovar hot stage microscope. HPLC experiments 
were carried out using an Agilent Technologies 1220 Infinity LC with a reverse phase C18 
column using a solvent system of double distilled deionised Millipore© Direct-Q water and 
HPLC grade acetonitrile or a Daicel Chiracel OD (250 x 4.6 mm) column using HPLC grade 
hexane and HPLC grade isopropanol as the solvent system. High resolution mass spectrometry 
was performed on the Waters Synapt G2 instrument. All mass spectra were recorded using 
the electrospray positive (ES+) technique and the sample was introduced via an ESI probe 
injected into a stream of acetonitrile. 
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7.2 Benzimidazole Compounds 
7.2.1 Precursor 
4-(1H-Benzo[d]imidazol-2yl)aniline (1) 
 
   1 
4-Aminobenzoic acid (5.00 g, 36.46 mmols), o-phenylenediamine (3.94 g, 36.46 mmols) and 
PPA (50.0 g, 10 eq.) were added to a 50 mL reaction vessel with a drying tube and heated at 
220 °C, with stirring for 5 hr. The reaction progress was monitored by TLC using a 6:94 mixture 
of MeOH:DCM. The resulting mixture was washed with 200 mL hot water into a 10% NaHCO3 
solution (200 mL) and basified yielding a brown solid. This solid was washed with water  
(3 x 400 mL) and crystallized from methanol and water to yield light brown needle crystals of 
(1) (4.68 g, 61% yield). 
ATR-FTIR vmax /cm-1  3360, 3441 (NH2); M.p. 240 - 241 °C (lit. 240 - 241 °C)174; Rf (MeOH/DCM 
6:94) 0.49; δH (DMSO-d6, 400 MHz) 5.54 (s, 2H, NH2), 6.68 (d, J = 8.6 Hz, 2H, H-12, H-14), 7.11 
(m, 2H, H-1, H-2), 7.49 (m, 2H, H-3, H-6), 7.86 (d, J = 8.6 Hz, 2H, H-11, H-15); δC (DMSO-d6, 
100.6 MHz) 113.5 (CH), 113.5 (CH), 114.2 (Cquat), 117.3 (Cquat), 121.2 (CH), 127.7 (CH), 150.5 
(Cquat), 152.6 (Cquat); HRMS-ES+ Calculated: 210.1031 [M+H]+ for C13H12N3, Observed: 
210.1031; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 99.1%. 
7.2.2 Benzimidazole Derivatives  
7.2.2.1 Procedure for the preparation of acid chlorides  
Using a typical scale of 2.0 mmols, the appropriate aryl carboxylic acid (2.0 mmols) was added 
to a small round-bottomed flask, which was flushed with nitrogen. Thionyl chloride (3 mL,  
41.4 mmols) was added after which the reaction mixture was refluxed, with stirring, at 80 °C 
and left overnight to ensure complete conversion. The reaction mixture was cooled and 
excess thionyl chloride was completely removed under reduced pressure. The crude acid 
chloride was then used as a reagent for subsequent reactions. 
155 
 
7.2.2.2 Synthetic procedure for preparation of N-(4-1H-benzo[d]imidazol-2-
yl)phenyl)benzamides from the appropriate acid chlorides 
Using a typical scale of  1.0 mmol, 1 (1.0 mmol) was dissolved in anhydrous pyridine (2 mL) in 
a small round-bottomed flask and the mixture was cooled to -40 °C after which the aryl acid 
chloride (2.0 mmols; purchased or prepared as above) in dry THF or DMF (2 mL) was added 
dropwise over 20 min with vigorous stirring. After 2-6 hr the reaction mixture was warmed to 
room temperature and the solvent reduced under reduced pressure. Without using a work-
up the crude product was purified by column chromatography directly using MeOH/DCM 
mixtures (1:99 to 2:8).  
N-4-(1H-Benzo[d]imidazol-2-yl)phenyl)benzamide (2) 
      
2 
Benzoyl chloride (197 mg, 1.4 mmols) and 1 (146 mg, 0.7 mmols) afforded a off-white solid. 
The resulting solid was recrystallized from methanol to afford cream crystals of (2) (132 mg, 
60% yield). 
ATR-FTIR vmax /cm-1 1641 (C=O amide); M.p. 340 - 341 °C (lit. M.p 335 °C)175; Rf (MeOH/DCM 
5:95) 0.38; δH (DMSO-d6, 400 MHz) 7.28 (m, 2H, H-1, H-2), 7.53-7.63 (m, 3H, H-21, H-22, H-
23), 7.65 (m, 2H, H-3, H-6), 7.98-8.02 (m, 2H, H-20, H-24), 8.03 (d, J = 8.9 Hz, 2H, H-12, H-14), 
8.22 (d, J = 8.9 Hz, 2H, H-11, H-15), 10.54 (s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 114.6 (CH), 
120.3 (CH), 122.8 (CH), 123.3 (Cquat), 127.4 (CH), 127.7 (CH), 128.4 (CH), 131.7 (Cquat), 134.6 
(Cquat), 137.4 (Cquat), 141.4 (Cquat), 150.5 (Cquat), 165.8 (CO); HRMS-ES+ Calculated: 314.1293 
[M+H]+ for C20H16N3O, Observed: 314.1293; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile 
(40:60), 98.2%. 
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N-(4-(1H-benzo[d]imidazole-2-yl)phenyl)-3-bromobenzamide (3) 
     
3 
3-Bromobenzoic acid (804 mg, 4.0 mmols) and 1 (418 mg, 2.0 mmols) afforded a brown solid. 
The resulting solid was recrystallized from methanol to afford light-brown crystals of (3) (668 
mg, 85% yield). 
ATR-FTIR vmax /cm-1 3248 (NH), 1652 (C=O amide); M.p. 324 - 325 °C; Rf (MeOH/DCM 5:95) 
0.39; δH (DMSO-d6, 400 MHz) 7.20 (m, 2H, H-1, H-2), 7.63 – 7.79 (m, 3H, H-3, H-6, H-21), 7.81 
(d, J = 7.8 Hz, 1H, H-22), 7.98 (m, 3H, H-12, H-14, H-20), 8.19 (m, 3H, H-11, H-15, H-24), 10.54 
(s, 1 H, H-16), 12.80 (s, 1 H, H-9); δC (DMSO-d6, 100.6 MHz) 111.1 (CH), 118.6 (CH), 120.4 (CH), 
121.5 (CH), 121.7 (CH), 122.3 (Cquat), 125.6 (Cquat), 126.9 (CH), 126.9 (CH), 130.3 (CH), 130.6 (CH), 
134.4 (CH), 135.0 (Cquat), 136.9 (Cquat), 140.3 (Cquat), 143.9 (Cquat), 151.1 (Cquat), 164.1 (CO); 
HRMS-ES+ Calculated: 392.0398 [M+H]+ for C20H15Br79N3O, Observed: 392.0399; C18 HPLC, 
flow rate: 1 mL/min, H2O / acetonitrile (40:60), 99.8%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-3-(trifluoromethyl)benzamide (4) 
     
4 
3-(Trifluoromethyl)benzoic acid (266 mg, 1.4 mmols) and 1 (146 mg, 0.7 mmols) afforded a 
white solid. The resulting solid was recrystallized from ethanol to afford white crystals of (4) 
(119 mg, 45% yield). 
ATR-FTIR vmax /cm-1  3267 (NH), 1655 (C=O amide); M.p. 302 – 303 °C; Rf (MeOH/DCM 5:95) 
0.30; δH (DMSO-d6, 400 MHz) 7.16-7.23 (m, 2H, H-1, H-2), 7.52 (d, J = 7.4 Hz, 1H, H-6), 7.65 (d, 
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J = 7.1 Hz, 1H, H-3), 7.81 (t, J = 7.8 Hz, 1H, H-21), 7.96-8.00 (m, 3H, H-20, H-12, H-14), 8.20 (d, 
J = 8.8 Hz, 2H, H-11, H-15), 8.30 (d, J = 7.8 Hz, 1H, H-22), 8.34 (s, 1H, H-24), 10.66 (s, 1H, H-
16), 12.81 (s, 1H, H-9); δC (DMSO-d6, 100.6 MHz) 111.1 (CH), 118.6 (CH), 120.5 (CH), 121.5 (CH), 
122.3 (CH), 124.2 (CH), 125.7 (Cquat), 125.3 (Cquat), 126.9 (CH), 128.2 (CH), 129.2 (q, J  = 127.7 Hz, 
C-25), 129.7 (CH), 131.8 (CH), 135.0 (Cquat), 135.6 (Cquat), 140.2 (Cquat), 143.9 (Cquat), 151.0 (Cquat), 
164.2 (CO); HRMS-ES+ Calculated: 382.1167 [M+H]+ for C21H15N3OF3, Observed: 382.1166; C18 
HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 99.6%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-5-bromonicotinamide (5) 
 
5 
5-Bromopyridine-3-carboxylic acid (283 mg, 1.4 mmols) and 1 (146 mg, 0.7 mmols) afforded 
a white solid. The resulting solid was recrystallized from ethanol to afford white crystals of (5) 
(211 mg, 77% yield). 
ATR-FTIR vmax /cm-1  3306 (NH), 1653 (C=O amide); M.p. 325-326 °C; Rf (MeOH/DCM 1:9) 0.82; 
δH (DMSO-d6, 400 MHz) 7.20 (m, 2H, H-1, H-2), 7.58 (m, 2H, H-3, H-6), 7.95 (d, J = 8.8 Hz, 2H, 
H-12, H-14), 8.19 (d, J = 8.8 Hz, 2H, H-11, H-15), 8.58 (t, J = 2.1 Hz, 1H, H-24), 8.92 (d, J = 2.2 
Hz , 1H, H-20), 9.10 (d, J = 1.9 Hz, 1H, H-22), 10.69 (s, 1H, H-16), 12.83 (s, 1H, H-9); δC (DMSO-
d6, 100.6 MHz) 111.3 (CH), 118.7 (CH), 120.0 (Cquat), 120.3 (CH), 121.8 (CH), 121.8 (CH), 125.8 
(Cquat), 127.0 (CH), 132.0 (Cquat), 135.0 (Cquat), 137.7 (CH), 140.0 (Cquat), 143.8 (Cquat), 147.4 (CH), 
151.0 (Cquat), 152.8 (CH), 162.7 (CO); HRMS-ES+ Calculated: 393.0351 [M+H]+ for C19H14BrN4O, 
Observed: 393.0354; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 98.4%. 
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N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-4-(tert-butyl)benzamide (6) 
             
6 
4-tert-Butylbenzoic acid (357 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a white solid. 
The resulting solid was recrystallized from ethanol to afford white crystals of (6) (297 mg, 87% 
yield). 
ATR-FTIR vmax /cm-1 1652 (C=O amide); M.p. 317-318 °C; Rf (MeOH/DCM 7:93) 0.92; δH (DMSO-
d6, 400 MHz) 1.34 (s, 9H, H-26, H-27, H-28), 7.52 (m, 2H, H-1, H-2), 7.57 (d, J = 8.6 Hz, 2H, H-
12, H-14), 7.81 (m, 2H, H-3, H-6), 7.95 (d, J = 8.6 Hz, 2H, H-11, H-15), 8.13 (d, J = 8.9 Hz, 2H, H-
21, H-23), 8.36 (d, J = 8.9 Hz, 2H, H-20, H-24), 10.67 (s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 
30.9 (CH3), 34.7 (Cquat), 113.8 (CH), 118.0 (Cquat), 120.2 (CH), 125.2 (CH), 125.4 (CH), 127.7 (CH), 
128.8 (CH), 131.7 (Cquat), 132.3 (Cquat), 143.7 (Cquat), 148.7 (Cquat), 154.9 (Cquat), 166.0 (CO); 
HRMS-ES+ Calculated: 370.1919 [M+H]+ for C24H24N3O, Observed: 370.1914; C18 HPLC, flow 
rate: 1 mL/min, H2O / acetonitrile (40:60), 99.7%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-2,4-dichlorobenzamide (7) 
     
7 
2,4-Dichlorobenzoic acid (267 mg, 1.4 mmols) and 1 (146 mg, 0.7 mmols) afforded a brown 
solid. The resulting solid was recrystallized from methanol to afford light- brown crystals of 
(7) (186 mg, 70% yield). 
ATR-FTIR vmax /cm-1 1657 (C=O amide); M.p. 273-275 °C (lit. M.p 242 °C)175; Rf (MeOH/DCM 
1:9) 0.50; δH (DMSO-d6, 400 MHz) 7.16-7.24 (m, 2H, H-1, H-2), 7.50-7.60 (m, 2H, H-3, H-20), 
7.62-7.70 (m, 2H, H-6, H-21), 7.78 (m, 1H, H-23), 7.89 (d, J = 8.6 Hz, 2H, H-12, H-14), 8.18 (d, J 
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= 8.6 Hz, 2H, H-11, H-15), 10.75 (s, 1H, H-16), 12.81 (s, 1H, H-9); δC (DMSO-d6, 100.6 MHz) 
111.1 (CH), 118.6 (CH), 119.6 (CH), 121.5 (CH), 122.3 (CH), 125.7 (Cquat), 127.1 (CH), 127.4 (CH), 
129.2 (CH), 130.3 (CH), 131.2 (Cquat), 135.0 (Cquat), 135.5 (Cquat), 140.0 (Cquat), 143.8 (Cquat), 143.8 
(Cquat), 151.0 (Cquat), 164.1 (CO); HRMS-ES+ Calculated: 382.0514 [M+H]+ for C20H14Cl2N3O, 
Observed: 382.0508; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 99.6%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-2-methoxybenzamide (8) 
     
8 
2-Methoxybenzoic acid (304 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown solid. 
The resulting solid was recrystallized from methanol and water to afford dark brown crystals 
of (8) (280 mg, 82% yield). 
ATR-FTIR vmax /cm-1  3331 (NH), 1661 (C=O amide); M.p. 133-134 °C; Rf (MeOH/DCM 1:9) 0.93; 
δH (DMSO-d6, 400 MHz) 3.93 (s, 3H, H-25), 7.09 (t, J = 7.4 Hz, 1H, H-21), 7.18-7.23 (m, 3H, H-
1, H-2, H-20), 7.52 (m, 1H, H-22), 7.59 (m, 2H, H-3, H-6), 7.69 (m, 1H, H-23), 7.93 (d, J = 8.4 Hz, 
2H, H-11, H-15), 8.16 (d, J = 8.4 Hz, 2H, H-12, H-14), 10.32 (s, 1H, H-16); δC (DMSO-d6, 100.6 
MHz) 55.6 (CH3), 112.0 (CH), 114.8 (CH), 119.7 (CH), 120.5 (CH), 121.9 (CH), 124.7 (Cquat), 125.0 
(Cquat), 127.0 (CH), 129.7 (CH), 132.2 (CH), 139.2 (Cquat), 140.5 (Cquat), 151.1 (Cquat), 156.5 (Cquat), 
164.6 (CO); HRMS-ES+ Calculated: 344.1399 [M+H]+ for C21H18N3O2, Observed: 344.1393; C18 
HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 98.3%. 
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N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-3-(trifluoromethyl)benzamide (9) 
      
             9 
5-(Trifluoromethyl)pyridine-3-carboxylic acid (191 mg, 1.0 mmol) and 1 (105 mg, 0.5 mmols) 
afforded a white solid. The resulting solid was recrystallized from ethanol to afford white 
crystals of (9) (116 mg, 68% yield). 
ATR-FTIR vmax /cm-1 1661 (C=O amide); M.p. 318-320 °C; Rf (MeOH/DCM 1:9) 0.11; δH (DMSO-
d6, 400 MHz) 7.20 (m, 2H, H-1, H-2), 7.59 (m, 2H, H-3, H-6), 7.97 (d, J = 8.8 Hz, 2H, H-11, H-
15), 8.21 (d, J = 8.8 Hz, 2H, H-12, H-14), 8.71 (m, 1H, H-24), 9.20 (m, 1H, H-20), 9.41 (m, 1H, 
H-21), 10.81 (s, 1H, H-16); δC (DMSO- d6, 100.6 MHz) 115.1 (CH), 120.4 (CH), 122.0 (CH), 124.9 
(q, J = 127.8 Hz, Cquat), 125.8 (Cquat), 127.0 (CH), 130.5 (Cquat), 132.7 (Cquat), 132.7 (CH), 139.9 
(Cquat), 148.6 (CH), 148.6 (Cquat), 150.9 (Cquat), 152.6 (CH), 162.7 (CO); HRMS-ES+ Calculated: 
383.1120 [M+H]+ for C20H14F3N4O, Observed: 383.1117; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (40:60), 95.0%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-2-nitrobenzamide (10) 
    
          10 
2-Nitrobenzoyl chloride (223 mg, 1.2 mmols) and 1 (126 mg, 0.6 mmols) afforded a yellow 
solid. The resulting solid was recrystallized from methanol to afford yellow crystals of (10) 
(145 mg, 67% yield). 
ATR-FTIR vmax /cm-1 1652 (C=O amide), 1527 ( N-O stretch); M.p. 308-309 °C; Rf (MeOH/DCM 
5:95) 0.36; δH (DMSO-d6, 400 MHz) 7.16-7.24 (m, 2H, H-1, H-2), 7.48-7.57 (m, 1H, H-6), 7.61-
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7.69 (m, 1H, H-3), 7.74-7.93 (m, 5H, H-11, H-15, H-20, H-21, H-22), 8.14-8.22 (m, 3H, H-12, H-
14, H-23), 10.80 (s, 1H, H-16), 12.73 (s, 1H, H-9); δC (DMSO-d6, 100.6 MHz) 110.9 (CH), 118.5 
(CH), 119.6 (CH), 121.3 (CH), 122.1 (CH), 124.0 (CH), 125.6 (Cquat), 127.0 (CH), 129.1 (CH), 130.8 
(CH), 132.4 (Cquat), 133.9 (CH), 134.9 (Cquat), 140.0 (Cquat), 143.8 (Cquat), 146.3 (Cquat), 150.9 
(Cquat), 164.1 (CO); HRMS-ES+ Calculated: 359.1144 [M+H]+ for C20H15N4O3, Observed: 
359.1151; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 99.8%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-3,5-dinitrobenzamide (11) 
     
           11 
3,5-Dinitrobenzoyl chloride (461 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a yellow 
solid. The resulting solid was recrystallized from methanol to afford yellow crystals of (11) 
(355 mg, 89% yield). 
ATR-FTIR vmax /cm-1  3304 (NH), 1661 (C=O amide), 1531 (N-O stretch); M.p. 338-339 °C; Rf 
(MeOH/DCM 1:9) 0.68; δH (DMSO-d6, 400 MHz) 7.48 (m, 2H, H-1, H-2), 7.78 (m, 2H, H-3, H-6), 
8.12 (d, J = 8.4 Hz, 2H, H-12, H-14), 8.37 (d, J = 8.4 Hz, 2H, H-11, H-15), 9.02 (s, 1H, H-22), 9.20 
(s, 2H, H-20, H-24), 11.25 (s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 113.7 (CH), 119.9 (Cquat), 
120.5 (CH), 120.9 (CH), 124.6 (CH), 127.8 (CH), 128.2 (CH), 133.2 (Cquat), 136.8 (Cquat), 141.8 
(Cquat), 147.8 (Cquat), 148.6 (Cquat), 161.5 (CO); HRMS-ES+ Calculated: 404.0995 [M+H]+ for 
C20H14N5O5, Observed: 404.1004; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 
99.2%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-2,6-dichloroisonicotinamide (12) 
     
            12 
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2,6-Dichloropyridine-4-carboxylic acid (384 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) 
afforded a yellow solid. The resulting solid was recrystallized from methanol and water to 
afford pale yellow crystals of (12) (264 mg, 69% yield). 
ATR-FTIR vmax /cm-1 1664 (C=O amide); M.p. 348-349 °C; Rf (MeOH/DCM 1:9, 1% Et3N) 0.32; 
δH (DMSO-d6, 400 MHz) 7.20 (m, 2H, H-1, H-2), 7.59 (m, 2H, H-3, H-6), 7.93 (d, J = 8.8 Hz, 2H, 
H-12, H-14), 8.03 (s, 2H, H-20, H-24), 8.20 (d, J = 8.8 Hz, 2H, H-11, H-15), 10.80 (s, 1H, H-16), 
12.80 (s, 1H, H-9); δC (DMSO-d6, 100.6 MHz) 111.1 (CH), 111.4 (CH), 118.3 (CH), 120.4 (CH), 121.8 
(CH), 121.8 (CH), 126.2 (Cquat), 127.0 (CH), 139.5 (Cquat), 144.1 (Cquat), 144.1 (Cquat), 148.0 (Cquat), 
149.8 (Cquat), 150.9 (Cquat), 161.3 (CO); HRMS-ES+ Calculated: 383.0466 [M+H]+ for 
C19H13Cl2N4O, Observed: 383.0468; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 
98.7%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-2-chlorobenzamide (13) 
     
            13 
2-Chlorobenzoic acid (313 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown solid. 
The resulting solid was recrystallized from methanol to afford brown crystals of (13) (184 mg, 
53% yield). 
ATR-FTIR vmax /cm-1 1657 (C=O amide); M.p. 275-276 °C (lit. M.p 311 °C)175; Rf (MeOH/DCM 
6:94) 0.95; δH (DMSO-d6, 400 MHz) 7.46-7.51 (m, 1H, H-21), 7.53–7.57 (m, 3H, H-1, H-2, H-
22), 7.58-7.61 (m, 1H, H-20), 7.63-7.67 (m, 1H, H-23), 7.82 (m, 2H, H-3, H-6), 8.04 (d, J = 8.8 
Hz, 2H, H-12, H-14), 8.44 (d, J = 8.8 Hz, 2H, H-11, H-15), 11.03 (s, 1H, H-16); δC (DMSO-d6, 100.6 
MHz) 113.8 (CH), 118.0 (Cquat), 119.7 (CH), 125.6 (CH), 127.3 (CH), 129.0 (CH), 129.2 (CH), 129.7 
(CH), 129.9 (Cquat), 131.4 (CH), 131.9 (Cquat), 136.3 (Cquat), 143.2 (Cquat), 148.4 (Cquat), 165.5 (CO); 
HRMS-ES+ Calculated: 348.0904 [M+H]+ for C20H15ClN3O, Observed: 348.0901; C18 HPLC, flow 
rate: 1 mL/min, H2O / acetonitrile (40:60), 100%. 
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N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-3-chlorobenzamide (14) 
     
                         14 
3-Chlorobenzoic acid (313 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a cream solid. 
The resulting solid was recrystallized from methanol to afford off-white crystals of (14) (319 
mg, 92% yield). 
ATR-FTIR vmax /cm-1 1669 (C=O amide); M.p. 320-322 °C (lit. M.p 312 °C)175; Rf (MeOH/DCM 
6:94) 0.95; δH (DMSO-d6, 400 MHz) 7.50-7.55 (m, 2H, H-1, H-2), 7.58 (t, J = 7.9 Hz, 1H, H-21), 
7.67 (m, 1H, H-22), 7.79-7.84 (m, 2H, H-3, H-6), 7.99 (dt, J = 1.4, 7.8 Hz, 1H, H-20), 8.07 (t, J = 
1.8 Hz, 1H, H-24), 8.13 (d, J = 8.9 Hz, 2H, H-12, H-14), 8.42 (d, J = 8.9 Hz, 2H, H-11, H-15), 10.78 
(s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 113.6 (CH), 118.0 (Cquat), 120.3 (CH), 125.3 (CH), 126.4 
(CH), 127.3 (CH), 128.7 (CH), 130.1 (CH), 131.4 (CH), 132.0 (Cquat), 133.1 (Cquat), 136.1 (Cquat), 
143.1 (Cquat), 148.4 (Cquat), 164.4 (CO); HRMS-ES+ Calculated: 348.0904 [M+H]+ for 
C20H15ClN3O, Observed: 348.0899; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 
95.9%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)-4-chlorobenzamide (15) 
    
            15 
4-Chlorobenzoic acid (313 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown solid. 
The resulting solid was recrystallized from methanol to afford brown crystals of (15) (260 mg, 
75% yield). 
ATR-FTIR vmax /cm-1 1650 (C=O amide); M.p. 331-333 °C (lit. M.p 323 °C)175; Rf (MeOH/DCM 
6:94) 0.94; δH (DMSO-d6, 400 MHz) 7.49-7.54 (m, 2H, H-1, H-2), 7.61 (d, J = 8.6 Hz 2H, H-21, 
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H-23), 7.79-7.84 (m, 2H, H-3, H-6), 8.06 (d, J = 8.6 Hz, 2H, H-20, H-24), 8.12 (d, J = 8.9 Hz, 2H, 
H-12, H-14), 8.40 (d, J = 8.9 Hz, 2H, H-11, H-15), 10.70 (s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 
113.5 (CH), 118.1 (Cquat), 120.2 (CH), 125.1 (CH), 128.1 (CH), 128.5 (CH), 129.4 (CH), 132.2 (Cquat), 
132.9 (Cquat), 136.5 (Cquat), 143.1 (Cquat), 148.5 (Cquat), 164.7 (CO); HRMS-ES+ Calculated: 
348.0904 [M+H]+ for C20H15ClN3O, Observed: 348.0898; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (40:60), 100%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)nicotinamide (16)  
   
             16 
Nicotinic acid (246 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown solid. The 
resulting solid was recrystallized from methanol and water to afford light brown crystals of 
(16)  
(211 mg, 67% yield). 
ATR-FTIR vmax /cm-1  3276 (NH), 1648 (C=O amide); M.p. 332-333 °C; Rf (MeOH/DCM 15:85) 
0.17; δH (DMSO-d6, 400 MHz) 7.16-7.24 (m, 2H, H-1, H-2), 7.50-7.72 (m, 3H, H-3, H-6, H-23), 
7.97 (m, 2H, H-12, H-14), 8.12-8.24 (m, 2H, H-11, H-15), 8.30-8.36 (m, 1H, H-24), 8.76-8.81 (m, 
1H, H-22), 9.14-9.19 (m, 1H, H-20), 10.64 (s, 1H, H-16), 12.81 (s, 1H, H-9); δC (DMSO-d6, 100.6 
MHz) 115.1 (CH), 120.2 (CH), 121.6 (CH), 123.2 (CH), 125.6 (Cquat), 126.8 (CH), 130.3 (Cquat), 135.1 
(CH), 140.0 (Cquat), 142.9 (Cquat), 148.4 (CH), 150.9 (Cquat), 151.9 (CH), 164.0 (CO); HRMS-ES+ 
Calculated: 315.1246 [M+H]+ for C19H15N4O, Observed: 315.1249; C18 HPLC, flow rate: 1 
mL/min, H2O / acetonitrile (40:60), 97.7%. 
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N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)thiophene-2-carboxamide (17)  
    
            17 
2-Thiophenecarboxylic acid (256 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown 
solid. The resulting solid was recrystallized from methanol and water to afford light brown 
crystals of (17) (158 mg, 49% yield). 
ATR-FTIR vmax /cm-1 1650 (C=O amide); M.p. 344-346 °C; Rf (MeOH/DCM 1:9) 0.95; δH (DMSO-
d6, 400 MHz) 7.24 (t, J = 4.3 Hz, 1H, H-21), 7.42-7.47 (m, 2H, H-1, H-2), 7.73-7.79 (m, 2H, H-3, 
H-6), 7.87 (d, J = 5.0 Hz, 1H, H-22), 8.05-8.10 (d, J = 8.7 Hz, 2H, H-12, H-14), 8.17 (d, J = 3.8 Hz, 
1H, H-20), 8.29-8.34 (d, J = 8.7 Hz, 2H, H-11, H-15), 10.62 (s, 1H, H-16); δC (DMSO-d6, 100.6 
MHz) 113.8 (CH), 119.5 (Cquat), 120.1 (CH), 124.4 (CH), 127.8 (CH), 128.2 (CH), 129.7 (CH), 132.1 
(CH), 133.7 (Cquat), 139.2 (Cquat), 142.4 (Cquat), 149.1 (Cquat), 160.1 (CO); HRMS-ES+ Calculated: 
320.0858 [M+H]+ for C18H14SN3O, Observed: 320.0862; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (40:60), 97.3%. 
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)furan-2-carboxamide (18) 
    
            18 
2-Furoic acid (224 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown solid. The 
resulting solid was recrystallized from methanol to afford a light brown solid of (18) (232 mg, 
75% yield). 
ATR-FTIR vmax /cm-1 1650 (C=O amide); M.p. 252-253 °C (lit. M.p 301 °C)175; Rf (MeOH/DCM 
1:9) 0.86; δH (DMSO-d6, 400 MHz) 6.72 (dd, J = 1.7, 3.5 Hz, 1H, H-21), 7.49 (d, J = 3.5 Hz, 1H, 
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H-22), 7.51-7.56 (m, 2H, H-1, H-2), 7.79-7.84 (m, 2H, H-3, H-6), 7.95 (m, 1H, H-20), 8.12 (d, J = 
8.9 Hz, 2H, H-12, H-14), 8.37 (d, J = 8.9 Hz, 2H, H-11, H-15), 10.60 (s, 1H, H-16); δC (DMSO-d6, 
100.6 MHz) 112.0 (CH), 113.6 (CH), 115.5 (CH), 117.9 (Cquat), 120.1 (CH), 125.3 (CH), 128.7 (CH), 
132.1 (Cquat), 142.9 (Cquat), 145.9 (CH), 146.9 (Cquat), 148.5 (Cquat), 156.3 (CO); HRMS-ES+ 
Calculated: 304.1086 [M+H]+ for C18H14N3O2, Observed: 304.1072; C18 HPLC, flow rate: 1 
mL/min, H2O / acetonitrile (40:60), 95.1%.  
N-(4-(1-Benzo[d]imidazole-2-yl)phenyl)1H-pyrrole-2-carboxamide (19) 
    
            19 
Pyrrole-2-carboxylic acid (222 mg, 2.0 mmols) and 1 (209 mg, 1.0 mmol) afforded a brown 
solid. The resulting solid was recrystallized from methanol and water to afford a light brown 
solid of (19) (162 mg, 54% yield). 
ATR-FTIR vmax /cm-1 1654 (C=O amide); M.p. 292-293 °C; Rf (MeOH/DCM 1:9) 0.61; δH (DMSO-
d6, 400 MHz) 6.21 (m, 1H, H-21), 7.03 (m, 1H, H-20), 7.17 (m, 1H, H-22), 7.49-7.54 (m, 2H, H-
1, H-2), 7.77-7.83 (m, 2H, H-3, H-6), 8.08-8.13 (d, J = 8.9 Hz, 2H, H-12, H-14), 8.25-8.30 (d, J = 
8.9 Hz, 2H, H-11, H-15), 10.28 (s, 1H, H-16), 11.84 (s, 1H, H-9); δC (DMSO-d6, 100.6 MHz) 109.1 
(CH), 112.5 (CH), 113.8 (CH), 117.6 (Cquat), 119.7 (CH), 123.3 (CH), 125.2 (CH), 125.6 (Cquat), 128.6 
(CH), 132.7 (Cquat), 143.8 (Cquat), 149.1 (Cquat), 159.3 (CO); HRMS-ES+ Calculated: 303.1246 
[M+H]+ for C18H15N4O, Observed: 303.1233; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile 
(40:60), 95.0%. 
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7.2.3 Fragment Benzimidazole Derivatives 
N-(4-(1-Benzoyl-1H-benzo[d]imidazole-2-yl)phenyl)-3-bromobenzamide (20) 
        
20 
Compound 3 (300 mg, 0.76 mmols), was added to a solution of anhydrous pyridine (2 mL) and 
THF (2 mL) in a 25 mL reaction vessel under nitrogen. Benzoyl chloride (0.8 mL, 6.9 mmols) 
was added and the solution left to stir for 18 hr at room temperature. The reaction mixture 
was quenched with MeOH, acidified with 1M HCl to pH 5 and the combined organic 
components extracted, first using MeOH: chloroform (1:3, 20 mL) and then chloroform (2x 20 
mL). The organic extracts were dried over anhydrous Na2SO4  and the crude product purified 
using column chromatography with MeOH: DCM (1:99 to 7:93) mixtures. The resulting solid 
was further recrystallized from acetone and H2O which afforded a light brown solid of (20) 
(146 mg, 39% yield) 
ATR-FTIR vmax /cm-1 1657 (C=O amide); M.p. 222-223 °C; Rf (MeOH/DCM 1:9) 0.90; δH (DMSO-
d6, 400 MHz) 7.30-7.33 (m, 2H, H-1, H-2), 7.35-7.41 (m, 1H, H-3), 7.44-7.52 (m, 3H, H-6, H-12, 
H-14), 7.60-7.65 (m, 3H, H-11, H-15, H-21), 7.75-7.80 (m, 5H, H-29, H-30, H-31, H-32, H-33), 
7.84 (dt, J = 0.9, 7.9 Hz, 1H, H-22), 7.94 (ddd, J = 1.0, 1.6, 7.8 Hz, 1H, H-20), 8.13 (t, J = 1.8 Hz, 
1H, H-24), 10.45 (s, 1H, H-16); δC (DMSO-d6, 100.6 MHz) 112.7 (CH), 119.6 (CH), 119.7 (CH), 
121.6 (Cquat), 124.2 (CH), 124.4 (CH), 125.3 (Cquat), 126.8 (CH), 128.9 (CH), 129.6 (CH), 130.2 (CH), 
130.3 (CH), 130.6 (CH), 132.7 (Cquat), 134.3 (CH), 134.4 (CH), 134.6 (Cquat), 136.7 (Cquat), 140.2 
(Cquat), 142.6 (Cquat), 153.2 (Cquat), 164.1 (CO), 168.9 (CO); HRMS-ES+ Calculated: 496.0661 
[M+H]+ for C27H19 BrN3O2, Observed: 496.0654; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (40:60), 96.6%. 
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5-Bromo-N-phenylnicotinamide (21) 
    
21 
5-Bromopyridine-3-carboxylic acid (404 mg, 2.0 mmols) was added to a 25 mL reaction vessel 
and flushed with nitrogen. Thionyl chloride (2 mL) was added under dry conditions and the 
resulting mixture was stirred at 80 °C, overnight to ensure complete conversion to the aryl 
acid chloride. The reaction mixture was cooled and excess thionyl chloride was completely 
removed under pressure. 
Aniline (102 mg, 1.1 mmols) was added to a 25 mL reaction flask, dissolved in anhydrous 
pyridine (2 mL) and cooled to -40 °C under inert conditions. A mixture of the previously 
formed 5-bromopyridine-3-carbonyl chloride (≈ 2 mmols) and THF (1.5 mL) was added 
dropwise over 20 min, with vigourous stirring and the reaction mixture slowly warmed to 
room temperature. After complete conversion, determined by TLC, the resulting mixture was 
quenched with MeOH and basifiied to pH 7 using anhydrous NaHCO3. The combined organic 
components were extracted using DCM (3x 20 mL) and dried over Na2SO4. The crude product 
was then purified by column chromatography using MeOH/DCM (1:99 to 2:98) mixtures. The 
resulting compound was recrystallized from DCM to yield white crystals of (21) (287 mg, 94% 
yield). 
ATR-FTIR vmax /cm-1  3294 (NH), 1650 (C=O amide); M.p. 182 - 183 °C; Rf (MeOH/DCM 1:99) 
0.21; δH (DMSO-d6, 400 MHz) 7.11-7.16 (m, 1H, H-2), 7.35-7.40 (m, 2H, H-1, H-3), 7.75 (m, 2H, 
H-4, H-6), 8.54 (m, 1H, H-15), 8.90 (m, 1H, H-13), 9.07 (m, 1H, H-11), 10.47 (s, 1H, NH) ; δC 
(DMSO- d6, 100.6 MHz) 119.9 (Cquat), 120.3 (CH), 124.1 (CH), 128.6 (CH), 132.1 (Cquat), 137.6 (CH), 
138.5 (Cquat), 147.3 (CH), 152.6 (CH), 162.4 (CO); HRMS-ES+ Calculated: 276.9977 [M+H]+ for 
C12H10BrN2O, Observed: 276.9974; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (40:60), 
98.5%. 
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5-Bromo-N-methylnicotinamide (22) 
 
22 
5-Bromopyridine-3 carboxylic acid (303 mg, 1.5 mmols) was added to a 25 mL reaction vessel 
and flushed with nitrogen. Thionyl chloride (4 mL) was added under dry conditions and the 
resulting mixture was stirred at 80 °C, overnight to ensure complete conversion to the aryl 
acid chloride. The reaction mixture was cooled and excess thionyl chloride was completely 
removed under pressure.  
Methylamine.HCl (50 mg, 0.75 mmols) and freshly distilled, anhydrous triethylamine (1 mL) 
was added to a 25 mL reaction flask, which was added dropwise to the mixture of the 
previously formed 5-bromopyridine-3-carbonyl chloride in dry THF (2 mL). The mixture was 
allowed to stir vigourously at room temperature under nitrogen until complete conversion, 
via TLC monitoring, after which the mixture was acidified to pH 7 using 1 M HCl and the 
organic material extracted using MeOH:chloroform (1:1, 20 mL) followed by chloroform  
(2x 20 mL). The combined extracts were dried over anhydrous Na2SO4 and the crude product 
purified by column chromatography using MeOH/DCM (2:99 to 7:93) mixtures. The resulting 
solid was recrystallized using acetone to yield light yellow crystals of (22) (81 mg, 50% yield). 
ATR-FTIR vmax /cm-1  3294 (NH), 1641 (C=O amide); M.p. 142 - 143 °C; Rf (MeOH/DCM 5:95) 
0.17; δH (Acetone-d6, 400 MHz) 2.93 (d, J = 4.7 Hz, 3H, H-11), 7.96 (s, 1H, NH), 8.35 (t, J = 2.1 
Hz, 1H, H-6), 8.78 (d, J = 2.2 Hz, 1H, H-4), 8.98 (m, 1H, H-2); δC (Acetone-d6, 100.6 MHz) 26.8 
(CH3), 121.1 (Cquat), 133.0 (Cquat), 138.2 (CH), 147.7 (CH), 153.5 (CH), 165.0 (CO); HRMS-ES+ 
Calculated: 214.9820 [M+H]+ for C7H8N2OBr, Observed: 214.9814; C18 HPLC, flow rate:  
1 mL/min, H2O / acetonitrile (40:60), 99.5%. 
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N-(4-(1H-Benzo[d]imidazole-2-yl)phenyl)acetamide (23) 
 
23 
A solution of compound 1 (209 mg, 1.0 mmol), acetic anhydride (0.1 mL, 1.1 mmols) and 
toluene (3 mL) was refluxed at 115 °C for 2 hr and subsequently cooled. The precipitate was 
filtered and washed with hot ethyl acetate and toluene to give (23) (216 mg, 86% yield) as a 
white solid. 
ATR-FTIR vmax /cm-1 1673 (C=O amide); M.p. 302 - 303 °C (lit. 308 – 309 °C)156; Rf (MeOH/DCM 
5:95) 0.30; δH (DMSO-d6, 600 MHz) 2.09 (s, 3H, H-19), 7.18 (m, 2H, H-1, H-2), 7.57 (m, 2H, H-
3, H-6), 7.75 (d, J = 8.8 Hz, 2H, H-12, H-14), 8.10 (d, J = 8.8 Hz, 2H, H-11, H-15), 10.16 (s, 1H, 
H-9); δC (DMSO- d6, 150.9 MHz) 24.1 (CH3), 114.9 (CH), 118.9 (CH), 121.9 (CH), 124.5 (Cquat), 
127.1 (CH), 139.1 (Cquat), 140.8 (Cquat), 151.1 (Cquat), 168.6 (CO); HRMS-ES+ Calculated: 252.1137 
[M+H]+ for C15H14N3O, Observed: 252.1135; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile 
(40:60), 98.6%. 
7.3 Carbazole Derivatives 
7.3.1 General Procedure for the Synthesis of Epoxide Precursors 
To a solution of NaH (482 mg, 12.05 mmols) in anhydrous DMF (2 mL) at 0 °C was added a 
solution of carbazole (2.00 g, 11.97 mmols) in anhydrous DMF (3 mL) dropwise over 20 min. 
The reaction mixture was warmed to room temperature and stirred for 1 hr to allow for 
complete deprotonation. Thereafter, epichlorohydrin (1.00 mL, 13.17 mmols) was added to 
the reaction mixture dropwise and stirred for 16 hr. The reaction mixture was quenched with 
a saturated NH4Cl solution and the combined organic components were extracted using 
EtOAc (2x 20 mL). The combined extracts were washed with H2O (9x 10 mL) and brine (10 mL) 
and then dried over Na2SO4. The crude product was purified by column chromatography using 
EtOAc/ hexane (0:100 to 1:9) mixtures and the resulting solid was recrystallized from ethanol 
to yield colourless crystals as needles. 
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9-(Oxiran-2-ylmethyl)-9H-carbazole (24) 
 
24 
(±)-Epichlorohydrin was used to yield 24 as a racemic mixture (1.094 g, 41% yield). 
M.p. 106 - 107 °C (lit. 113 °C)176; Rf (EtOAc/hexane 1:9) 0.26; δH (Acetone-d6, 400 MHz) 2.59 
(dd, J = 2.5, 5.1 Hz, 1H, H-17), 2.76 (dd, J = 4.0, 5.1 Hz, 1H, H-17), 3.34 (m, 1H, H-15), 4.42 (dd, 
J = 5.5, 15.9 Hz, 1H, H-14), 4.81 (dd, J = 3.0, 15.9 Hz, 1H, H-14), 7.22 (m, 2H, H-2, H-11), 7.45 
(m, 2H, H-1, H-12), 7.63 (d, J = 8.3 Hz, 2H, H-6, H-13), 8.13 (m, 2H, H-3, H-10); δC (Acetone-d6, 
100.6 MHz) 45.4 (CH), 45.6 (CH), 51.3 (CH), 110.4 (CH), 120.1 (CH), 121.0 (CH), 123.8 (Cquat), 126.7 
(CH), 141.9 (Cquat). 
(S)-9-(Oxiran-2-ylmethyl)-9H-carbazole (25) 
 
25 
(S)-Epichlorohydrin was used to yield 25 as a pure enantiomer (1.346 g, 48% yield). 
M.p. 73 - 74 °C; Rf (EtOAc/hexane 1:9) 0.26; δH (acetone-d6, 400 MHz) 2.59 (dd, J = 2.5, 5.1 Hz, 
1H, H-17), 2.76 (dd, J = 4.0, 5.1 Hz, 1H, H-17), 3.34 (m, 1H, H-15), 4.42 (dd, J = 5.5, 15.9 Hz, 1H, 
H-14), 4.81 (dd, J = 3.0, 15.9 Hz, 1H, H-14), 7.22 (m, 2H, H-2, H-11), 7.45 (m, 2H, H-1, H-12), 
7.63 (d, J = 8.3 Hz, 2H, H-6, H-13), 8.13 (m, 2H, H-3, H-10); δC (acetone-d6, 100.6 MHz) 45.4 
(CH), 45.6 (CH), 51.3 (CH), 110.4 (CH), 120.1 (CH), 121.0 (CH), 123.8 (Cquat), 126.7 (CH), 141.9 
(Cquat). 
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(R)-9-(Oxiran-2-ylmethyl)-9H-carbazole (26) 
 
26 
(R)-Epichlorohydrin was used to yield 26 as a pure enantiomer (1.292 g, 50% yield). 
M.p. 81 - 82 °C; Rf (EtOAc/hexane 1:9) 0.26; δH (acetone-d6, 400 MHz) 2.59 (dd, J = 2.5, 5.1 Hz, 
1H, H-17), 2.76 (dd, J = 4.0, 5.1 Hz, 1H, H-17), 3.34 (m, 1H, H-15), 4.42 (dd, J = 5.5, 15.9 Hz, 1H, 
H-14), 4.81 (dd, J = 3.0, 15.9 Hz, 1H, H-14), 7.22 (m, 2H, H-2, H-11), 7.45 (m, 2H, H-1, H-12), 
7.63 (d, J = 8.3 Hz, 2H, H-6, H-13), 8.13 (m, 2H, H-3, H-10); δC (Acetone-d6, 100.6 MHz) 45.4 
(CH), 45.6 (CH), 51.3 (CH), 110.4 (CH), 120.1 (CH), 121.0 (CH), 123.8 (Cquat), 126.7 (CH), 141.9 
(Cquat). 
7.3.2 Miscellaneous Precursors 
9-(3-Bromopropyl)-9H-carbazole (27) 
  
27 
To a solution of NaH (271 mg, 6.78 mmols) and anhydrous THF (3 mL) at 0 °C, was added a 
solution of carbazole (1.50 g, 8.97 mmols) in THF (10 mL) dropwise over 20 min. The reaction 
mixture was warmed to room temperature and stirred for 1 hr to allow for complete 
deprotonation. 1,3-Dibromopropane (1.37 mL, 13.46 mmols, 1.5 eq.) was added to the 
reaction mixture and allowed to stir for 16 hr at room temperature. The reaction mixture was 
quenched with a saturated NH4Cl solution and the combined organic components were 
extracted using EtOAc (2x 20 mL). The combined extracts were dried over anhydrous Na2SO4 
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and the crude product purified by column chromatography using 100% hexane to yield 27 as 
a white solid (404 mg, 16% yield). 
M.p. 149 - 150 °C (lit. 148 – 150 °C)177; Rf (EtOAc/hexane 1:9) 0.48; δH (DMSO-d6, 300 MHz) 
2.31 (p, J = 6.9 Hz, 2H, H-15), 3.52 (t, J = 6.6 Hz, 2H, H-16), 4.51 (t, J = 6.9 Hz, 2H, H-14), 7.17-
7.24 (m, 2 H, H-2, H-11), 7.42-7.50 (m, 2 H, H-1, H-12), 7.63 (d, J = 8.3 Hz, 2H, H-6, H-13), 8.16 
(d, J = 7.7 Hz, 2H, H-3, H-10). 
7-(Benzyloxy)-1H-indole (28) 
 
28 
To a 0 °C solution of NaH (126 mg, 3.15 mmols) and anhydrous THF (2 mL) was added a 
solution of 7-hydroxyindole (500 mg, 3.76 mmols) in THF (5 mL) drop wise over 20 min. The 
reaction mixture was warmed to room temperature and stirred for 1 hr to allow for complete 
deprotonation. Benzyl bromide (0.58 mL, 4.88 mmols) was added to the reaction mixture and 
stirred for 12 hr. The reaction mixture was quenched with a saturated NH4Cl solution and the 
combined organic components were extracted using EtOAc (2x 20 mL). The combined extracts 
were dried over Na2SO4 and the crude product purified by column chromatography using 
EtOAc/ hexane (0:100 to 2:8) mixtures to yield 28 as a brown solid (373 mg, 44% yield). 
M.p. 72 - 73 °C (lit. 73 °C)178; Rf (EtOAc/Hexane 3:8) 0.67; δH (chloroform-d, 300 MHz) 5.19 (s, 
2H, H-11), 6.51 (m, 1H, H-7), 6.70 (d, J = 7.7 Hz, 1H, H-5), 6.99 (t, J = 7.8 Hz, 1H, H-6), 7.12-7.15 
(m, 1H, H-8), 7.20-7.48 (m, 6H, H-1, H-13, H-14, H-15, H-16, H-17), 8.38 (s, 1H, NH). 
7.3.3 Procedure for Preparation of Carbazole Indoles 29-32 
To a solution of NaH (42 mg, 1.05 mmols) in anhydrous THF (2 mL) was added drop wise a 
solution of Indole (122 mg, 1.04 mmols) in THF (4 mL) at 0 °C. The mixture was warmed to 
room temperature and allowed to stir for 1 hr. The appropriate epoxide or bromide derivative 
(1.04 mmols, 1 eq.) was added and the mixture was refluxed at 70 °C for 12 hr. The reaction 
mixture was cooled, quenched using a saturated NH4Cl solution (2 mL) and then reduced 
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under reduced pressure to remove the residual THF. The combined organic components were 
dissolved in EtOAc and extracted (3 x 15 mL). The organic mixture was dried over Na2SO4 and 
purified by column chromatography using EtOAc / hexane (2:98 to 20:80) mixtures. The 
resulting solids were recrystallized from pentane. 
9-(3-(1H-Indol-1-yl)propyl)-9H-carbazole (29) 
          
29 
27 was used to yield 29 as a white solid (172 mg, 51% yield). 
M.p. 65 - 66 °C; Rf (EtOAc/hexane 2:8) 0.55; δH (chloroform-d, 400 MHz) 2.45-2.53 (p, J = 7.1 
Hz, 2H, H-15), 4.18-4.23 (t, J = 7.0 Hz, 2H, H-14/H16), 4.31-4.36 (t, J = 7.2 Hz, 2H, H-14/H-16), 
6.58 (dd, J = 0.6, 3.2 Hz, 1H, H-20), 7.11 (d, J = 3.2 Hz, H-21), 7.12-7.18 (m, 1H, HAr), 7.19-7.28 
(m, 6H, HAr), 7.44 (m, 2H, HAr), 7.69 (m, 1H, HAr) 8.13 (m, 2H, HAr); δC (chloroform-d, 100.6 
MHz) 29.4 (C-15), 40.5 (C-14/C-16), 44.0 (C-14/C-16), 101.9 (CH), 108.6 (CH), 109.4 (CH), 119.3 
(CH), 119.7 (CH), 120.6 (CH), 121.3 (CH), 121.9 (CH), 123.3 (Cquat), 126.0 (CH), 127.5 (CH), 129.0 
(Cquat), 136.2 (Cquat), 140.4 (Cquat); HRMS-ES+ Calculated: 325.1705 [M+H]+ for C23H21N2, 
Observed: 325.1693; C18 HPLC, flow rate: 1 mL/min, H2O / acetonitrile (30:70), 99.7%. 
1-(9H-Carbazol-9-yl)-3-(1H-indol-1-yl)propan-2-ol (30) 
            
30 
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Racemic 24 was used to yield 30 as a white solid (192 mg, 54% yield). 
ATR-FTIR vmax /cm-1  3538 (OH); M.p. 51 - 52 °C; Rf (EtOAc/hexane 2:8) 0.35; δH (chloroform-d, 
400 MHz) 1.99 (s, 1H, OH) 4.25-4.32 (m, 2H, H-14/H-16), 4.33-4.46 (m, 2H, H-14/H-16), 4.56-
4.65 (m, 1H, H-15), 6.57 (dd, J = 0.76, 3.2 Hz, 1H, H-20), 7.12-7.17 (m, 2H, HAr), 7.18-7.23 (m, 
1H, HAr), 7.23-7.30 (m, 3H, HAr), 7.34 (m, 2H, HAr), 7.44-7.49 (m, 2H, HAr), 7.67 (m, 1H, HAr), 
8.12 (m, 2H, HAr); δC (chloroform-d, 100.6 MHz) 47.2 (C-14/C-16), 50.4 (C-14/C-16), 70.6 (CH), 
102.4 (CH), 109.0 (CH), 109.4 (CH), 119.7 (CH), 120.0 (CH), 120.6 (CH), 121.4 (CH), 122.1 (CH), 
123.4 (Cquat), 126.2 (CH), 128.5 (CH), 129.0 (Cquat), 136.4 (Cquat), 140.8 (Cquat); HRMS-ES+ 
Calculated: 341.1654 [M+H]+ for C23H21N2O, Observed: 341.1645; C18 HPLC, flow rate: 1 
mL/min, H2O / acetonitrile (30:70), 98.0%; Chiral OD HPLC, flow rate 1.0 mL/min, i-PrOH / 
hexane (20:80), τ Major: 17.8 min, τ Minor: 23.1 min. 
(R)-1-(9H-Carbazol-9-yl)-3-(1H-indol-1-yl)propan-2-ol (31) 
 
31 
26 [(R)-isomer] was used to yield 31 as a white solid (252 mg, 72% yield). 
ATR-FTIR vmax /cm-1  3538 (OH); M.p. 53 - 54 °C; Rf (EtOAc/hexane 2:8) 0.35; δH (chloroform-d, 
400 MHz) 1.99 (s, 1H, OH) 4.25-4.32 (m, 2H, H-14/H-16), 4.33-4.46 (m, 2H, H-14/H-16), 4.56-
4.65 (m, 1H, H-15), 6.57 (dd, J = 0.76, 3.2 Hz, 1H, H-20), 7.12-7.17 (m, 2H, HAr), 7.18-7.23 (m, 
1H, HAr), 7.23-7.30 (m, 3H, HAr), 7.34 (m, 2H, HAr), 7.44-7.49 (m, 2H, HAr), 7.67 (m, 1H, HAr), 
8.12 (m, 2H, HAr); δC (chloroform-d, 100.6 MHz) 47.2 (C-14/C-16), 50.4 (C-14/C-16), 70.6 (CH), 
102.4 (CH), 109.0 (CH), 109.4 (CH), 119.7 (CH), 120.0 (CH), 120.6 (CH), 121.4 (CH), 122.1 (CH), 
123.4 (Cquat), 126.2 (CH), 128.5 (CH), 129.0 (Cquat), 136.4 (Cquat), 140.8 (Cquat); HRMS-ES+ 
Calculated: 341.1654 [M+H]+ for C23H21N2O, Observed: 341.1637; C18 HPLC, flow rate: 1 
mL/min, H2O / acetonitrile (30:70), 95.9%; Chiral OD HPLC, flow rate 1.0 mL/min, i-PrOH / 
hexane (20:80), τ Major: 17.8 min, τ Minor: 23.7 min. 
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(S)-1-(9H-Carbazol-9-yl)-3-(1H-indol-1-yl)propan-2-ol (32) 
          
32 
25 [(S)-isomer] was used to yield 32 as a white solid (248 mg, 70% yield). 
ATR-FTIR vmax /cm-1  3538 (OH); M.p. 52 - 53 °C; Rf (EtOAc/hexane 2:8) 0.35; δH (chloroform-d, 
400 MHz) 1.99 (s, 1H, OH) 4.25-4.32 (m, 2H, H-14/H-16), 4.33-4.46 (m, 2H, H-14/H-16), 4.56-
4.65 (m, 1H, H-15), 6.57 (dd, J = 0.76, 3.2 Hz, 1H, H-20), 7.12-7.17 (m, 2H, HAr), 7.18-7.23 (m, 
1H, HAr), 7.23-7.30 (m, 3H, HAr), 7.34 (m, 2H, HAr), 7.44-7.49 (m, 2H, HAr), 7.67 (m, 1H, HAr), 
8.12 (m, 2H, HAr); δC (chloroform-d, 100.6 MHz) 47.2 (C-14/C-16), 50.4 (C-14/C-16), 70.6 (CH), 
102.4 (CH), 109.0 (CH), 109.4 (CH), 119.7 (CH), 120.0 (CH), 120.6 (CH), 121.4 (CH), 122.1 (CH), 
123.4 (Cquat), 126.2 (CH), 128.5 (CH), 129.0 (Cquat), 136.4 (Cquat), 140.8 (Cquat); HRMS-ES+ 
Calculated: 341.1654 [M+H]+ for C23H21N2O, Observed: 341.1639; C18 HPLC, flow rate: 1 
mL/min, H2O / acetonitrile (30:70), 93.0%; Chiral OD HPLC, flow rate 1.0 mL/min, i-PrOH / 
hexane (20:80), τ Major: 22.4 min, τ Minor: 17.8 min. 
7.3.4 General Procedure for Carbazole Indoles 33-35 
To a solution of NaH (40 mg, 1.0 mmol) in anhydrous NMP (1 mL) was added drop wise a 
solution of 28 (223 mg, 1.0 mmol) in NMP (2 mL) at 0 °C. The mixture was warmed to room 
temperature and allowed to stir for 1 hr. The appropriate epoxide (288 mg, 1.0 mmol) was 
added and the mixture was refluxed at 130 °C for 16 hr. The reaction mixture was cooled, 
quenched using a saturated NH4Cl solution and extracted using EtOAc (3 x 15 mL). The organic 
mixture was washed with H2O (9x 10 mL) and brine (10 mL) to remove the NMP, dried over 
Na2SO4 and purified by column chromatography with EtOAc / hexane (2:98 to 30:70) mixtures. 
The resulting solid was dissolved in anhydrous MeOH (4 mL) in a reaction vessel flushed with 
nitrogen and 10 mol% of Pd-C (90 mg, 0.76 mmols) was added. A balloon filled with hydrogen 
was fitted to the vessel and the solution was stirred for 12 hr at room temperature. The 
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reaction was filtered through Celite© and reduced under reduced pressure to remove the 
excess solvent.  The resulting solids were purified by column chromatography using EtOAc / 
hexane (2:8 to 3:7) mixtures and recrystallized using DCM. 
1-(3-(9H-Carbazol-9-yl)-2-hydroxypropyl)-1H-indol-7-ol (33) 
          
33 
Racemic 24 was used to yield 33 as a white solid (123 mg, 35% yield). 
ATR-FTIR vmax /cm-1  3457 (OH), 3218 (OH); M.p. 198 - 199 °C; Rf (EtOAc/hexane 2:8) 0.15; δH 
(methanol-d4, 400 MHz) 4.29-4.35 (dd, J = 3.2, 15.0 Hz, 1H, H-15), 4.40-4.45 (m, 1H, H-15) 
4.46-4.51 (m, 1H, H-17), 4.60-4.68 (m, 1H, H-16), 4.90 (m, 1H, H-17), 6.46 (d, J = 3.1 Hz, 1H, H-
21), 6.60 (dd, J = 0.9, 7.8 Hz, 1H, H-24) 6.87-6.92 (t, J = 7.8 Hz, 1H, H-25) 7.13 (dd, J = 0.9, 7.8 
Hz, 1H, H-26) 7.19-7.24 (m, 3H, H-6, H-11, H-22) 7.38-7.44 (m, 4H, H-4, H-5, H-12, H-13) 8.10 
(m, 2H, H-1, H-10); δC (methanol-d4, 100.6 MHz) 48.2 (CH), 53.9 (CH), 72.9 (CH), 102.2 (CH), 
107.7 (CH), 110.3 (CH), 113.4 (CH), 119.8 (CH), 120.8 (CH), 121.1 (CH), 124.2 (Cquat), 126.6 (CH), 
127.0 (Cquat), 131.0 (CH), 133.2 (Cquat), 142.3 (Cquat), 145.6 (Cquat); HRMS-ES+ Calculated: 
357.1603 [M+H]+ for C23H21N2O2, Observed: 357.1588; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (30:70), 96.3%; Chiral OD HPLC, flow rate 0.9 mL/min, i-PrOH / hexane (25:75), 
τ Major: 11.9 min, τ Minor: 20.2 min. 
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(R)-1-(3-(9H-Carbazol-9-yl)-2-hydroxypropyl)-1H-indol-7-ol (34)  
         
34 
25 [(S)-isomer] was used to yield 34 as a white solid (141 mg, 40% yield). 
ATR-FTIR vmax /cm-1  3538 (OH), 3250 (OH); M.p. 175 - 176 °C; Rf (EtOAc/hexane 2:8) 0.15; δH 
(methanol-d4, 400 MHz) 4.29-4.35 (dd, J = 3.2, 15.0 Hz, 1H, H-15), 4.40-4.45 (m, 1H, H-15) 
4.46-4.51 (m, 1H, H-17), 4.60-4.68 (m, 1H, H-16), 4.90 (m, 1H, H-17), 6.46 (d, J = 3.1 Hz, 1H, H-
21), 6.60 (dd, J = 0.9, 7.8 Hz, 1H, H-24) 6.87-6.92 (t, J = 7.8 Hz, 1H, H-25) 7.13 (dd, J = 0.9, 7.8 
Hz, 1H, H-26) 7.19-7.24 (m, 3H, H-6, H-11, H-22) 7.38-7.44 (m, 4H, H-4, H-5, H-12, H-13) 8.10 
(m, 2H, H-1, H-10); δC (methanol-d4, 100.6 MHz) 48.2 (CH), 53.9 (CH), 72.9 (CH), 102.2 (CH), 
107.7 (CH), 110.3 (CH), 113.4 (CH), 119.8 (CH), 120.8 (CH), 121.1 (CH), 124.2 (Cquat), 126.6 (CH), 
127.0 (Cquat), 131.0 (CH), 133.2 (Cquat), 142.3 (Cquat), 145.6 (Cquat); HRMS-ES+ Calculated: 
357.1603 [M+H]+ for C23H21N2O2, Observed: 357.1591; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (30:70), 95.7%; Chiral OD HPLC, flow rate 0.9 mL/min, i-PrOH / hexane (25:75), 
 τ Major: 11.9 min, τ Minor: 20.6 min. 
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(S)-1-(3-(9H-Carbazol-9-yl)-2-hydroxypropyl)-1H-indol-7-ol (35) 
         
35 
26 [(R)-isomer] was used to yield 35 as a white solid (162 mg, 45% yield). 
ATR-FTIR vmax /cm-1  3538 (OH), 3236 (OH); M.p. 193 - 194 °C; Rf (EtOAc/hexane 2:8) 0.15; δH 
(methanol-d4, 400 MHz) 4.29-4.35 (dd, J = 3.2, 15.0 Hz, 1H, H-15), 4.40-4.45 (m, 1H, H-15) 
4.46-4.51 (m, 1H, H-17), 4.60-4.68 (m, 1H, H-16), 4.90 (m, 1H, H-17), 6.46 (d, J = 3.1 Hz, 1H, H-
21), 6.60 (dd, J = 0.9, 7.8 Hz, 1H, H-24) 6.87-6.92 (t, J = 7.8 Hz, 1H, H-25) 7.13 (dd, J = 0.9, 7.8 
Hz, 1H, H-26) 7.19-7.24 (m, 3H, H-6, H-11, H-22) 7.38-7.44 (m, 4H, H-4, H-5, H-12, H-13) 8.10 
(m, 2H, H-1, H-10); δC (methanol-d4, 100.6 MHz) 48.2 (CH), 53.9 (CH), 72.9 (CH), 102.2 (CH), 
107.7 (CH), 110.3 (CH), 113.4 (CH), 119.8 (CH), 120.8 (CH), 121.1 (CH), 124.2 (Cquat), 126.6 (CH), 
127.0 (Cquat), 131.0 (CH), 133.2 (Cquat), 142.3 (Cquat), 145.6 (Cquat); HRMS-ES+ Calculated: 
357.1603 [M+H]+ for C23H21N2O2, Observed: 357.1598; C18 HPLC, flow rate: 1 mL/min, H2O / 
acetonitrile (30:70), 96.4%; Chiral OD HPLC, flow rate 0.9 mL/min, i-PrOH / hexane (25:75), τ 
Major: 20.0 min, τ Minor: 12.0 min.  
7.4 General Analytical Methods 
All reagents used were purchased from commercial sources (Fluka, Kimix and Sigma Aldrich). 
Double distilled deionised Millipore© Direct-Q water was used for all experiments. Eppendorf 
single and multi-channel micropipettes were used to deliver all micro-volumes manually. All 
pH measurements were carried out using a Crison 2000 MicropH meter which was calibrated 
using standard phosphate buffer solutions (pH 7.00 ± 0.02 and 4.00 ± 0.02) before use. 
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7.5 NP-40 Mediated β-Haematin Inhibition Assay 
The β-haematin inhibition assay as described by Carter et al 92 was modified for manual liquid 
delivery. Test compounds and standards were dissolved in DMSO to make up 20 mM stock 
solutions and 20 μL of each solution was added to column 12 of a 96-well plate together with 
AR grade acetone (70 μL), NP40 (40 μL , 305.5 μM) and water (70 μL). A solution containing 
water/ acetone/ NP40 (305.5 μM) / DMSO at a v/v ratio of 35%/35%/20%/10% was made up 
and 100 μL was added to columns 1 to 11. A serial dilution from column 12 to column 2 was 
carried out leaving column 1 as the blank column. A solution of haematin (25mM) was 
prepared by sonicating haemin in DMSO for 1 min and then suspending 178.8 μL in 20 mL of 
a previously prepared 1M acetate buffer (pH 4.8). 100 μL of this haematin solution was added 
to all 96 wells. The plate was covered and incubated in an incubator at 37 °C for 5-6 hr. The 
plate was analysed using the pyridine-ferrichrome method developed by Ncokazi and Egan.67 
A solution of pyridine/ water/ acetone/ 2M HEPES buffer (pH 7.4) in ratios (v/v) of 50%/ 20%/ 
20%/ 10% was prepared and 32 μL was added to each well. Lastly 60 μL of acetone was added 
to all wells to assist in the dispersion of haematin. The 96-well plate was shaken by mechanical 
means followed by the UV-visible absorbance being read using a SpectraMax P340 plate 
reader. Sigmoidal dose-response curves were plotted using the absorbance data together 
with Graphpad Prism v4.00. 179 
7.6 Turbidimetric Solubility Assay 
A phosphate-buffered saline (PBS) (0.01M, pH 7.4) solution was prepared using five intact PBS 
tablets in 1 L of H2O. Test compounds and hydrocortisone (standard) were dissolved in DMSO 
to make up 10 mM solutions and used to prepare a pre-dilution plate by serial dilution of the 
compounds in triplicate, in a 96-well plate, to yield concentrations from 8.0 mM to 0.25 mM. 
A final 96-well plate was prepared by pipetting 196 μL of DMSO in half of the wells in the plate 
and 196 μL of the previously prepared 0.01M PBS buffer. 4 μL of each solution in the  
pre-dilution plate was pipetted in triplicate into both the DMSO and PBS buffer containing 
wells for a final volume of 200 μL and concentration range of 200 μM to 0 μM (Figure 7.1). 
The plate was covered and left to equilibrate for 2 hr at ambient temperature. 
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40.0             
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Figure 7.1: 96-Well plate layout  
The UV-visible absorbance of the 96-well plate was read on a SpectraMax P340 plate reader 
and the corrected absorbance was calculated using the following formula: Absorbance at conc 
X – Blank absorbance = corrected absorbance for all wells. Plots of absorbance against 
compound concentration were prepared using MS excel 2013. 
7.7 Computational Methods 
7.7.1 Bayesian Modelling  
All structures were drawn in Marvin sketch 180 and imported into Discovery Studio v4.0 169 
where all Bayesian statistic calculations was carried out using and the Bayesian models 
described by Wicht et al.127 All structural data was analysed using the predetermined cut-offs 
of the relevant Bayesian models.  
7.7.2 Docking Studies 
All docking studies was carried out on Materials Studio 2016 version 16.1.0.21162 using 
preformed β-haematin crystal structure faces ((001) and (011)) and an optimised force-field 
specifically designed for this system developed by the de Villiers group at Stellenbosch 
University (unpublished work). Compounds were drawn in Chemdraw Ultra 12.0.2181, 
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imported to Material Studio and optimised using a Forcite geometry optimisation calculation 
(quality: Ultra-fine, Charge: charge using Qeq and max iterations: 20000). These optimised 
compounds were adsorbed onto both the β-haematin crystal structure faces using the 
adsorption locator (5 cycles, 70000 steps per cycle, current charge). The lowest energy 
adsorption complexes that were plausible were subjected to a Forcite anneal calculation 
(quality: ultra-fine, annealing cycles: 100, Charge: use current). The lowest plausible energy 
configuration of the complex was lastly subjected to a Forcite energy calculation (quality: 
ultra-fine, Charge: use current). The adsorption energy of the Inhibitor was calculated 
according to equation 6.1:  
Eads (kcal.mol-1) = E final – E initial 
                = E (crystal + inhibitor) – E (crystal) – E (inhibitor)    6.1 
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